![]() | Stephen V Faraone∗Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 | Departments of Psychiatry and Neuroscience and ... |
Currículum de kol para Stephen V Faraone∗
Year | |
---|---|
2022 | Department of Psychiatry and Behavioral Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210 |
2021 | Department of Neuroscience and Physiology, State University of New York Upstate Medical University, Syracuse, New York Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts General Hospital, Boston, Massachusetts, USA |
2020 | K.G. Jebsen Centre for Psychiatric Disorders, Department of Biomedicine, University of Bergen, Bergen, Norway Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical Center, Syracuse, NY, USA Department of Psychiatry and of Neuroscience and Physiology, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, United States The full list of authors in the ENIGMA working groups, author affiliations, author disclosures, and acknowledgments are provided in online supplements. |
2019 | Departments of Psychiatry and Neuroscience and Physiology, SUNY Upstate Medical University, New York, USA The Department of Human Genetics, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Klein, Bralten, Roth Mota, Arias-Vasquez, Franke); University Medical Center Utrecht, UMC Utrecht Brain Center, Department of Psychiatry, Utrecht, the Netherlands (Klein); the Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston (Walters, Neale); Program in Medical and Population Genetics (Walters) and Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, Mass (Walters, Neale); the Department of Biomedicine and the Center for Integrative Sequencing, Aarhus University, Aarhus, Denmark (Demontis, Mattheisen, Børglum); the Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Denmark (Demontis, Børglum); the Department of Genetics and the Neuroscience Center, University of North Carolina, Chapel Hill (Stein); the Imaging Genetics Center, USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles (Hibar, Thompson); the Department of Epidemiology and the Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands (Adams); the Department of Psychiatry and the Research Institute, Hospital for Sick Children, University of Toronto, Toronto (Schachar); the Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology, and Neuroscience, King's College London (Sonuga-Barke); the Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Germany (Mattheisen); the Department of Clinical Neuroscience, Center for Psychiatric Research, Karolinska Institute, Stockholm (Mattheisen); Stockholm Health Care Services, Stockholm County Council, Stockholm (Mattheisen); the Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles (Thompson); the Quantitative Genetics Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia (Medland); the Department of Psychiatry and the Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, N.Y. (Faraone); the K.G. Jebsen Center for Neuropsychiatric Disorders, University of Bergen, Bergen, Norway (Faraone); and the Department of Psychiatry, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands (Roth Mota, Arias-Vasquez, Franke). Department of Psychiatry, Upstate Medical University, Syracuse, New York; Department of Neuroscience and Physiology, Upstate Medical University, Syracuse, New York. SUNY Upstate Medical University, Syracuse, NY |
Stephen V Faraone∗: Estadísticas de influencia
Concept | World rank |
---|---|
co‐expression modules | #1 |
genotype calling procedures | #1 |
innovative sms intervention | #1 |
benefit‐risk ratio | #1 |
ldx sizes | #1 |
familial risk analyses | #1 |
trypotphan hydroxylase | #1 |
risk anxiety disorders | #1 |
adhd oppositional | #1 |
adhd risk factors | #1 |
disorder relatives | #1 |
nonreferred sample | #1 |
criteria☆ | #1 |
n6979 | #1 |
age stimulant treatment | #1 |
schizophrenia code | #1 |
asrs | #1 |
conduct disorder probands | #1 |
diagnoses adhd | #1 |
ptsd familial disorders | #1 |
229 families | #1 |
pilot study adhd | #1 |
hyperactivity cognition | #1 |
longitudinal analysis childhood | #1 |
shr iiv | #1 |
cohorts age groups | #1 |
hamiltondepression | #1 |
hyperactivity pdi | #1 |
pippi longstocking | #1 |
relatives children | #1 |
inattentive symptoms adults | #1 |
adhd drug dependence | #1 |
children bpi disorder | #1 |
prescription stimulant adults | #1 |
adhd comorbid dbds | #1 |
maternal inattention anxiety | #1 |
oih cpt | #1 |
suds neurocognitive functions | #1 |
familial subtype | #1 |
paternal overtransmission | #1 |
comorbidity conduct | #1 |
disorder schizotaxia | #1 |
pinslbl | #1 |
adhd asthma | #1 |
adhd valid | #1 |
rs11568324 | #1 |
adhd adhd probands | #1 |
prescription stimulant nonmedical | #1 |
desr subjects | #1 |
disorders comorbid mania | #1 |
diagnoses valid | #1 |
major depression youth | #1 |
adhd brain alterations | #1 |
sud bpdsud | #1 |
mania clinical interview | #1 |
adhd switches | #1 |
adhd diagnosed | #1 |
efficacy outcome adhd | #1 |
children idiopathic adhd | #1 |
rs3792452 | #1 |
cortical thickness adhd | #1 |
switches bipolar disorder | #1 |
77e08 | #1 |
hyperactivity disorder | #1 |
fspds | #1 |
142 combined subtype | #1 |
probands rates | #1 |
relatives bipolar | #1 |
future dsm | #1 |
teacher combined | #1 |
treatment mts | #1 |
adhd sample | #1 |
adhd predictors | #1 |
sud adolescent | #1 |
dsmiv subtypes adhd | #1 |
abnormalities adhd | #1 |
association evidence | #1 |
neuropsychologic function schizophrenia | #1 |
non‐adhd children | #1 |
dbds adhddbds | #1 |
suds nicotine dependence | #1 |
smoking schizophrenia families | #1 |
pain tolerance oih | #1 |
prss psychiatric disorders | #1 |
psychopharmacologic | #1 |
compared adhd | #1 |
adhd phenotypes | #1 |
predicted clinical response | #1 |
youth bpi disorder | #1 |
anxiousdepressed | #1 |
stimulant treatment adhd | #1 |
rs12843268 | #1 |
genes sexdifferentiated effects | #1 |
relatives multiplex | #1 |
dat1 untranslated regions | #1 |
adhd genetic | #1 |
substantial genetic component | #1 |
subcortical structure volume | #1 |
bipolar disorders psud | #1 |
risk aggressive symptoms | #1 |
pediatric bpi disorder | #1 |
sensitive adhd | #1 |
neuroanatomic predictors | #1 |
cbcldesr | #1 |
stimulant nonmedical | #1 |
reproducibility adolescent | #1 |
smoking wm microstructure | #1 |
12allele | #1 |
paternal smoking conception | #1 |
siblings adolescent | #1 |
genetic variants adhd | #1 |
onset criterion adhd | #1 |
adhd proband | #1 |
aadhd cadhd | #1 |
late‐onset adhd | #1 |
persistence disorder | #1 |
large controlled study | #1 |
depression offspring variables | #1 |
motor skills attention | #1 |
non‐random error | #1 |
efs girls | #1 |
schizotaxia schizophrenia | #1 |
subjects ldx | #1 |
siblings adhd probands | #1 |
np functioning chr | #1 |
schizophrenic probands1portions | #1 |
4‐year follow‐up study | #1 |
symptoms aggregation | #1 |
individuals attention | #1 |
schizophrenia notch4 | #1 |
braingenie | #1 |
siblings males | #1 |
trait impulsivity adhdct | #1 |
pdd mania | #1 |
impactnl | #1 |
git1 adhd | #1 |
adhd income loss | #1 |
vivo neuroreceptor imaging | #1 |
mtbi adhd | #1 |
p179e06 | #1 |
relatives adhd girls | #1 |
alcohol disorders offspring | #1 |
adhd neuropsychological impairments | #1 |
smd higher rates | #1 |
qms adult adhd | #1 |
disorder adhd | #1 |
stimulants childhood | #1 |
adhd mini | #1 |
offspring parental adhd | #1 |
adult adhd differences | #1 |
exposure parental adhd | #1 |
girls disorder | #1 |
parental adhd sud | #1 |
treating adhd | #1 |
adhd candidate genes | #1 |
clinical interview mania | #1 |
snpssnpsa | #1 |
rs6000200 | #1 |
mitigates stimulant | #1 |
taf9bp2 | #1 |
adhd sex | #1 |
relbps | #1 |
parental probands | #1 |
structured interview pdd | #1 |
17year | #1 |
elevated rates adhd | #1 |
suds adhd | #1 |
controls adhd children | #1 |
oih fm | #1 |
desr probands siblings | #1 |
18 items impairment | #1 |
zmynd17 genes | #1 |
depressed children depression | #1 |
placebo ldx treatment | #1 |
oral methylphenidate treatment | #1 |
treatment moderated | #1 |
adhd fam | #1 |
ldx size children | #1 |
schizophrenia familybased studies | #1 |
selfreport adhd | #1 |
efds youth | #1 |
adhd educational deficits | #1 |
suds crosssectional studies | #1 |
adhd genetic studies | #1 |
diagnosis adhd | #1 |
conduct disorder aspd | #1 |
context adhd | #1 |
evidence stimulant treatment | #1 |
risk adhd | #1 |
interobserver agreement measures | #1 |
symptoms versus impairment | #1 |
onset adult subjects | #1 |
adhd highiq youths | #1 |
efds functional outcomes | #1 |
prospective datasets | #1 |
bipolar disorder girls | #1 |
40basepairrepeat | #1 |
5q23q31 | #1 |
familial evidence | #1 |
prs58502974 | #1 |
probands comorbidity | #1 |
relatives diagnoses | #1 |
affective symptoms children | #1 |
ldx masir | #1 |
sbrv adhd | #1 |
112 80 | #1 |
add pdics | #1 |
maf⩾1 | #1 |
association evidence schizophrenia | #1 |
cigarette smoking siblings | #1 |
cortical surface adhd | #1 |
female individuals adhd | #1 |
parental sud sud | #1 |
adhd functional | #1 |
asthma motor preference | #1 |
asrs scores | #1 |
type attention | #1 |
onset distribution | #1 |
adult persistence adhd | #1 |
mania conduct disorder | #1 |
rs2469758–rs2461489 | #1 |
cardinal symptom mania | #1 |
effects lisdexamfetamine dimesylate | #1 |
notch4 polymorphisms | #1 |
adolescents genetic risk | #1 |
treatment masxr | #1 |
adhd findings | #1 |
authors adhd | #1 |
qelbree | #1 |
metabias | #1 |
disorder molecular | #1 |
vcfs manic symptoms | #1 |
haplotypes adhd | #1 |
self‐reported adhd | #1 |
nmu nasal nmu | #1 |
behavioral disinhibition offspring | #1 |
standardized manner | #1 |
smd greater severity | #1 |
adhd genetic variants | #1 |
adhd genetic correlation | #1 |
fiveminutespeechsample | #1 |
dust addictive drug | #1 |
suggestive linkage signals | #1 |
preschool comorbidity | #1 |
hyperactivity comorbidity | #1 |
psud controls | #1 |
genes association studies | #1 |
time qualitative review | #1 |
familial moderators | #1 |
studies adhd | #1 |
elevated risk adhd | #1 |
adhd conclusions | #1 |
ldx expected height | #1 |
rs11133767 | #1 |
motor preference | #1 |
schizotaxia subjects | #1 |
gene attention | #1 |
snp quantitative phenotype | #1 |
patients adhdpi | #1 |
diagnoses relatives | #1 |
unipolar relatives bipolars | #1 |
asrs‐v11 | #1 |
nmu oral | #1 |
palauans maps loci | #1 |
expressed emotion children | #1 |
childhood adhd adulthood | #1 |
control probands | #1 |
timely renewal | #1 |
treatment bsd | #1 |
nonreferred adult | #1 |
adhd alcohol dependence | #1 |
relatives bpi probands | #1 |
diagnostic criteria adhd | #1 |
slc9a9 disease associations | #1 |
comt maoa interaction | #1 |
relatives drug dependence | #1 |
weaknesses comorbidity | #1 |
bipolar disorder switches | #1 |
hyperactivity cross | #1 |
hypothesized precursors | #1 |
association syp | #1 |
adhd somatosensory functioning | #1 |
adhd community sample | #1 |
adulthood genetic architecture | #1 |
report adhd | #1 |
risk female relatives | #1 |
dna methylation adhd | #1 |
ld addh children | #1 |
adhd african | #1 |
rf041 | #1 |
addh dmi | #1 |
male individuals adhd | #1 |
consensus statement combination | #1 |
diagnoses probands | #1 |
autistic traits presence | #1 |
schizophrenia rs1076560t | #1 |
gene studies | #1 |
parental panic disorder | #1 |
parental polygenic risk | #1 |
df39 | #1 |
tic persistence | #1 |
anxiety disorders relatives | #1 |
treatment stimulants | #1 |
onset distributions | #1 |
pediatric bipolar spectrum | #1 |
psychiatric conditions adults | #1 |
genes etiology | #1 |
positive peer affiliation | #1 |
adhd genetic receptors | #1 |
social adjustment inventory | #1 |
postmortem brain identifies | #1 |
adhd disorders comorbidity | #1 |
bpprss | #1 |
noninhibited children | #1 |
mr006 | #1 |
relatives add probands | #1 |
disorders parents | #1 |
years adhd | #1 |
meaningful anxiety phenotype | #1 |
adhd girls | #1 |
sud nicotine dependence | #1 |
hyperactivity body | #1 |
adhdtd | #1 |
rs9325032 | #1 |
adhd | #1 |
comt maoa | #1 |
drd2 risk gene | #1 |
oih pain tolerance | #1 |
adhdrs5 | #1 |
parental children | #1 |
relatives control probands | #1 |
anxiety disorders baseline | #1 |
cbclbp | #1 |
lod213 | #1 |
regions lgi | #1 |
exposure clinical features | #1 |
arch ger psychiatry | #1 |
genetic overlap adhd | #1 |
120 normal controls | #1 |
mgh studies | #1 |
euphoria cardinal symptom | #1 |
pdics | #1 |
disorder attention | #1 |
psychiatric comorbidities adhd | #1 |
pdd mania mania | #1 |
validity diagnosis | #1 |
cortical networks attention | #1 |
unexplored void | #1 |
comt fsiq | #1 |
disorganized symptom dimensions | #1 |
ptsd siblings | #1 |
relatives wm performance | #1 |
valid psychiatric disorder | #1 |
adhd dsm | #1 |
volume alterations | #1 |
genetic risk severity | #1 |
dopamine d4 gene | #1 |
iiv hyperactivity behavior | #1 |
anxiety disorders findings | #1 |
expected height weight | #1 |
subthreshold adhd | #1 |
persistence adhd | #1 |
adhd clinical | #1 |
adhd dbds | #1 |
discipline problem | #1 |
smoking cessation controls | #1 |
bpi disorder efds | #1 |
longacting medications | #1 |
bipolar disorder bpprss | #1 |
d10s195 | #1 |
dsmiiir dsmiv adhd | #1 |
git1 association adhd | #1 |
relatives risk adhd | #1 |
persistent adhd symptoms | #1 |
studies adhd children | #1 |
motor preference disability | #1 |
stimulant treatment risk | #1 |
bpi disorder relatives | #1 |
visual memory deficit | #1 |
pdag mdd mdd | #1 |
dat1 vntr | #1 |
sodasmph | #1 |
manic symptoms disorder | #1 |
adhd stimulant treatment | #1 |
sexdifferentiated effects traits | #1 |
135–526 | #1 |
adhd females | #1 |
subjects adhd | #1 |
sud adolescent patients | #1 |
ldx sizes children | #1 |
relatives adhd status | #1 |
snps drd4 gene | #1 |
n55374 | #1 |
disorder meta | #1 |
valid disorder | #1 |
onset mania | #1 |
idir aversion | #1 |
cigarette smoking metaanalysis | #1 |
clinical response orosmph | #1 |
bipolars unipolar relatives | #1 |
nonmental diseases adhd | #1 |
or133 | #1 |
scz palau | #1 |
pediatric bipolari disorder | #1 |
rs3027400 | #1 |
31item | #1 |
onset attention | #1 |
rare protective allele | #1 |
studies depressed children | #1 |
schizophrenia bipolar psychoses | #1 |
dsm bipolar disorder | #1 |
adhd probands relatives | #1 |
combination scientific data | #1 |
quantitative analyses treatment | #1 |
p0499 | #1 |
10repeats | #1 |
qms adhd | #1 |
persistence pediatric disorder | #1 |
potential endophenotypes adhd | #1 |
genetic correlations schizophrenia | #1 |
187 children | #1 |
biomarkers adhd | #1 |
cdh13 memory performance | #1 |
bpi probands | #1 |
adhd antisocial | #1 |
syp female adhd | #1 |
relatives multiplex families | #1 |
9 nhe9 | #1 |
deficits expected growth | #1 |
mania rates | #1 |
p20e04 | #1 |
multi‐stage study | #1 |
adhd girls adhd | #1 |
subjects lateonset adhd | #1 |
antisocial disorder relatives | #1 |
relatives control | #1 |
adhd smoking | #1 |
nonreferred siblings | #1 |
specific psychopathology children | #1 |
adhd medications placebo | #1 |
opd add opd | #1 |
siblings antisocial families | #1 |
adhd cigarette smoking | #1 |
rs9610449 | #1 |
key conceptual issues | #1 |
4q28 | #1 |
parental suds | #1 |
hyperactivity disorder scores | #1 |
dat1 adhd | #1 |
rs9627183 | #1 |
adhd gene | #1 |
putamen volume alterations | #1 |
callingalgorithms | #1 |
drug frequency variables | #1 |
adverse impact adhd | #1 |
adherence stimulant treatment | #1 |
chronological age age | #1 |
disorders aa | #1 |
groups girls | #1 |
896 cases | #1 |
nimh genetics initiative | #1 |
adults ldx sizes | #1 |
adhd control probands | #1 |
iiv shr | #1 |
variance oppositional symptoms | #1 |
illness child comorbidity | #1 |
adhd baseline assessment | #1 |
teacher report | #1 |
bpd parents | #1 |
adhd aud | #1 |
concurrent adhd | #1 |
growth outcomes adhd | #1 |
genetic variation nr3c1 | #1 |
subthreshold pediatric | #1 |
adhd screening | #1 |
add relatives | #1 |
adhd personality traits | #1 |
nasal nmu nmu | #1 |
adhddbds adhd | #1 |
increasing resource demand | #1 |
bpd firstdegree relatives | #1 |
adhd euphoria | #1 |
risk comt gene | #1 |
siblings control probands | #1 |
adult samples model | #1 |
140 adhd probands | #1 |
aklt01 adhd | #1 |
experts abstinence | #1 |
gender adhd | #1 |
adhd increased | #1 |
risk opioid dependence | #1 |
relatives girls | #1 |
rs1051312 | #1 |
neuropsychological performance adhd | #1 |
ermph placebo groups | #1 |
disorder versus disability | #1 |
chi28783 | #1 |
european treatment guideline | #1 |
convergent functional genomic | #1 |
sud adolescence | #1 |
disorder boys | #1 |
mothers fam | #1 |
1236a | #1 |
stimulants abuse potential | #1 |
mwq adhd module | #1 |
depression symptoms aggregation | #1 |
rs1633445 | #1 |
adhdtd siblings | #1 |
affective symptoms dbds | #1 |
late onset adhd | #1 |
odd control | #1 |
low attention | #1 |
controls adhd probands | #1 |
unfamiliar challenges | #1 |
nfspd | #1 |
criteria age | #1 |
emotional problems pmee | #1 |
cbt intervention adolescents | #1 |
desr adult probands | #1 |
consensus combination | #1 |
adhd aes | #1 |
adhd baseline | #1 |
vntr haplotype | #1 |
valid diagnosis | #1 |
bmi ldx | #1 |
transmission adhd | #1 |
mania referred children | #1 |
oral nmu nmu | #1 |
adult adhd diagnosis | #1 |
adhd hyperactivity automobile | #1 |
odd disorders follow | #1 |
diagnosis bpi disorder | #1 |
severe dysregulation | #1 |
highiq adults | #1 |
adhd antisocial disorders | #1 |
girls learning disabilities | #1 |
genetic frontal schizophrenia | #1 |
adhd youth ld | #1 |
adhd adhdtd | #1 |
adhd asm snps | #1 |
cgsq ermph | #1 |
treatment stimulant | #1 |
adhd oxidative stress | #1 |
transmission parents | #1 |
actual motor performance | #1 |
findings adhd | #1 |
probands clinical status | #1 |
followup assessment | #1 |
persistent adhd adults | #1 |
aspd youth | #1 |
5‐generation | #1 |
prodromal overt psychosis | #1 |
substance disorders relatives | #1 |
subsets linkage | #1 |
rs6077690 | #1 |
stress exposure connectivity | #1 |
adhd prss adhd | #1 |
adhd concurrent sud | #1 |
hartsough | #1 |
drd4 7repeat allele | #1 |
manic children pdd | #1 |
boys social disability | #1 |
genetic sexual dimorphism | #1 |
stimulant treatment youth | #1 |
adhd drd4 | #1 |
diagnostic continuity | #1 |
adhd antisocial comorbidity | #1 |
suggestive linkage | #1 |
familiar disease | #1 |
deficits time | #1 |
adhd children ld | #1 |
features adhd | #1 |
copy organization | #1 |
adhd efds | #1 |
genetic heterogeneity adhd | #1 |
adhd prs rtv | #1 |
5ht1b receptor gene | #1 |
individuals adhd | #1 |
illness adolescent | #1 |
drugplacebo response curve | #1 |
age onset criterion | #1 |
children antisocial disorders | #1 |
siblings adhd | #1 |
relatives 3 probands | #1 |
population screen | #1 |
adhd total score | #1 |
normal sexual dimorphisms | #1 |
rationaleadhd | #1 |
cbcl clinical scales | #1 |
psychopathology implications | #1 |
assess adult adhd | #1 |
linkage wave | #1 |
adhd adverse impact | #1 |
children general psychopathology | #1 |
nonreferred siblings probands | #1 |
twin adoption | #1 |
etiology adhd | #1 |
risk factor psud | #1 |
adhd follow | #1 |
gsprs adhd | #1 |
adhd prss | #1 |
99item cbs | #1 |
measurement invariance study | #1 |
impairments adults | #1 |
74±77 | #1 |
relszs | #1 |
schizotypal relatives | #1 |
psychopathology reward dysfunction | #1 |
predictors persistence | #1 |
adhd degree relatives | #1 |
growth deficits deficits | #1 |
symptoms adult | #1 |
pdd pdd subjects | #1 |
vall66 | #1 |
female gender boys | #1 |
racial heterogeneity | #1 |
bpi relatives | #1 |
stimulants height | #1 |
gene comt | #1 |
hyperactivity child genome | #1 |
matter volumes volumes | #1 |
lateandmoderate | #1 |
adhd probands | #1 |
adoption studies | #1 |
etiology disorder | #1 |
p758e08 | #1 |
masir | #1 |
smaller total brain | #1 |
gsprss | #1 |
adhd neuropsychological functioning | #1 |
adhd adhd cases | #1 |
adhd comorbid odd | #1 |
adolescents sud treatment | #1 |
mr005 | #1 |
stimulant treatment differences | #1 |
cacng2 genes schizophrenia | #1 |
studies method | #1 |
childhoodonset mania | #1 |
referred parents | #1 |
familial risk gender | #1 |
antisocial disorders bpd | #1 |
a409p | #1 |
adolescents concurrent adhd | #1 |
adult adhd | #1 |
validity adhd | #1 |
ldx growth delays | #1 |
anachronisms | #1 |
paliperidone monotherapy | #1 |
adhd chinese population | #1 |
familial vulnerability schizophrenia | #1 |
gender familial risk | #1 |
tass adhd | #1 |
rs3776512 | #1 |
probands adhd | #1 |
neuropsychological probes | #1 |
parents md | #1 |
desipraminestimulants | #1 |
adult adhd treatment | #1 |
adhd highly | #1 |
mdd pdag mdd | #1 |
neurocognitive functions suds | #1 |
rs916455 | #1 |
rs552655 | #1 |
mph adult adhd | #1 |
association attention | #1 |
prescription stimulant nmu | #1 |
adhd risk alleles | #1 |
adherence xr | #1 |
drugplacebo | #1 |
proband child | #1 |
sob sob association | #1 |
children ermph | #1 |
desr siblings | #1 |
impulsive subtype | #1 |
youth informant source | #1 |
temperamental risk factor | #1 |
palau scz | #1 |
“3 | #1 |
motor preference asthma | #1 |
daily parent rating | #1 |
adhd children exposure | #1 |
peer environmental factors | #1 |
higher prevalence girls | #1 |
palau early | #1 |
attention deficit | #1 |
adhd susceptibility genes | #1 |
volumes participants | #1 |
disorder | #1 |
adhd stronger connectivity | #1 |
opd add | #1 |
childhood genetic background | #1 |
starsadhd | #1 |
norepinephrine transporter gene | #1 |
adhd followup | #1 |
fam mothers | #1 |
risk childhood onset | #1 |
2276ct | #1 |
morbidity adhd | #1 |
hyperactive impulsive symptoms | #1 |
interviews disease humans | #1 |
genetic association rorb | #1 |
neuropsychological testing individuals | #1 |
adhd genetic exome | #1 |
1 relatives | #1 |
ldx amses | #1 |
ldx growth | #1 |
molecular psychiatric genetics | #1 |
adhd snps | #1 |
comparison subjects participants | #1 |
idir proteins siblings | #1 |
pdd subjects mania | #1 |
2327t | #1 |
abstinence pharmacological treatment | #1 |
adhd mdd prss | #1 |
83097 | #1 |
parents proband youth | #1 |
multiplex sample | #1 |
asd weaknesses | #1 |
severe emotional dysregulation | #1 |
school reliability | #1 |
genetic correlation adhd | #1 |
latrophilin 3 gene | #1 |
adhd maternal smoking | #1 |
chronic emotional dysregulation | #1 |
psychiatric comorbidity md | #1 |
dyscalculia adhd | #1 |
pathways adhd | #1 |
aud adhd | #1 |
adhd druggable genes | #1 |
offspring parental md | #1 |
asds clinical scales | #1 |
exposure maternal smoking | #1 |
oral nmu | #1 |
adherence stimulant medication | #1 |
productivity adhd | #1 |
risk disorder | #1 |
“forgetfulness | #1 |
maoa impulsivity | #1 |
tass adhdrs | #1 |
downward extension adolescents | #1 |
add 73 probands | #1 |
week treatment response | #1 |
d10s2327 | #1 |
pediatric panic disorder | #1 |
risk substance disorders | #1 |
adhd candidate | #1 |
adhd dyscalculia | #1 |
rs2279805 | #1 |
healthy cortical development | #1 |
parents sud | #1 |
treatment effects values | #1 |
interaction adhd | #1 |
adhd ads | #1 |
transient financial stress | #1 |
clinical correlates ocd | #1 |
lifetime adhd | #1 |
dependence controls | #1 |
inattention shr | #1 |
ats siblings | #1 |
subthreshold diagnoses valid | #1 |
parental md | #1 |
adhdfamilies | #1 |
adhd comorbid | #1 |
prsanalyses | #1 |
p97e−03 | #1 |
anxious depressed subscales | #1 |
inattentive subtype adhd | #1 |
unique impairments | #1 |
anx relatives | #1 |
asrs aisrs | #1 |
schizophrenia fhrs | #1 |
bpd anx bpd | #1 |
comorbid oppositional | #1 |
sp067 | #1 |
overlapping symptoms | #1 |
adults adhd subjects | #1 |
risk subsequent substance | #1 |
adhd module mwq | #1 |
autism‐associated brain regions | #1 |
cbclbp profile | #1 |
dao gene schizophrenia | #1 |
laboratory driving simulation | #1 |
14 children pdd | #1 |
adhd obesity overweight | #1 |
genes disorder | #1 |
adhd smoking risk | #1 |
families adhd | #1 |
brain activity flow | #1 |
adhd pattern | #1 |
pain tolerance fm | #1 |
c2orf82 | #1 |
clinical features adhd | #1 |
boys female gender | #1 |
48basepairrepeat | #1 |
adhd bipolar comorbidity | #1 |
parental panic depression | #1 |
comorbid odd adhd | #1 |
adhd pdics | #1 |
140 adhd | #1 |
higher pdi | #1 |
aggregate cutoff score | #1 |
repeat allele | #1 |
foursnp | #1 |
familial association adhd | #1 |
fidgety philipp | #1 |
persons rels | #1 |
covariates dopamine receptors | #1 |
51 genes | #1 |
rs550818 | #1 |
dsm5 adult adhd | #1 |
stimulant therapy youths | #1 |
p44e05 | #1 |
disorder familial | #1 |
bpd hypothesis | #1 |
neuropsychological impairments relatives | #1 |
shlod | #1 |
relatives alcohol dependence | #1 |
relatives conduct disorder | #1 |
adhd efficacy outcome | #1 |
serotonin genetic | #1 |
schizotaxia negative symptoms | #1 |
nr3c1 stress exposure | #1 |
suds genetic studies | #1 |
familybased studies association | #1 |
nonreferred | #1 |
moderating effects patterns | #1 |
tourettes syndrome adhd | #1 |
adhd single nucleotide | #1 |
nonreferred samples | #1 |
nonreferred subjects | #1 |
odd familial disorders | #1 |
adhd gwas | #1 |
executive functioning adults | #1 |
neural network correlates | #1 |
levels dysfunction | #1 |
affs add | #1 |
adhd psychiatric | #1 |
cognitive endophenotypes adhd | #1 |
confusability analyses | #1 |
nonmental diseases | #1 |
adhd seconddegree relatives | #1 |
groundskeeper | #1 |
adults stimulant sizes | #1 |
time reproduction children | #1 |
nhe inhibitors adhd | #1 |
new diagnoses age | #1 |
biological schizophrenia stress | #1 |
adhd long term | #1 |
alphaglx | #1 |
caregiver strain cgsq | #1 |
p446e08 | #1 |
95 hrr | #1 |
bmi mts | #1 |
mph controls | #1 |
adhd gsprs | #1 |
teachers cbt intervention | #1 |
masxr treatment | #1 |
adhd reliability | #1 |
adhd teenage parents | #1 |
genetics adhd | #1 |
association slc6a3 | #1 |
juvenile antisocial traits | #1 |
adults neurodevelopmental disorder | #1 |
mddprss | #1 |
motheronly | #1 |
2276tc | #1 |
hypothesis disorders | #1 |
loci asd symptoms | #1 |
rates relatives | #1 |
adhdrsivinv | #1 |
fhraff | #1 |
d15s1012 | #1 |
molecular genetics network | #1 |
interaction adhd severity | #1 |
n122 | #1 |
risk suds | #1 |
hyperactivity biomarkers aadhd | #1 |
slc9a9 | #1 |
children motor competence | #1 |
rs1799835 | #1 |
relatives bpi | #1 |
inattention adhd | #1 |
nonaffected siblings children | #1 |
children mania diagnosis | #1 |
rutters | #1 |
greater risk adhd | #1 |
dopamine receptor polymorphism | #1 |
marijuana smoking metaanalysis | #1 |
bpd anx relatives | #1 |
behavioral inhibition parents | #1 |
deletioncarrier | #1 |
daorasd2 | #1 |
adhd scores | #1 |
life adult adhd | #1 |
items 99item cbs | #1 |
schizotaxia negative schizotypy | #1 |
rs2449340 | #1 |
familial disorders adhd | #1 |
competitivep | #1 |
pharmacogenetics predictors | #1 |
anterior insular lobule | #1 |
drug dependence relatives | #1 |
quantitative phenotype snp | #1 |
rs2272080 | #1 |
disorder hyperactivity | #1 |
remission definition | #1 |
adhd bipolar studies | #1 |
adhd iiv | #1 |
manic symptoms vcfs | #1 |
growth delays weight | #1 |
gene interaction comt | #1 |
adhd symptoms crf | #1 |
neurocognitive traits | #1 |
evidence sud phenotypes | #1 |
expression adhd | #1 |
add parent report | #1 |
adhd social class | #1 |
mspi allele | #1 |
impulsive drive | #1 |
ldx adult adhd | #1 |
adhd responders | #1 |
bipolar adhd | #1 |
autism symptoms adhd | #1 |
bpd girls | #1 |
adhd population | #1 |
administration marijuana | #1 |
nonverbal social–emotional cues | #1 |
bipolar disorder parents | #1 |
disorders hypothesis | #1 |
intron8 | #1 |
2064 trios | #1 |
rate symptoms | #1 |
stimulant treatment adults | #1 |
add aff | #1 |
aud alcohol disorders | #1 |
efficacy adderall | #1 |
adhd mp | #1 |
impulsiveness inattention | #1 |
24 gm day | #1 |
20183 | #1 |
expected growth children | #1 |
endophenotypic construct | #1 |
9r allele | #1 |
hyperactive impulsive | #1 |
youth adhd | #1 |
distribution child | #1 |
relatives adhd probands | #1 |
onset chronological age | #1 |
akt1 snp markers | #1 |
anxiety disorders twins | #1 |
greater risk add | #1 |
european treatment guidelines | #1 |
african children adhd | #1 |
loci adhd | #1 |
outcome adhd | #1 |
galantamine hydrogen bromide | #1 |
adhd children bpd | #1 |
fhrscz | #1 |
proband youth bpd | #1 |
comorbid adult adhd | #1 |
cbclbp profile children | #1 |
odd relatives | #1 |
adolescent follow youth | #1 |
schizophrenia nonpsychotic relatives | #1 |
adhd sexes | #1 |
highiq adults adhd | #1 |
adhd adult adhd | #1 |
vcfsadhd adhd | #1 |
bpd probands | #1 |
motorendophenotypes | #1 |
fm pain tolerance | #1 |
inflation personal satisfaction | #1 |
addictive drugs dust | #1 |
shifting sands | #1 |
adhd disorder | #1 |
adhd studies | #1 |
adolescence longitudinal analysis | #1 |
clinical controls | #1 |
training raters | #1 |
rels persons | #1 |
bpi disorder children | #1 |
adhd module | #1 |
increased expression methylation | #1 |
tomoxetine adult adhd | #1 |
adhd depressed children | #1 |
alcohol dependence relatives | #1 |
c759t | #1 |
adhd specific | #1 |
studies attention | #1 |
pepple | #1 |
slc9a9 adhd | #1 |
rs41084 | #1 |
bpd bpdsud | #1 |
cyp2d6 hypothesis | #1 |
scales risk | #1 |
adhdmethodcurves | #1 |
learning disabilities girls | #1 |
neurocognitive marker | #1 |
adhd clinical obesity | #1 |
sud phenotypes | #1 |
druggable genome adhd | #1 |
re‐review | #1 |
increased methylation genes | #1 |
adolescent psychiatric cohort | #1 |
regulation desr | #1 |
adhd adoption studies | #1 |
antisocial disorders risk | #1 |
highiq youths adhd | #1 |
mania manic features | #1 |
adhd sample model | #1 |
paternal over‐transmission | #1 |
adolescent attention | #1 |
stress adhd severity | #1 |
parental bpd | #1 |
comt intelligence | #1 |
aadhd hyperactivity biomarkers | #1 |
adhd structural abnormalities | #1 |
p81e06 | #1 |
adhd neuropsychological | #1 |
20183 cases | #1 |
personality traits adults | #1 |
medications adult adhd | #1 |
21 circadian genes | #1 |
familial underpinnings | #1 |
bpi disorder | #1 |
higher adhd | #1 |
adhd children mania | #1 |
nonpsychotic relatives controls | #1 |
infas | #1 |
p647e07 | #1 |
2455 controls | #1 |
adhd subjects controls | #1 |
diagnostic efficiency analysis | #1 |
teenage parents individuals | #1 |
new psychometric definition | #1 |
hamshere | #1 |
odd disruptive behavior | #1 |
adolescent patients adhd | #1 |
deficit | #1 |
children teaes | #1 |
new phenotype definition | #1 |
genetic studies sud | #1 |
motor problems adhd | #1 |
structural differences children | #1 |
aisrs asrs | #1 |
sample adhd | #1 |
pdi hyperactivity | #1 |
ermph cgsq | #1 |
htf9c gene | #1 |
pdi impulsiveness | #1 |
rs1040399 | #1 |
prss adhd | #1 |
hyperactivity disorder adults | #1 |
tdt analysis | #1 |
prs rtv | #1 |
adult probands siblings | #1 |
adhd rat | #1 |
anx bpd | #1 |
adhde | #1 |
psud adhd probands | #1 |
add antisocial disorders | #1 |
adhd familial disorder | #1 |
candidate genes adhd | #1 |
children growth delays | #1 |
longitudinal outcome boys | #1 |
educational failure | #1 |
sex bpi disorder | #1 |
bpd relatives | #1 |
nonreferred adults | #1 |
suds relatives | #1 |
parental sud adhd | #1 |
lobe mri measures | #1 |
adhd attention | #1 |
adhd female individuals | #1 |
ldx bmi | #1 |
anxiety disorders siblings | #1 |
based association study | #1 |
locus adhd | #1 |
adhd dat1 gene | #1 |
adhd methods | #1 |
methylphenidate efficacy | #1 |
referred juveniles | #1 |
dysfunctional gene | #1 |
lifetime impairment | #1 |
falconer3 | #1 |
discordant twin study | #1 |
adhd clinical characteristics | #1 |
aklt01 tova api | #1 |
htf9c | #1 |
chinese outpatient sample | #1 |
bpi disorder sexes | #1 |
cadhd aadhd | #1 |
pregnancy adhd | #1 |
neurocognitive dysfunctions | #1 |
relatives greater activation | #1 |
comt odd | #1 |
13052159 | #1 |
persistence childhood adhd | #1 |
familial transmission adhd | #1 |
stimulant treatment profiles | #1 |
sob adhd | #1 |
allele adhd | #1 |
psychiatric risk vcfs | #1 |
adhddbds | #1 |
firstdegree relatives children | #1 |
adhd maoa | #1 |
adhd outcome | #1 |
stimulant nmu | #1 |
ermph clinical response | #1 |
major depression share | #1 |
concurrent adhd sud | #1 |
adolescent sud | #1 |
adhd maternal | #1 |
rs2469770 | #1 |
vulnerability indicators schizophrenia | #1 |
adhd linkage | #1 |
hyperactivity | #1 |
oros methylphenidate orosmph | #1 |
adhd adolescent | #1 |
deficit hyperactivity | #1 |
4q3121 | #1 |
placebo cgsq | #1 |
adhdassociated alleles | #1 |
adhd serotonin | #1 |
slc6a4 gene risk | #1 |
depressed children adhd | #1 |
predictors adhd | #1 |
selfreport adhd symptoms | #1 |
type adhd | #1 |
adhd clinical trial | #1 |
larger samples | #1 |
motor preference adhd | #1 |
orosmph adult adhd | #1 |
adhd cognition | #1 |
sexes bpi disorder | #1 |
scqscore | #1 |
kiaa1292 | #1 |
cacng2 gene | #1 |
connectivity executive control | #1 |
children motor domain | #1 |
parents behavioral disinhibition | #1 |
relatives pediatric probands | #1 |
p902e−07 | #1 |
adolescent response inhibition | #1 |
adult samples adhd | #1 |
pdd criteria | #1 |
hyperactivity child | #1 |
adults life | #1 |
controls rels | #1 |
2327ct | #1 |
adhd context | #1 |
adhd adult disorder | #1 |
bpi sza | #1 |
patients adhdct | #1 |
morbidity bipolar disorder | #1 |
model adult samples | #1 |
rf025 | #1 |
rs3746544 rs1051312 | #1 |
bpi disorder aspd | #1 |
mania pdd subjects | #1 |
ldx sizes adults | #1 |
stimulant treatment alcohol | #1 |
patients attentional disorders | #1 |
disability asthma | #1 |
dat110 6 | #1 |
17yearold boys | #1 |
impulsive behavioral aggression | #1 |
comorbid problems adhd | #1 |
adhd higher | #1 |
md parents | #1 |
adults diagnosis | #1 |
age 7repeat allele | #1 |
mania pdd | #1 |
family‐based association test | #1 |
bpdsud bpd | #1 |
familial links | #1 |
maoa adhd | #1 |
african‐american pedigrees | #1 |
genetic studies adhd | #1 |
bpi disorder youth | #1 |
matching fallacy | #1 |
pharmacological treatment adolescents | #1 |
adhd slc6a3 genotype | #1 |
stimulants comorbidity | #1 |
distal genomic region | #1 |
rs1076560t | #1 |
sud parents | #1 |
nfspds | #1 |
adhd 11 years | #1 |
adhd conduct disorder | #1 |
familially | #1 |
adhd social disability | #1 |
hyperactivity comorbidity humans | #1 |
antisocial families | #1 |
metaanalysis controlled study | #1 |
criteria pdd | #1 |
subthreshold adhd subjects | #1 |
stable behavioral inhibition | #1 |
adhd vntr | #1 |
adhd siblings | #1 |
diagnostic continuity adhd | #1 |
adhd background | #1 |
adhd cbcl | #1 |
relatives default network | #1 |
mania criteria | #1 |
distinct subtype | #1 |
hyperactivity biomarkers | #1 |
children disorder | #1 |
bpd anx | #1 |
neuroleptic nonresponse | #1 |
emotional symptoms adhd | #1 |
15q13 deletions | #1 |
molecular genetic studies | #1 |
2 familial factors | #1 |
genes adhd | #1 |
child psychiatry referrals | #1 |
subtype adhd | #1 |
h2053 | #1 |
hyperactivity databases | #1 |
method authors | #1 |
notch4 polymorphisms schizophrenia | #1 |
drd5 vntr | #1 |
criteria mania | #1 |
female adhd | #1 |
odd affective symptoms | #1 |
efds bpi disorder | #1 |
adhd 5 | #1 |
adhd asd youth | #1 |
paediatric adhd | #1 |
differences medications | #1 |
“schizotypes | #1 |
35191 | #1 |
bipolar mdd | #1 |
medications adhd | #1 |
affective psychosis hraff | #1 |
unaffected siblings volumes | #1 |
shared endophenotypes | #1 |
lifetime impairment survey | #1 |
1350t | #1 |
adhd community | #1 |
adhd gender | #1 |
35191 controls | #1 |
psychiatric comorbidity girls | #1 |
children pdag parents | #1 |
risk tourette spectrum | #1 |
referred samples | #1 |
proband youth bpdsud | #1 |
paediatric patients adhd | #1 |
adhd african children | #1 |
sob association adhd | #1 |
adhd comorbid disorders | #1 |
twin adoption studies | #1 |
impaired sensorimotor timing | #1 |
adhdi prenatal exposure | #1 |
schizophrenia european samples | #1 |
prevalence attention | #1 |
siblings adhd children | #1 |
drd2 disrupts | #1 |
biased maternal reporting | #1 |
association dopamine receptors | #1 |
analysis adhd | #1 |
trypotphan | #1 |
ctcata | #1 |
clock genes rorb | #1 |
adhd neuroimage study | #1 |
adhd volumetric reductions | #1 |
sud remittent adhd | #1 |
depression adhd child | #1 |
impact tic disorders | #1 |
anxiety disorders families | #1 |
mp adhd | #1 |
phenotype adhd | #1 |
genomesignificance | #1 |
lateonset adhd | #1 |
symptom burden adults | #1 |
adhd alleles | #1 |
gene aggressive behavior | #1 |
rs1482337–rs2252471 | #1 |
psud relatives | #1 |
hyperactivity child humans | #1 |
thermenos | #1 |
adhd haplotype block | #1 |
rtv adhd prs | #1 |
adhd familial risk | #1 |
variants aggressive behavior | #1 |
adhd bpi disorder | #1 |
stimulant misuse | #1 |
inattention items | #1 |
adhd treatment treatment | #1 |
age1542 | #1 |
children adolescents cohorts | #1 |
daonrg1 | #1 |
insular lobule | #1 |
hyperactivity child child | #1 |
rs7118422 | #1 |
osa genetic heterogeneity | #1 |
adhd desr | #1 |
desr adhd | #1 |
ptsd bpi disorder | #1 |
overweight obesity males | #1 |
intelligence additive effects | #1 |
–rs2272080 | #1 |
tass internal consistency | #1 |
association psychiatric comorbidity | #1 |
disorder follow | #1 |
sud risk offspring | #1 |
children behavioral | #1 |
childhood predictors adhd | #1 |
versus disability | #1 |
impulsive symptoms | #1 |
rs7124601 | #1 |
amses amrs | #1 |
trait educational attainment | #1 |
risk factors opd | #1 |
marijuana cocaine crack | #1 |
comorbid problems | #1 |
tova api aklt01 | #1 |
masir ldx | #1 |
elaborative verbal encoding | #1 |
behaviors substances | #1 |
offspring sud parents | #1 |
pooleddata | #1 |
memory adults | #1 |
adhd adolescent patients | #1 |
female humans inhibition | #1 |
adolescent outcome adhd | #1 |
robust familiality | #1 |
adhd desr probands | #1 |
acting medications | #1 |
males overweight obesity | #1 |
youth adhd prss | #1 |
disorder report | #1 |
regions age | #1 |
fsiq comt | #1 |
common genetic risk | #1 |
comorbid psychopathology childhood | #1 |
criteria 14 children | #1 |
adhd probands adhd | #1 |
intellectual delays | #1 |
efficacy outcome week | #1 |
add opd | #1 |
maoa neuropsychological functioning | #1 |
hyperactivity female | #1 |
schizophrenia hrscz | #1 |
earlyandmoderate | #1 |
association adhd | #1 |
stimulant treatment | #1 |
structured interview mania | #1 |
schizophrenia current knowledge | #1 |
association behavioral inhibition | #1 |
patterns psychiatric comorbidity | #1 |
apol1 schizophrenia | #1 |
drd4 association | #1 |
offspring behavioral disinhibition | #1 |
genes hallucinations states | #1 |
comorbidity major depression | #1 |
bpi disorder adhd | #1 |
relatives 1 probands | #1 |
adhd prs gwas | #1 |
autistic traits youth | #1 |
sbrv | #1 |
aff add | #1 |
snps quantitative phenotypes | #1 |
height ldx | #1 |
ptsd adhd probands | #1 |
model ermph | #1 |
tidqam | #1 |
adhd france | #1 |
ainslbl | #1 |
clinically diagnosed obesity | #1 |
mwq inattention items | #1 |
druggable genome disorder | #1 |
probands add | #1 |
smoking adhd | #1 |
conduct bipolar disorders | #1 |
rs3916970 | #1 |
hyperactivity case | #1 |
aggressive symptoms risk | #1 |
adhd child comorbidity | #1 |
increased adhd symptoms | #1 |
faraone | #1 |
association tph2 | #1 |
adhd symptom counts | #1 |
daodisc1 | #1 |
neuropsychological functioning boys | #1 |
risk psud | #1 |
relation stress exposure | #1 |
association snap25 | #1 |
adhd children | #1 |
p27e05 | #1 |
inattentive hyperactive | #1 |
s034 | #1 |
rorb bipolar disorder | #1 |
psychiatric disorders adhd | #1 |
adhd psychoactive substance | #1 |
association maoa | #1 |
motorendophenotype | #1 |
adhd children depression | #1 |
schizophrenia families smoking | #1 |
chi25762 | #1 |
adhd psychiatric conditions | #1 |
adhdoddcd | #1 |
asd youth adhd | #1 |
adhd learning | #1 |
nplz | #1 |
male adolescents adhdct | #1 |
cdbpd | #1 |
subcortical volumes adhd | #1 |
learning disorders adhd | #1 |
children behavioral inhibition | #1 |
rs2498799 | #1 |
network‐level assessment | #1 |
adults cadhd | #1 |
high‐risk adolescent offspring | #1 |
pair health | #1 |
adult persistence | #1 |
cases adhd | #1 |
age groups cohorts | #1 |
bpd bpd anx | #1 |
dbds adhd | #1 |
desr adults | #1 |
adhd familial | #1 |
23 candidate genes | #1 |
highiq youths | #1 |
endosomal genes asds | #1 |
fbxo33 | #1 |
efficacy medications | #1 |
systematized delusions | #2 |
rs3746544 | #2 |
diabetes disorders | #2 |
adults attention | #2 |
adhd mph response | #2 |
adhd bipolar | #2 |
probands | #2 |
disorders similarities | #2 |
suggestive linkage loci | #2 |
efds adults | #2 |
key cognitive phenotypes | #2 |
cbcl profile | #2 |
6 17 | #2 |
adhd major depression | #2 |
g72 daao | #2 |
life social adjustment | #2 |
adhd acc | #2 |
expert clinician | #2 |
adhd adults | #2 |
methodological complexities | #2 |
risk add | #2 |
probands relatives | #2 |
adhd genes | #2 |
deficits adults | #2 |
stress adhd | #2 |
problems adhd | #2 |
expanded versions | #2 |
nonpsychotic relatives | #2 |
testretest reliability screener | #2 |
chromosomes 6 14 | #2 |
psychoactive substance disorders | #2 |
shared genetic background | #2 |
cigarette smoking suds | #2 |
case subjects adhd | #2 |
cnvs copy variants | #2 |
adhd risk gene | #2 |
bmi adhd symptoms | #2 |
young adult years | #2 |
concurrent attention | #2 |
schizophrenia genetic studies | #2 |
adhd height | #2 |
assessed structured | #2 |
psychiatrically | #2 |
qtl linkage adhd | #2 |
juvenile antisocial | #2 |
lgi regions | #2 |
adhd odd | #2 |
activation trigger | #2 |
serum neuroleptic activity | #2 |
ppv hyperactivity diagnostic | #2 |
neuropsychoanalytic treatment | #2 |
bipolar disorder relatives | #2 |
ncrl | #2 |
tourette spectrum | #2 |
disorder background | #2 |
blind raters | #2 |
familial risk analysis | #2 |
antisocial disorders relatives | #2 |
disorder girls | #2 |
adverse effects subjects | #2 |
preventing schizophrenia | #2 |
specific haplotype | #2 |
adhd combined subtype | #2 |
adhd neuropsychological tests | #2 |
adhd subjects | #2 |
adhd adhd children | #2 |
odd girls | #2 |
naltrexone adults | #2 |
comorbid conduct | #2 |
nicotine substance | #2 |
adhd growth | #2 |
adhd emotional symptoms | #2 |
n‐acetylcysteine treatment | #2 |
schizophrenia parahippocampal gyrus | #2 |
adhd major | #2 |
sex differences adhd | #2 |
underlying bipolarity | #2 |
jackknife procedure | #2 |
schizophrenia pedigrees | #2 |
mood disorders adhd | #2 |
function deficits | #2 |
adhd lifespan | #2 |
bipolar disorder symptomatology | #2 |
candidate genetic pathways | #2 |
disorder conclusions | #2 |
items screener | #2 |
deficits efds | #2 |
bidirectional overlap | #2 |
wky nhsd | #2 |
hantac | #2 |
pilot adult | #2 |
neuropsychological function girls | #2 |
subjects criteria | #2 |
child comorbidity | #2 |
background attention | #2 |
n328917 | #2 |
hyperactivity impulsiveness | #2 |
levels comorbidity | #2 |
adults adhd | #2 |
reward‐related activation | #2 |
comorbid aggression | #2 |
maternal smoking mothers | #2 |
schizophrenia interactions | #2 |
morning behavior | #2 |
s038 | #2 |
enigma adventure | #2 |
models adhd | #2 |
internal distractibility | #2 |
enigma adhd | #2 |
checklist clinical | #2 |
correlates adhd | #2 |
proinflammatory expansion | #2 |
treatment childhood adhd | #2 |
comorbidity disorder | #2 |
cbcl desr | #2 |
somatosensory functioning | #2 |
attention‐deficit hyperactivity | #2 |
disease humans receptors | #2 |
hypothetical task | #2 |
adhd risk factor | #2 |
2q143 | #2 |
adhd objective | #2 |
n11221 | #2 |
adult samples | #2 |
psychotic relatives | #2 |
developmental subtype | #2 |
anx bipolar disorder | #2 |
immune disorder | #2 |
affective probands | #2 |
stimulants adhd | #2 |
heterogeneity schizophrenia | #2 |
sud bpd | #2 |
adhd birth | #2 |
adhd disability | #2 |
scales sex | #2 |
adra2a polymorphism | #2 |
rates bpd | #2 |
comparative profile analysis | #2 |
opioid induced hyperalgesia | #2 |
emf impairments | #2 |
rs1800955 | #2 |
childhoodonset adhd | #2 |
efds | #2 |
adhd method | #2 |
euphorigenic effects | #2 |
current adult adhd | #2 |
ratio081 | #2 |
adhd autism symptoms | #2 |
disorder studies | #2 |
childhood adolescent adhd | #2 |
disorder impact | #2 |
rates odd | #2 |
control subjects adhd | #2 |
adhd genetics | #2 |
18 dsm | #2 |
n2455 | #2 |
target features | #2 |
comorbid conduct disorder | #2 |
personal satisfaction | #2 |
initial stimulant | #2 |
adhd relatives | #2 |
diagnosis attention | #2 |
hypothalamic abnormalities | #2 |
large controlled | #2 |
comparison probands | #2 |
adhd comorbid problems | #2 |
adhd comparison subjects | #2 |
ldsc genetic correlations | #2 |
n2246 | #2 |
risk factor adhd | #2 |
disorders suds | #2 |
adhd psychiatric disorders | #2 |
familial adhd | #2 |
actively reducing severity | #2 |
spectrum phenotypes | #2 |
schizotypy handedness | #2 |
d2s410 | #2 |
adhd conduct | #2 |
wwwhapmaporg | #2 |
deficits executive | #2 |
hypothesis adhd | #2 |
girls adhd | #2 |
adhd control subjects | #2 |
parent rating | #2 |
conjfdr005 | #2 |
allele schizophrenia | #2 |
psychotic mood disorder | #2 |
adhd neuropsychological deficits | #2 |
female probands | #2 |
psychiatric comorbidity | #2 |
pdd overlap | #2 |
structured diagnostic interviews | #2 |
ermph children | #2 |
adhd impact | #2 |
stimulants | #2 |
association data | #2 |
adhd assessed | #2 |
iii adhd | #2 |
consortium neuroscience | #2 |
familybased studies | #2 |
aggressive symptoms | #2 |
stimulants adults | #2 |
7point | #2 |
morbidity dysfunction | #2 |
asrs health organization | #2 |
factors attention | #2 |
association meta analysis | #2 |
major depression findings | #2 |
amses | #2 |
disorder oppositional | #2 |
adhd surface area | #2 |
d10s1432 | #2 |
genetic transmission | #2 |
rs6938431 | #2 |
cbsk | #2 |
cognition youth | #2 |
performancemeasures | #2 |
adhd combined | #2 |
siblings youth | #2 |
prior reports | #2 |
alleles attention | #2 |
comorbid oppositional defiant | #2 |
n1934 | #2 |
small literature | #2 |
investigator ratings | #2 |
youth meaningful | #2 |
comorbid conduct problems | #2 |
dsmiiir adhd | #2 |
status rating scales | #2 |
drug abuse dependence | #2 |
effects paternal smoking | #2 |
risk panic disorder | #2 |
evidence adhd | #2 |
mirsky | #2 |
disorder findings | #2 |
adhd case subjects | #2 |
disorder adolescent | #2 |
comorbidity probands | #2 |
trauma adhd | #2 |
hrscz | #2 |
studies adderall | #2 |
wky ncrl | #2 |
versus controls | #2 |
subthreshold diagnoses | #2 |
ldsc heritability | #2 |
overlap mania | #2 |
postcleavage | #2 |
adhd families | #2 |
bipolar disorder sud | #2 |
adhd physical conditions | #2 |
adhdprss | #2 |
schizophrenia twin studies | #2 |
relatives simplex families | #2 |
parents major depression | #2 |
rates adhd | #2 |
hyperactivity attention deficit | #2 |
disease humans inhibition | #2 |
boys maoa | #2 |
findings children | #2 |
hyperactivity diagnostic | #2 |
male psychiatric | #2 |
familial association | #2 |
deficit sustained attention | #2 |
qualitative review | #2 |
method subjects | #2 |
age onset distribution | #2 |
617 years | #2 |
infancy complications | #2 |
regions studies | #2 |
dsm adhd | #2 |
clinically referred | #2 |
juvenile bipolar phenotype | #2 |
6 17 years | #2 |
comorbidity disorders comorbidity | #2 |
child behavioral inhibition | #2 |
bias child child | #2 |
6‐year longitudinal study | #2 |
acpts | #2 |
child comorbidity illness | #2 |
adhd icv | #2 |
support genetic factors | #2 |
5 loci adhd | #2 |
weaknesses youth | #2 |
elusive indicators | #2 |
quetiapine monotherapy treatment | #2 |
6p243 | #2 |
parental anxiety disorders | #2 |
n17666 | #2 |
adolescents substance disorder | #2 |
hyperactivity female humans | #2 |
strong heritability | #2 |
referred youth | #2 |
millennium consortium | #2 |
ncrl wky | #2 |
adhd adhd patients | #2 |
10092 | #2 |
adherence stimulants | #2 |
galantamine hbr placebo | #2 |
consecutively referred children | #2 |
risk female cases | #2 |
factors adhd | #2 |
bpd sud | #2 |
screening diagnosis treatment | #2 |
age onset distributions | #2 |
desr children | #2 |
dimesylate treatment | #2 |
genome‐wide association data | #2 |
subjects adults | #2 |
≥210 | #2 |
p161e05 | #2 |
snp12snp2ctgn | #2 |
symptoms neuropsychological | #2 |
adhd lower | #2 |
consecutively referred | #2 |
polygenic resilience score | #2 |
add probands | #2 |
qualitative literature review | #2 |
youth rates | #2 |
cbcljbd children | #2 |
chromosomes inclusion | #2 |
work needed | #2 |
relatives | #2 |
molecular genetics schizophrenia | #2 |
attentional control effects | #2 |
dysfunction offspring | #2 |
derived phenotypes | #2 |
association mtbi | #2 |
structure adult adhd | #2 |
subsequent substance | #2 |
idiopathic adhd | #2 |
informant source | #2 |
d0·18 | #2 |
manic children | #2 |
adhd risk icv | #2 |
unweighted screener asrs | #2 |
methylphenidate attention | #2 |
adhd suds | #2 |
disorder inattentive | #2 |
clinically referred children | #2 |
manic switches | #2 |
multigenic inheritance | #2 |
combinedtype | #2 |
viloxazine extendedrelease | #2 |
subjects desr | #2 |
rs1801028 | #2 |
addicted | #2 |
expanded symptom criteria | #2 |
galantamine hbr | #2 |
families schizophrenia patients | #2 |
scales adolescent | #2 |
adhd report | #2 |
subjects conduct disorder | #2 |
adhdonly | #2 |
subsyndromal manifestations | #2 |
adhd comparison | #2 |
dsmiv subtypes | #2 |
neuroleptic dose reduction | #2 |
adhdliability | #2 |
comorbidity attention | #2 |
variants adhd | #2 |
140 girls | #2 |
disorder adults | #2 |
disorder children | #2 |
oral prescription | #2 |
parents disorder | #2 |
disorders adhd | #2 |
efficacy stimulants | #2 |
persistent attention | #2 |
dsm subtypes | #2 |
relatives adhd | #2 |
rs40184 | #2 |
stimulant therapy | #2 |
conners adult adhd | #2 |
modest evidence | #2 |
youth selfreports | #2 |
lallele homozygotes | #2 |
twin studies adhd | #2 |
dsmiv adhd | #2 |
familial trait | #2 |
actively reducing | #2 |
genome‐wide association scan | #2 |
scale asrs | #2 |
dsmjbd | #2 |
scz data | #2 |
adhd ldx | #2 |
iii attention | #2 |
separation attention deficit | #2 |
deficits sustained attention | #2 |
default network schizophrenia | #2 |
disorders findings | #2 |
derived diagnosis | #2 |
schizotaxia discussion | #2 |
checklist scales | #2 |
relatives add | #2 |
cbcl clinical | #2 |
cpt oih | #2 |
wm deficits | #2 |
selfmedicating | #2 |
adhd african americans | #2 |
deficit hyperactivity disorder | #2 |
relatives schizophrenic | #2 |
eye vergence responses | #2 |
adhd choice | #2 |
pediatrically | #2 |
comorbidity adhd | #2 |
health organization asrs | #2 |
role adhd | #2 |
eye vergence | #2 |
variance adult | #2 |
bsfq | #2 |
cacng2 genes | #2 |
n3199 | #2 |
disorder add | #2 |
unipolar relatives | #2 |
wiatii | #2 |
treatment sud patients | #2 |
masxr | #2 |
youth attention | #2 |
executive function outcome | #2 |
bpd adhd | #2 |
schizophrenia calcineurin | #2 |
antisocial disorders | #2 |
adhd bpd | #2 |
structured diagnostic | #2 |
multicenter adhd | #2 |
maoa comt | #2 |
adhd outcomes | #2 |
patterns comorbidity | #2 |
stin2vntr | #2 |
aklt01 | #2 |
cgsq | #3 |
global neuroscience decade | #3 |
amphetamines attention | #3 |
adhd mtbi | #3 |
faraone reply | #3 |
structural imaging findings | #3 |
controls 6 disorders | #3 |
adhd polygenic | #3 |
adhd mdd | #3 |
schizophrenia allele | #3 |
dose response effects | #3 |
petronis | #3 |
snps haplotype | #3 |
adhd rare cnvs | #3 |
caarsss | #3 |
asd ocd groups | #3 |
cpt deficits | #3 |
intron13 | #3 |
md females | #3 |
enigma wgs wgs | #3 |
drd5 marker | #3 |
evidence genetic association | #3 |
large battery | #3 |
firstdegree relatives | #3 |
excess transmission | #3 |
prenatal adversities | #3 |
disorder conduct | #3 |
youths ocd | #3 |
drd4 7 | #3 |
schizophrenia schizotaxia | #3 |
enigma neuroimaging genetics | #3 |
observed age | #3 |
ldx amphetamine | #3 |
drug nicotine | #3 |
stimulants treatment | #3 |
adolescent adhd | #3 |
mtbi studies | #3 |
association confounders | #3 |
13q222 | #3 |
nmu prescription stimulants | #3 |
familial risk factors | #3 |
adult psychiatric outcomes | #3 |
teacher reports | #3 |
adhd wm deficits | #3 |
remittent | #3 |
smoking probands | #3 |
comorbidities adhd | #3 |
sibling trait | #3 |
anxiety behavioral inhibition | #3 |
manic symptoms youth | #3 |
adhd implications | #3 |
asthma adhd | #3 |
smds scz | #3 |
psychopathologic conditions | #3 |
nervous stimulants | #3 |
probands parental | #3 |
interactions schizophrenia | #3 |
predisposition schizophrenia | #3 |
schizoaffective bipolar disorder | #3 |
relationship adhd | #3 |
children adhd diagnosis | #3 |
psychiatric comorbidity adhd | #3 |
dsmiiir diagnosis | #3 |
vulnerability indicators | #3 |
intra‐individual variability | #3 |
comorbidity diagnosis | #3 |
relatives persons | #3 |
learning disabilities adhd | #3 |
abstraction verbal memory | #3 |
n5827 | #3 |
schizophrenic outpatients | #3 |
adolescents mania | #3 |
variance severity | #3 |
social perception skills | #3 |
npl scores | #3 |
comorbidity panic disorder | #3 |
conduct disorder adhd | #3 |
n1777 | #3 |
growth deficits | #3 |
alcohol adhd | #3 |
hyperactivity bipolar | #3 |
adhd mania | #3 |
adhd comorbid conditions | #3 |
common disorders brain | #3 |
familial nature | #3 |
notch4 schizophrenia | #3 |
relatives proband groups | #3 |
adhd combined type | #3 |
emotional dysregulation adhd | #3 |
networks adhd | #3 |
md adhd | #3 |
parents panic | #3 |
non500 | #3 |
brain methylation | #3 |
9rcarriers | #3 |
67e07 | #3 |
adhdpi | #3 |
comt adhd | #3 |
nicotine disorders | #3 |
adhd systematic review | #3 |
“negativity | #3 |
international adhd | #3 |
adhd ptsd | #3 |
adhd presence | #3 |
disabilities male | #3 |
genetics initiative | #3 |
bipolar psychoses | #3 |
anxiety disorders authors | #3 |
substance disorders adhd | #3 |
studies square | #3 |
cigarette smoking children | #3 |
enuresis adhd | #3 |
reln promoter | #3 |
response methylphenidate | #3 |
adhd metaanalysis | #3 |
n2271 | #3 |
dat1 | #3 |
sexdifferentiated effects | #3 |
defined adhd | #3 |
schizotaxia | #3 |
wonderlic personnel test | #3 |
impairment adhd | #3 |
morbidity risk | #3 |
adhd psud | #3 |
chromosome 10q22 | #3 |
nonpsychotic relatives persons | #3 |
tsuang | #3 |
ermph | #3 |
major depression comorbidity | #3 |
htr1e | #3 |
weight effects | #3 |
asrs v11 | #3 |
methylphenidate studies | #3 |
tic disorders adhd | #3 |
parents panic disorder | #3 |
highly heritable disorder | #3 |
adhd pairwise correlations | #3 |
neurological polymorphism | #3 |
oprm1 variants | #3 |
childhood attention‐deficit | #3 |
ptsd adhd | #3 |
z280 | #3 |
candidate gene studies | #3 |
clinically referred adults | #3 |
7repeat allele | #3 |
impulsivity errors | #3 |
genetic receptors serotonin | #3 |
manic symptoms children | #3 |
hyperactivity central | #3 |
risk panic | #3 |
cognition comorbidity | #3 |
disorders conclusions | #3 |
sud youths | #3 |
children vcfsadhd | #3 |
schizophrenia neurocognitive performance | #3 |
bpd rates | #3 |
disease humans interviews | #3 |
cbcl scales | #3 |
mania children | #3 |
inattentive subtype | #3 |
subjects sud | #3 |
sirolimus 12 months | #3 |
resilience score | #3 |
morning school | #3 |
lambdasib | #3 |
ocd groups asd | #3 |
adhd common | #3 |
children mania | #3 |
7 repeat | #3 |
bipolar disease | #3 |
children adhd | #3 |
similarities genetic etiology | #3 |
psychotic behaviour | #3 |
risk factors sud | #3 |
potential gene | #3 |
dmi addh | #3 |
gsprs | #3 |
vcfsadhd | #3 |
deficient emotional | #3 |
relatives bipolar disorder | #3 |
comt promoter | #3 |
n2323 | #3 |
schizophrenia genotype | #3 |
anxiety disorders parents | #3 |
adhd psychiatric comorbidity | #3 |
rs6565113 | #3 |
impact adhd | #3 |
sud offspring | #3 |
girls attention | #3 |
sud children | #3 |
pdd adhd | #3 |
disproportionate impairment | #3 |
adhd stimulant medication | #3 |
hyperactivity attention | #3 |
pairwise correlations disorders | #3 |
longitudinal follow | #3 |
cortical thickness cases | #3 |
temperamental correlates | #3 |
siblings young | #3 |
qtl linkage | #3 |
adhd control | #3 |
adhd emotional | #3 |
deficits height | #3 |
lbw adhd | #3 |
checklist cbcl | #3 |
desr | #3 |
disorder comorbid | #3 |
experienced pain | #3 |
educational deficits | #3 |
simulated workplace laboratory | #3 |
adhd risk | #3 |
atomoxetine response | #3 |
adhd bipolar disorder | #3 |
enigma global neuroscience | #3 |
zakzanis | #3 |
adhd mental disorders | #3 |
metadoxine extended release | #3 |
508e7 | #3 |
adhd data | #3 |
27 risk loci | #3 |
model adhd | #3 |
persistence psychiatric disorders | #3 |
parental substance disorders | #3 |
neuropsychiatric disorders similarities | #3 |
substances symptoms | #3 |
european‐american | #3 |
mania disorders | #3 |
naltrexone methylphenidate | #3 |
control probands relatives | #3 |
syndromatic | #3 |
topic adolescent | #3 |
adhd pharmacotherapy | #4 |
treatment adhd | #4 |
transporter genotypes | #4 |
total score week | #4 |
adhd participants | #4 |
maoa | #4 |
distinct disorder | #4 |
comorbid aggression adhd | #4 |
rs140700 | #4 |
choice adhd | #4 |
rate switching | #4 |
schizophrenia genetic factors | #4 |
adhd youth | #4 |
quantitative phenotype | #4 |
adhd substance abuse | #4 |
suds adolescents | #4 |
pavgrnk000417 | #4 |
adhd pdd | #4 |
4th international meeting | #4 |
4year followup | #4 |
developmental improvement | #4 |
nonoral routes administration | #4 |
vcfs adhd | #4 |
adhd pharmacogenetic studies | #4 |
humans lisdexamfetamine | #4 |
rs1079727 | #4 |
depression parental depression | #4 |
substance disorders suds | #4 |
objective studies | #4 |
subsequent substance disorders | #4 |
cbclaps | #4 |
enrichment adhd | #4 |
disorders comorbidity | #4 |
children comorbid adhd | #4 |
remittent adhd | #4 |
female probands relatives | #4 |
addictive drug | #4 |
impaired intellect | #4 |
comorbidity humans | #4 |
psychiatric gene discoveries | #4 |
adhd status | #4 |
secondary psychotic symptoms | #4 |
reported adhd | #4 |
global neuroscience | #4 |
cbcl | #4 |
cbcljbd phenotype | #4 |
genetic heterogeneity schizophrenia | #4 |
adhd subgroups | #4 |
d4s1644 | #4 |
adhd adulthood | #4 |
enigmaadhd | #4 |
shr ncrl | #4 |
factors substance | #4 |
adhd association | #4 |
snpbased | #4 |
adhd children mph | #4 |
controls basal ganglia | #4 |
angerirritability | #4 |
mts growth | #4 |
psychiatric comorbidity risk | #4 |
pord05 | #4 |
psychiatrically referred | #4 |
risk factors adhd | #4 |
anxiety disorders mdd | #4 |
coordination problems | #4 |
risk gene schizophrenia | #4 |
preterm sample | #4 |
mhlod | #4 |
odd adhd | #4 |
report scale | #4 |
deficits executive functioning | #4 |
families girls | #4 |
metadoxine placebo | #4 |
adhd etiology | #4 |
attention adhd | #4 |
disorder objective | #4 |
hemmings | #4 |
lifetime dimensions | #4 |
tests psychiatric | #4 |
asd mood disorders | #4 |
disorders neuropsychological | #4 |
vcfs sample | #4 |
poor motor performance | #4 |
bpd sud bpd | #4 |
selenbp1 schizophrenia | #4 |
comorbid attention | #4 |
adhd brain regions | #4 |
rs3916971 | #4 |
sud bpd sud | #4 |
subthreshold | #4 |
rs3785143 | #4 |
child behavior checklist | #4 |
adhd individuals | #4 |
panic disorder pregnancy | #4 |
adhd md | #4 |
adhd control children | #4 |
neuropsychological performance schizophrenia | #4 |
treatment stimulant medication | #4 |
d4s2361 | #4 |
psc35 | #4 |
adhd symptom | #4 |
comorbid psychiatric | #4 |
rates psychiatric | #4 |
homogeneous subtypes | #4 |
support mechanism | #4 |
receiver operator characteristic | #4 |
adderall methylphenidate | #4 |
rutters indicators | #4 |
psud | #4 |
height deficits | #4 |
hypescheme | #4 |
adhd neuropsychological performance | #4 |
time reproduction | #4 |
openlabel studies | #4 |
aggregation adhd | #4 |
adolescent outcome | #4 |
phenotypes adhd | #4 |
subjects schizotaxia | #4 |
rels | #4 |
intelligence snps | #4 |
strattera | #4 |
familial vulnerability | #4 |
adhd controls | #4 |
treatment seeking patients | #4 |
rs3916968 | #4 |
notch4 locus | #4 |
sd133 | #4 |
findings risk | #4 |
psychiatrically referred youth | #4 |
vulnerability schizophrenia | #4 |
stimulantnaïve | #4 |
adhd impairments | #4 |
presence adhd | #4 |
lgi age | #4 |
independent transmission | #4 |
increased neural responses | #4 |
handedness schizotypy | #4 |
risk variants adhd | #4 |
risk factors bpd | #4 |
jbd | #4 |
inhibition anxiety | #4 |
roh risk | #4 |
reward dysfunction | #4 |
rutter | #4 |
primary substance abuse | #4 |
scores adhd | #4 |
onset adhd | #4 |
safren | #4 |
achievement goal orientation | #4 |
snps intelligence | #4 |
adhd reported | #4 |
disease genome humans | #4 |
46222 | #4 |
inattentive adhd | #4 |
parental panic | #4 |
neuropsychoanalytic | #4 |
metaanalyzes | #4 |
adolescent years | #4 |
health female | #4 |
offspring sud | #4 |
gxr adhd | #4 |
image sample | #4 |
behavior checklist | #4 |
acting formulations | #4 |
adhd based | #4 |
fmri replication | #4 |
functioning adhd | #4 |
disorders panic | #4 |
boys higher prevalence | #4 |
expected height | #4 |
quantitative models | #4 |
pediatric mania | #4 |
17q111q12 | #4 |
parents bpd | #4 |
differences adults | #4 |
gender children | #4 |
bpd sud patients | #4 |
maternal smoking alcohol | #4 |
bipolar disorder linkage | #4 |
growing literature | #4 |
adults | #4 |
motor coordination problems | #4 |
reported findings | #4 |
chinese sample | #4 |
md individuals | #4 |
treatment adult adhd | #4 |
executive function deficits | #4 |
relatives normal controls | #4 |
relatives controls | #4 |
anxiety disorders offspring | #4 |
disorders attention | #4 |
behavioral inhibition children | #5 |
adolescent alleles | #5 |
pathways association | #5 |
referred children | #5 |
function adhd | #5 |
d22s683 | #5 |
psychiatric correlates | #5 |
female individuals | #5 |
wcst scores | #5 |
schizophrenia palau | #5 |
hyperactivity caregivers | #5 |
desistent | #5 |
desipramine placebo | #5 |
combined subtype | #5 |
risk factors schizophrenia | #5 |
kiddieschedule | #5 |
large collaborative study | #5 |
2nd cohort | #5 |
onset criterion | #5 |
dsm age | #5 |
scale adhd | #5 |
nt5dc1 | #5 |
cbcl data | #5 |
proband risk | #5 |
maternal reports | #5 |
familial subtypes | #5 |
disorder anxiety | #5 |
report screening | #5 |
checklist child | #5 |
auditory vigilance | #5 |
parents psychiatric | #5 |
youth vcfs | #5 |
adhdlike symptoms | #5 |
hyperactivity clinical trials | #5 |
torture review | #5 |
cardinal symptom | #5 |
disorder rating | #5 |
adhd adult | #5 |
bipolar disorder pedigrees | #5 |
3q13 | #5 |
memantine hydrochloride | #5 |
comorbid disorders | #5 |
impaired parents humans | #5 |
zmynd17 | #5 |
adhd tic disorders | #5 |
relatives female probands | #5 |
iiv adhd | #5 |
kuntsi | #5 |
major depression parents | #5 |
psychiatric disorders study | #5 |
mania adhd | #5 |
sms intervention | #5 |
effects adhd | #5 |
xr adults | #5 |
prembr | #5 |
intellectually capable adults | #5 |
child child behavior | #5 |
risk relatives | #5 |
children ldx | #5 |
panic disorder parents | #5 |
diagnosis mania | #5 |
screener | #5 |
adhd treated | #5 |
serum neuroleptic | #5 |
children dbds | #5 |
shared haplotypes | #5 |
oppositional defiant disorder | #5 |
nonaffected siblings | #5 |
adhd cases | #5 |
familial risk adhd | #5 |
psychosis velocardiofacial syndrome | #5 |
adhd youths | #5 |
disorder parents | #5 |
initial responsiveness | #5 |
humans interview | #5 |
social disability | #5 |
impairment baseline | #5 |
pdd subjects | #5 |
adhd inattentive type | #5 |
interview psychological | #5 |
highly heritable | #5 |
adhd bupropion | #5 |
grubb | #5 |
risk anxiety | #5 |
adhd response | #5 |
familial distribution | #5 |
pleiotropic effects disorders | #5 |
bipolar disorder bpd | #5 |
adults adult | #5 |
referred sample | #5 |
organization adult | #5 |
aagc | #5 |
elevated rates | #5 |
disorder sud | #5 |
mothers anxiety disorders | #5 |
rs1799836 | #5 |
anxiety disorders anx | #5 |
inattentive symptoms | #5 |
multivariate endophenotypes | #5 |
lifetime impact | #5 |
symptoms hyperactivity | #5 |
neuropsychiatric comorbidity | #5 |
methylphenidate adults | #5 |
pdmd | #5 |
disorders follow | #5 |
height weight | #5 |
criteria schizotaxia | #5 |
palauan | #5 |
neuropsychological risk | #5 |
adult attention | #5 |
adhd ld | #5 |
tass | #5 |
depression panic disorder | #5 |
impairment survey | #5 |
disorder genetic | #5 |
clinical obesity | #5 |
mood disorders asd | #5 |
boys attention | #5 |
adult probands | #5 |
parental sud | #5 |
sex adhd | #5 |
referred youths | #5 |
asrs screener | #5 |
ncrl rats | #5 |
resilience project | #5 |
study genetic factors | #5 |
psychosis scale | #5 |
disorders psychiatric | #5 |
puwma | #5 |
dopamine risk | #5 |
inhibited children | #5 |
ascertainment source | #5 |
hechtman | #5 |
oosterlaan | #5 |
sud | #5 |
3 probands | #5 |
conventional medications | #5 |
adhd nonaffected siblings | #5 |
ppp3cc schizophrenia | #5 |
genetic linkage schizophrenia | #5 |
severe scores | #5 |
adhd comorbid anxiety | #5 |
growth dysregulation | #5 |
parental adhd | #5 |
etiopathologies | #5 |
nonmedical nmu | #5 |
adolescence adhd | #5 |
unipolar mdd | #5 |
year prospective | #5 |
wm performance patients | #6 |
cpg sites methylation | #6 |
total gray matter | #6 |
clinical scales | #6 |
dnajc9 | #6 |
schizophrenia premorbid | #6 |
genetic linkage genome | #6 |
loci autism | #6 |
symptoms disorder | #6 |
schizophrenia deficit | #6 |
disorder combined | #6 |
parents major | #6 |
scales psychometrics | #6 |
facial memory | #6 |
schizophrenic probands | #6 |
liability schizophrenia | #6 |
adhd mental retardation | #6 |
referred adults | #6 |
disorders relatives | #6 |
oppositional defiant | #6 |
hyperactivity disease models | #6 |
psychoactive substance | #6 |
xp114p113 | #6 |
chromosome 15 locus | #6 |
child delayed | #6 |
druggable genome | #6 |
t518 | #6 |
year recall | #6 |
combined condition | #6 |
referred children adolescents | #6 |
premorbid cognitive ability | #6 |
symptoms adhd | #6 |
psychiatric disorders prss | #6 |
ppp3cb | #6 |
schizophrenia spectrum schizophrenia | #6 |
differences cortical thickness | #6 |
neuropsychological functioning | #6 |
normal sexual dimorphism | #6 |
bpd comorbid | #6 |
niacin schizophrenia | #6 |
oceanic palau | #6 |
hyperactivity child chromosomes | #6 |
behavioral inhibition | #6 |
psychiatric | #6 |
driving simulation | #6 |
adhd firstdegree relatives | #6 |
adhd women | #6 |
pediatric bipolar | #6 |
gxr efficacy | #6 |
stimulant prescription | #6 |
benefitrisk ratio | #6 |
parental major depression | #6 |
bpdsud | #6 |
seidman | #6 |
concurrent validation | #6 |
pseudocontrols | #6 |
dopamine transporter gene | #6 |
dsm iii | #6 |
relatives probands | #6 |
value09 | #6 |
adhd children adults | #6 |
nmu | #6 |
environmental adversity | #6 |
ascertained | #6 |
combined subtypes | #6 |
hierarchical factor model | #6 |
mixed amphetamine | #6 |
adhd life | #6 |
taan | #6 |
anxiety disorder relatives | #6 |
cbcljbd | #6 |
objective marker | #6 |
risk attention | #6 |
genome‐wide | #6 |
followup studies | #6 |
placebo response response | #6 |
adhd increased risk | #6 |
interpreting estimates | #6 |
adhd genetic factors | #6 |
vulnerability indicator | #6 |
tmcq | #6 |
adhdia | #6 |
pediatric mood disorders | #6 |
enigma wgs | #6 |
140 children | #6 |
males adhd | #6 |
familial loadings | #6 |
irmph | #6 |
t515 | #6 |
life adults | #6 |
nhe inhibitors | #6 |
pavgrnk | #6 |
fspd | #6 |
teenage parenthood | #6 |
male odds | #6 |
altered neural connectivity | #6 |
4634 | #6 |
risk sud | #6 |
nonparanoid schizophrenia | #6 |
p1e04 | #6 |
association studies schizophrenia | #6 |
children relatives | #6 |
literature efficacy | #6 |
females adhd | #6 |
adhd tic | #6 |
cognitive impairments adhd | #6 |
individual alleles | #6 |
pediatric bpd | #6 |
unfamiliar situations | #6 |
cognition adults | #6 |
large heterogeneous | #6 |
clinical features children | #6 |
prevalence adult adhd | #6 |
psychopathology children | #6 |
disorders adolescent | #6 |
bpd controls | #6 |
depression panic | #6 |
neuroleptic activity | #6 |
stimulant treatment children | #6 |
paternal age schizophrenia | #6 |
groups adults | #6 |
schizophrenia g72 | #6 |
adhd mood disorders | #6 |
adults disorder | #6 |
adhd compared | #6 |
specific predictor | #6 |
maniclike symptoms | #6 |
prior stimulant treatment | #6 |
adhd variability | #6 |
genetic child | #6 |
downward extension | #6 |
criteria adhd | #6 |
parents prevalence | #7 |
adhd improvement | #7 |
mph adhd adults | #7 |
adhdct | #7 |
conduct disorder girls | #7 |
pediatric major depression | #7 |
adhd authors | #7 |
chromosome workshop | #7 |
snap25 adhd | #7 |
children tourettes syndrome | #7 |
boys adhd | #7 |
nalysis | #7 |
association cdh13 | #7 |
long repeats | #7 |
candidate gene schizophrenia | #7 |
markov chain analysis | #7 |
sensorimotor timing | #7 |
statistical measure | #7 |
disorder substance | #7 |
odd | #7 |
asd asd youth | #7 |
teachers boys | #7 |
swedish registry data | #7 |
pdag mdd | #7 |
relatives schizophrenic patients | #7 |
adhd boys girls | #7 |
parents psychiatric disorders | #7 |
flush response | #7 |
haplotype schizophrenia | #7 |
myosin5b | #7 |
attention task | #7 |
seeking substance | #7 |
dimensional measures | #7 |
polygenic scores adhd | #7 |
adhd symptoms association | #7 |
nrp104 | #7 |
hraff | #7 |
bipolar unipolar disorders | #7 |
relatives risk | #7 |
authors goal | #7 |
tomoxetine | #7 |
ldx treatment | #7 |
pdqr | #7 |
adhd emotional dysregulation | #7 |
systematic chart review | #7 |
locus haplotypes | #7 |
methylphenidate therapy | #7 |
asd youth | #7 |
child impaired | #7 |
exon15 | #7 |
childhood disorder | #7 |
outpatient child | #7 |
saica | #7 |
exome chip analyses | #7 |
adhd criteria | #7 |
measures adhd | #7 |
skin flush response | #7 |
wonderlic | #7 |
adhd overweight obesity | #7 |
development adhd | #7 |
qlesqsf | #7 |
palauans | #7 |
pmee | #7 |
children bpd | #7 |
methylomics | #7 |
drd5 | #7 |
genome‐wide association | #7 |
adhd asrs | #7 |
persistence anxiety disorders | #7 |
mph adhd | #7 |
members schizophrenia | #7 |
velo‐cardio‐facial | #7 |
confusability | #7 |
parent reports | #7 |
highrisk siblings | #7 |
adhd persistence | #7 |
implicating | #7 |
spn812 | #7 |
ancestry attention | #7 |
mdd pdag | #7 |
nmu prescription | #7 |
coming years | #7 |
6 psychiatric disorders | #7 |
children learning disorders | #7 |
n1031 | #7 |
neuroimage study | #7 |
adhd sud sud | #7 |
kgas | #7 |
adhd symptoms | #7 |
adhd substance disorders | #7 |
studies dopamine | #7 |
idir | #7 |
neurocognitive performances | #7 |
adhdrs | #7 |
combined type adhd | #7 |
prevention schizophrenia | #7 |
disorders probands | #7 |
controls probands | #7 |
dependence rates | #7 |
hyperactivity brain | #7 |
unaffected siblings adhd | #8 |
avoidant disorder | #8 |
probands risk | #8 |
polygenic associations | #8 |
pliszka | #8 |
affairs cooperative | #8 |
negative symptoms scale | #8 |
subjects children | #8 |
mwq | #8 |
agreement measures | #8 |
cadhd | #8 |
symptoms behaviors | #8 |
adhd remission | #8 |
behavioral inhibition anxiety | #8 |
schizophrenia polymorphisms | #8 |
rs3916965 | #8 |
adhdcd | #8 |
symptoms impairment | #8 |
male multifactorial inheritance | #8 |
10q223 | #8 |
biological relatives | #8 |
offspring trios | #8 |
metaanalysis schizophrenia | #8 |
euphoria | #8 |
analysis association | #8 |
attention | #8 |
volumetric reductions | #8 |
adhd stimulant | #8 |
diagnosed adhd | #8 |
pempirical | #8 |
bpd disorders | #8 |
stimulanttreated | #8 |
notch4 | #8 |
adhdhi | #8 |
adhd associations | #8 |
familial aggregation adhd | #8 |
substantial evidence | #8 |
prescription stimulant | #8 |
familybased association study | #8 |
shared familial effects | #8 |
studies provide | #8 |
nonverbal social | #8 |
promising directions | #8 |
impulsivity adhd | #8 |
participants adhd | #8 |
dimesylate ldx | #8 |
disease humans polymorphism | #8 |
link adhd | #8 |
impaired motor performance | #8 |
sample youth | #8 |
human aggression | #8 |
adhd unaffected | #8 |
rs3916966 | #8 |
adhd manic symptoms | #8 |
abbreviated questionnaire | #8 |
biederman | #8 |
multigenerational pedigree | #8 |
disorders families | #8 |
presence autistic traits | #8 |
psychiatric genomics | #8 |
treatment sirolimus | #8 |
nonpsychotic | #8 |
adhd adolescence | #8 |
adhd symptom scores | #8 |
gender effects | #8 |
ordered subsets | #8 |
n1314 | #8 |
attention deficit adhd | #8 |
adhd boys | #8 |
pvalues005 | #8 |
behavioral inhibition risk | #8 |
disorder probands | #8 |
controls relatives | #8 |
hemideletion | #8 |
adhd inattentive | #8 |
child diagnostic | #8 |
childhood mania | #8 |
autistic traits children | #8 |
adhd dat1 | #8 |
treatment lead | #8 |
behavior attention | #8 |
diagnosis major depression | #8 |
mph adults | #8 |
control adhd | #8 |
differential utility | #8 |
crossover comparison | #8 |
indicators schizophrenia | #8 |
therapeutic dilemmas | #8 |
adhd rtv | #8 |
onset bpd | #8 |
aversion adhd | #8 |
chromosome schizophrenia | #8 |
schizophrenia members | #8 |
disorders baseline | #8 |
hhrr | #9 |
nonparanoids | #9 |
rs685012 | #9 |
snp7 | #9 |
adhd enuresis | #9 |
childhood psychosis | #9 |
alzheimer disease schizophrenia | #9 |
depression offspring | #9 |
netherlands twin registry | #9 |
stimulant medication | #9 |
disruptive behavior disorders | #9 |
serotonin gene polymorphisms | #9 |
adderall | #9 |
g×s interaction disorders | #9 |
rasd2 | #9 |
orosmph irmph | #9 |
moderate sensitivity | #9 |
etiologically | #9 |
adhdi | #9 |
aisrs | #9 |
schizotaxic | #9 |
nonreplications | #9 |
adult symptoms | #9 |
children assessed | #9 |
adhd article | #9 |
sustained attention schizophrenia | #9 |
ads individuals | #9 |
adhd loci | #9 |
comorbidity female | #9 |
extendedrelease methylphenidate | #9 |
ecpbhs | #9 |
comparison girls | #9 |
ldps | #9 |
serotonin genes | #9 |
endophenotypic | #9 |
festschrift | #9 |
taiwanese families | #9 |
39 datasets | #9 |
proband groups | #9 |
lag sequential analysis | #9 |
mdd youth | #9 |
rpdr | #9 |
symptoms mania | #9 |
n41 | #9 |
adult report | #9 |
hyperactivity humans | #9 |
haplotype snps | #9 |
nuremberg code | #9 |
neuropsychologic function | #9 |
dao gene | #9 |
male nuclear | #9 |
diagnostic efficiency | #9 |
disorders sex interaction | #9 |
schizophrenia resilience | #9 |
pregnancy depression | #9 |
gwas psychiatric disorders | #9 |
substantial risk | #9 |
blindly | #9 |
hum genet | #9 |
sud bipolar disorder | #9 |
25e07 | #9 |
addh | #9 |
deficit disruptive | #9 |
genes risk factors | #9 |
adhd healthy | #9 |
inattentive | #9 |
hyperactivity automobile | #9 |
subtypes adhd | #9 |
normal sexual | #10 |
risk md | #10 |
reassessed | #10 |
untreated adhd | #10 |
association death | #10 |
anxiety disorders children | #10 |
shared neurobiology | #10 |
genetic vulnerability schizophrenia | #10 |
pthreshold | #10 |
parent‐of‐origin effects | #10 |
comorbidity depressive | #10 |
evidence genetic | #10 |
adult years | #10 |
childhood adhd symptoms | #10 |
irmph orosmph | #10 |
case identification | #10 |
caadid | #10 |
genes disorders | #10 |
asd tourette syndrome | #10 |
new specialty | #10 |
groups boys | #10 |
noninhibited | #10 |
adhd childhood | #10 |
kruglyak | #10 |
adulthood association | #10 |
comorbidity | #10 |
sleep problems adhd | #10 |
genetics network | #10 |
slod | #10 |
preteen | #10 |
stimulants child | #10 |
systematic qualitative review | #10 |
ascertainment methods | #10 |
probands bpd | #10 |
small effects | #10 |
bipolar disorder probands | #10 |
psychiatric clinic | #10 |
adhd quality | #10 |
4th | #10 |
adhd unaffected siblings | #10 |
sexual dimorphisms | #10 |
deficits adhd | #10 |
comorbid odd | #10 |
rates abuse | #10 |
adhd substance disorder | #10 |
rorb | #10 |
diminished risk | #10 |
severity adhd | #10 |
preschool depressive | #10 |
association dat1 | #10 |
adhd sud | #10 |
nonpharmacologic treatments | #10 |
young adult outcome | #10 |
psychiatric genetic studies | #10 |
nephews | #10 |
aged attention | #10 |
panic depression | #10 |
dms1 | #10 |
linkage analyses | #10 |
conduct disorder | #10 |
cbclap | #10 |
stimulants humans | #10 |
disorder age | #10 |
d4 receptor gene | #10 |
gwas adhd | #10 |
adhd difficulties | #10 |
drd4 | #10 |
comorbid bpd | #10 |
image project | #10 |
amphetamine salts | #10 |
release methylphenidate | #11 |
attention deficit disorder | #11 |
diagnosis adults | #11 |
adhd intellectual disability | #11 |
differences parents | #11 |
maternal antenatal anxiety | #11 |
vcfs | #11 |
fbatpc | #11 |
adolescents adhd | #11 |
multiple domains | #11 |
shr model | #11 |
hyperactivity child cross | #11 |
offspring bipolar parents | #11 |
agoraphobia anxiety | #11 |
adhd onset | #11 |
differences adhd | #11 |
lisdexamfetamine ldx | #11 |
adhd female humans | #11 |
dopamine d5 receptors | #11 |
achievement adolescent | #11 |
disorder pedigrees | #11 |
growth delays | #11 |
inhibition adhd | #11 |
adhd substance | #11 |
disorders mothers | #11 |
etiology pathophysiology | #11 |
markers adhd | #11 |
children bipolar | #11 |
rora rorb | #11 |
real progress | #11 |
ldx placebo | #11 |
inattentive type | #11 |
cardinal symptoms | #11 |
hydrochloride attention | #11 |
youth bpd | #11 |
informativeness | #11 |
preschool depressive disorder | #11 |
remission adhd | #11 |
nosologists | #11 |
adhd time | #11 |
neuropsychological test scores | #11 |
symptom subtype | #11 |
nonadhd controls | #11 |
shared familial | #11 |
study perspective | #11 |
juvenile mania | #11 |
disorders | #11 |
adhd psychopathology | #11 |
disease humans schizophrenia | #11 |
n136 | #11 |
female relatives | #11 |
deficits schizophrenia patients | #11 |
dimesylate | #11 |
gene adhd | #11 |
adult relatives | #11 |
rs1137070 | #11 |
psychiatric disorders youth | #11 |
prodromal psychosis | #11 |
defiant disorder | #11 |
paternal smoking | #11 |
serotonin genetic receptor | #11 |
panic disorder comorbidity | #11 |
4372 | #11 |
children addh | #11 |
pediatric bipolar disorder | #11 |
comorbidity patterns | #11 |
polymorphism 5 | #11 |
differentiated genetic | #11 |
studies mtbi | #11 |
major depression adhd | #11 |
familybased association test | #11 |
ppp3cc | #11 |
cutraits | #11 |
effects genes | #11 |
sample adults | #11 |
thalamic activation | #12 |
obesity risk alleles | #12 |
adolescent adult age | #12 |
hawi | #12 |
convergent functional | #12 |
sample consisted | #12 |
probands siblings | #12 |
perceived motor competence | #12 |
youths bpd | #12 |
systematized | #12 |
juvenile bipolar | #12 |
sud adhd | #12 |
common disorders | #12 |
metan | #12 |
symptom rating | #12 |
nhe9 | #12 |
sexually dimorphic effects | #12 |
kappa coefficients | #12 |
ksadse | #12 |
assessment adhd | #12 |
n1397 | #12 |
obesity adhd | #12 |
girls relationship | #12 |
adhd offspring | #12 |
impaired parents child | #12 |
40–48 | #12 |
effects time | #12 |
nonoral | #12 |
onelevel | #12 |
impulsivity children | #12 |
unaffected sibs | #12 |
deficits attention | #12 |
comorbidity diagnostic | #12 |
defiant | #12 |
dat1 polymorphism | #12 |
adhd age | #12 |
adhd symptoms adults | #12 |
psychiatric clinics | #12 |
impaired parents | #12 |
neurocognitive measures | #12 |
multiplex schizophrenia | #12 |
rs778293 | #12 |
sec23ip | #12 |
disorder subjects | #12 |
digital treatment | #12 |
sud patients adhd | #12 |
treatment attention | #12 |
striatal sensitivity | #12 |
functional impairments | #12 |
pleiotropic mechanisms | #12 |
adult outcome | #12 |
stimulant medication children | #12 |
treatment paliperidone | #12 |
disorder adult | #12 |
cbcl children | #12 |
genes methylation | #12 |
early psychosis study | #12 |
psychotic behavior | #12 |
psychotic mood disorders | #12 |
comorbid disorder | #12 |
rs947267 | #12 |
studies relatives | #12 |
variable age | #12 |
epilepsy mothers | #12 |
adhd core symptoms | #12 |
twins humans models | #12 |
psychiatric genetics | #12 |
covid19 restrictions children | #12 |
salts extended | #12 |
amfetamine | #12 |
cnvs risk | #12 |
adhd dopamine | #12 |
scales treatment | #12 |
common psychiatric | #12 |
lossavoidance | #12 |
unaffected siblings individuals | #12 |
response atomoxetine | #12 |
test wcst | #12 |
psychometric measure | #13 |
specific hypotheses | #13 |
cognitive impulsivity | #13 |
morbidity risks | #13 |
psychotic mood | #13 |
symptoms attention | #13 |
psychiatric risk | #13 |
diagnostic concepts | #13 |
adhd alterations | #13 |
persistence remission | #13 |
adverseevents | #13 |
iiv | #13 |
chi12 | #13 |
response inhibition adolescents | #13 |
necrotic death | #13 |
transdermal methylphenidate | #13 |
disorder childhood | #13 |
taiwanese sample | #13 |
colorado springs | #13 |
robust effects | #13 |
disorder youth | #13 |
methods subjects | #13 |
risk parents | #13 |
disorders child | #13 |
label studies | #13 |
adhd alcohol | #13 |
girls | #13 |
diagnostic threshold | #13 |
adderall mph | #13 |
risk mood | #13 |
bpd offspring | #13 |
disorders sud | #13 |
longallele | #13 |
pair 6 chromosomes | #13 |
scale studies | #13 |
male samples | #13 |
nonoral routes | #13 |
genomewide significance | #13 |
ravg | #13 |
velocardiofacial syndrome vcfs | #13 |
environment adolescent | #13 |
adhd cognitive | #13 |
permutation testing | #13 |
humans methylphenidate | #13 |
pkcm | #13 |
rates comorbidity | #13 |
adhdodd | #13 |
adhd diagnosis | #13 |
convergent functional genomics | #13 |
114 years | #13 |
weight bmi | #13 |
overanxious | #13 |
studies bipolar | #13 |
familial risk schizophrenia | #13 |
late onset | #13 |
psychometrics reproducibility | #13 |
differential heritability | #14 |
associations adhd | #14 |
common disorder | #14 |
selfcontained | #14 |
familial disorder | #14 |
factors schizophrenia | #14 |
lphn3 adhd | #14 |
geschwind | #14 |
comorbid condition | #14 |
sud patients | #14 |
children criteria | #14 |
quetiapine bipolar disorder | #14 |
adhd phenotype | #14 |
siblings cases | #14 |
stimulant abuse | #14 |
early precursors | #14 |
cautiously | #14 |
bipolar probands | #14 |
suds | #14 |
n643 | #14 |
subcortical brain volume | #14 |
mph adderall | #14 |
wraadds | #14 |
attention executive | #14 |
social school | #14 |
mixed amphetamine salts | #14 |
ocd scz | #14 |
lisdexamfetamine dimesylate ldx | #14 |
disorders comorbid | #14 |
teachers reports | #14 |
aadhd | #14 |
worldwide prevalence | #14 |
children bipolar disorder | #14 |
diagnosis mdd | #14 |
genetic studies schizophrenia | #14 |
children stimulants | #14 |
siblings probands | #14 |
emotional impulsivity | #14 |
unaffected siblings controls | #14 |
economic psychology | #14 |
adhd symptoms adulthood | #14 |
nimh genetics | #14 |
relatives male probands | #14 |
adhd brain | #14 |
hillside | #14 |
disorder child | #14 |
disorder odd | #14 |
symptoms psychiatric disorders | #14 |
cnvs park2 | #14 |
older adults adhd | #14 |
studies adults | #14 |
prss mdd | #14 |
genes schizophrenia | #14 |
association schizophrenia | #15 |
executive function theory | #15 |
zranb2 | #15 |
schizophrenia families | #15 |
bipolar schizoaffective disorder | #15 |
disorder evidence | #15 |
mphmlr | #15 |
wfirsp | #15 |
adults substance disorders | #15 |
adhd disorders | #15 |
poor perception | #15 |
sackett | #15 |
paediatric bipolar disorder | #15 |
disord | #15 |
interaction genotype | #15 |
velocardiofacial | #15 |
adhd functional connectivity | #15 |
nhsd | #15 |
seconddegree relatives | #15 |
adhd performance | #15 |
methylation gene expression | #15 |
d10s1423 | #15 |
rs2652511 | #15 |
behavior disorders | #15 |
metabolic syndrome obesity | #15 |
adhd treatment | #15 |
risk substance | #15 |
49 children | #15 |
snps methylation | #15 |
substance disorder patients | #15 |
adhd study | #15 |
symptoms adulthood | #15 |
ocd comorbid adhd | #15 |
card sorting | #15 |
gxr children | #15 |
study design features | #15 |
healthy comparison subjects | #15 |
persons schizophrenia | #15 |
cbclpbd | #15 |
agents attention | #15 |
tests psychomotor | #15 |
daily living administration | #15 |
male relatives | #15 |
psychiatric interviews | #15 |
chi2 | #15 |
treatment xr | #15 |
adhd diagnostic | #15 |
4669 | #15 |
diagnostic interviews | #15 |
male mood | #15 |
pregnancy risk factor | #15 |
asd mdd | #15 |
genderdifferences | #15 |
symptom count | #15 |
prodromal symptoms psychosis | #15 |
multiple test | #16 |
control participants participants | #16 |
brainbody | #16 |
scz risk | #16 |
factual factor analysis | #16 |
longitudinal assessments | #16 |
“difficulty | #16 |
familial relationship | #16 |
cprsr | #16 |
drug disorder | #16 |
n424 | #16 |
dbds | #16 |
dexedrine | #16 |
adhd symptom severity | #16 |
linkage findings | #16 |
geneenvironment interaction | #16 |
adhd anxiety symptoms | #16 |
youths adhd | #16 |
onset anticipation | #16 |
risk psychotic disorders | #16 |
delayed action | #16 |
growth children | #16 |
pervasive developmental disorder | #16 |
special classes | #16 |
parents anxiety disorders | #16 |
hyperkinetic disorders | #16 |
adhd obesity | #16 |
ntac | #16 |
regional cortical thickness | #16 |
adhd diagnoses | #16 |
rdoc framework | #16 |
informant assessment | #16 |
factors siblings | #17 |
prospective follow | #17 |
accn2 | #17 |
persistent adhd | #17 |
pediatric samples | #17 |
asd ocd | #17 |
hyperactivity attitude | #17 |
psychology schizotypal | #17 |
combined type | #17 |
parents adhd | #17 |
relation adhd | #17 |
schizophrenia psychosis | #17 |
rbfox1 | #17 |
samples children | #17 |
neuropsychiatric evaluation | #17 |
5071 | #17 |
association markers | #17 |
pediatric disorder | #17 |
larger sample | #17 |
mania | #17 |
association scan | #17 |
random forest regression | #17 |
prevalence adhd | #17 |
method participants | #17 |
condfdr | #17 |
adulthood adhd | #17 |
childhood predictors | #17 |
multiple anxiety disorders | #17 |
nonparametric linkage | #17 |
assessment positive symptoms | #17 |
driving behaviors | #17 |
response inhibition network | #17 |
resultsfirst | #17 |
study adhd | #17 |
studies psychiatric | #17 |
a161t | #17 |
ocd age | #17 |
depression md | #17 |
young offspring | #17 |
bipolar disorder subjects | #17 |
medication type | #17 |
diagnostic statistical | #17 |
substance disorders sud | #17 |
disability adhd | #17 |
ldx children | #17 |
considerable overlap | #17 |
4286 | #18 |
stimulant | #18 |
prolonged therapy | #18 |
lisdexamfetamine dimesylate | #18 |
adhd sud patients | #18 |
marijuana age | #18 |
transporter gene | #18 |
bipolar major | #18 |
kcnj4 | #18 |
adhd severity | #18 |
operationalized | #18 |
children vcfs | #18 |
psuds | #18 |
primary substance | #18 |
childhood traumas | #18 |
risk disorders | #18 |
poor tolerability | #18 |
neuropsychologic | #18 |
low dose naltrexone | #18 |
potential contributor | #18 |
schizophrenia patients relatives | #18 |
minisatellite repeats | #18 |
single nucleotide severity | #18 |
adhd groups | #18 |
dcdq | #18 |
linkage regions | #18 |
bipolar choice trial | #18 |
hrr 95 | #18 |
adhd cannabis | #18 |
unemotionality | #18 |
fullsiblings | #18 |
relatives control subjects | #18 |
conduct disorder children | #18 |
symptom overlap | #18 |
schizophrenia dtnbp1 | #18 |
preschool diagnostic | #18 |
meet criteria | #18 |
illness twins | #18 |
anxiety mdd | #18 |
depression genetic risk | #18 |
behavior scale | #18 |
unaffected siblings | #18 |
action preparations | #19 |
symptoms adolescent | #19 |
substance adhd | #19 |
euphoric effects | #19 |
adolescent age onset | #19 |
assessing outcome | #19 |
comorbidity rates | #19 |
improvement symptoms | #19 |
lod1 | #19 |
nature nurture | #19 |
casecontrol sample | #19 |
hyperconnectivity | #19 |
adhd neurodevelopmental | #19 |
mcgue | #19 |
verbal memory task | #19 |
mental health human | #19 |
familial transmission | #19 |
psychosocial features | #19 |
addicted patients | #19 |
disconfirmations | #19 |
candidate loci | #19 |
adhd young adults | #19 |
scz ocd | #19 |
adolescent age | #19 |
disorders adults | #19 |
rs3918342 | #19 |
medication trials | #19 |
neuropsychologically | #20 |
humanhap550v3 | #20 |
biological families | #20 |
depression adhd | #20 |
schizophrenia attention | #20 |
transmission ratio distortion | #20 |
ratings adhd | #20 |
dicap | #20 |
notch4 gene | #20 |
manual mental | #20 |
neuropsychological function | #20 |
disorders polymorphism | #20 |
mflynn | #20 |
linkage scans | #20 |
parent origin | #20 |
adolescent | #20 |
pedigree selection | #20 |
human ortholog | #20 |
parents risk | #20 |
response curve | #20 |
outcome attention | #20 |
sibpair | #20 |
slc6a2 | #20 |
gsma | #20 |
kiddie | #20 |
illness female humans | #20 |
nonpsychotic siblings | #20 |
deficits children | #20 |
prenatal exposure nicotine | #20 |
inhibition children | #20 |
rbfox1 gene | #20 |
neuroleptic dose | #20 |
controlled pilot study | #20 |
children comorbid | #21 |
monoamine oxidase maoa | #21 |
schizophrenia disease humans | #21 |
male probands | #21 |
palau | #21 |
prenatal exposure alcohol | #21 |
treatment growth | #21 |
genehunterplus | #21 |
risk offspring | #21 |
agler | #21 |
methods age | #21 |
schizophrenia taiwan | #21 |
11year followup | #21 |
children pdd | #21 |
childhood conduct disorder | #21 |
schizophrenia united | #21 |
bipolar pedigrees | #21 |
schizotypals | #21 |
prospective longitudinal | #21 |
cacng2 | #21 |
rat shr | #21 |
comorbid adhd | #21 |
humans linkage | #21 |
gender comparisons | #21 |
prescription stimulants | #21 |
psychiatric symptoms patients | #21 |
chronic tics | #21 |
sodium hydrogen exchanger | #21 |
motor problems | #21 |
rs778294 | #21 |
life enjoyment | #21 |
linkage chromosomes | #21 |
prevalent cases | #21 |
genetic phenotype | #22 |
association prs | #22 |
syndrome vcfs | #22 |
10p | #22 |
adhd stimulants | #22 |
preliminary reliability | #22 |
neurocognitive performance schizophrenia | #22 |
depression treatment patients | #22 |
polygenic overlap | #22 |
pre‐school | #22 |
overtransmission | #22 |
bpd subjects | #22 |
partial replication | #22 |
adderall xr | #22 |
adhd rating scale | #22 |
study methodology | #22 |
amphetamine methylphenidate | #22 |
controls | #22 |
disorders major | #22 |
6 disorders | #22 |
youth bipolar | #22 |
diagnostic interview | #22 |
stimulants children | #22 |
neuropsychological profiles | #22 |
adhd impulsivity | #22 |
disruptive | #22 |
rg022 | #22 |
familiality | #22 |
schizophrenia pgc | #22 |
adhd susceptibility | #22 |
niacin skin | #22 |
adhd anxiety | #22 |
ldx | #22 |
amygdala structure | #22 |
youth mdd | #22 |
children attention | #22 |
n449 | #23 |
kotkin | #23 |
disequilibrium male | #23 |
rs464049 | #23 |
mdd anxiety disorders | #23 |
anxious mothers | #23 |
phenotype definition | #23 |
scq asd | #23 |
asd scq | #23 |
male individuals | #23 |
genetic investigation | #23 |
comprehensively | #23 |
risk studies | #23 |
adolescents bpd | #23 |
executive functions efs | #23 |
syp | #23 |
adhd symptoms childhood | #23 |
notch4 receptors | #23 |
interacting molecules | #23 |
diagnostician | #23 |
wechsler scales | #23 |
propylamines | #23 |
twins genetic predisposition | #23 |
oppositional | #23 |
intrinsic curvature | #23 |
siblings | #23 |
snapiv | #23 |
interview dsm | #23 |
handful | #23 |
neuroleptic withdrawal | #23 |
serotonin receptor gene | #23 |
wide linkage | #23 |
heterogeneity genetic | #23 |
metadoxine | #23 |
deficits | #24 |
statistical manual | #24 |
adra2a | #24 |
expected growth | #24 |
female humans illness | #24 |
guanfacine extended release | #24 |
intelligence schizophrenia | #24 |
nonstimulant | #24 |
dsmiiir criteria | #24 |
stress exposure | #24 |
age regions | #24 |
snorting | #24 |
ocd asd | #24 |
conduct problems adhd | #24 |
refilled | #24 |
adhd characteristics | #24 |
child female humans | #24 |
neural activation patterns | #24 |
stroop task performance | #24 |
lithium bipolar disorder | #24 |
15q13 | #24 |
amrs | #24 |
sassr | #24 |
aggression anxiety | #24 |
children meeting | #24 |
receptor d4 | #24 |
actigraphy studies | #24 |
genome‐wide linkage scans | #24 |
0535 | #24 |
chromosomes 6 | #24 |
adhd comorbidities | #24 |
quantitative phenotypes | #24 |
symptoms psychosis | #24 |
mental control | #24 |
nieces | #24 |
wkht | #25 |
dyscalculia | #25 |
behavioral disinhibition | #25 |
anticipation schizophrenia | #25 |
exposure adhd | #25 |
symptom subtypes | #25 |
slc6a3 gene | #25 |
school failure | #25 |
major affective disorders | #25 |
screening scale | #25 |
liker | #25 |
task patients | #25 |
unique profile | #25 |
baseline assessment | #25 |
clinical interviews | #25 |
understanding adhd | #25 |
psychometrically | #25 |
vietnam twin registry | #25 |
or194 | #25 |
psychiatric nosology | #25 |
young relatives | #25 |
d22s283 | #25 |
maternal criticism | #25 |
splicing regulator | #25 |
nudt3 | #25 |
efficacy atomoxetine | #25 |
psychiatric disorders children | #25 |
neurocognitive predictors | #25 |
dapple | #25 |
association snps | #25 |
biased transmission | #25 |
bipolar choice | #25 |
copy variants schizophrenia | #25 |
conners parent | #25 |
decreased volume | #25 |
–environment interactions | #25 |
nonmedical prescription stimulants | #26 |
association allele | #26 |
rs3730358 | #26 |
psychometric measures | #26 |
selfmonitor | #26 |
n81 | #26 |
behavioral disorder | #26 |
adrenergic uptake | #26 |
inrich | #26 |
adults symptoms | #26 |
htr1d | #26 |
efpc | #26 |
affair | #26 |
core symptoms adhd | #26 |
agreement raters | #26 |
orosmethylphenidate | #26 |
twins humans | #26 |
alcohol drug abuse | #26 |
prenatal health | #26 |
voxel based morphometry | #26 |
gender risk | #26 |
label study | #26 |
controls adhd | #26 |
major depression md | #26 |
bipolar phenotype | #26 |
adhd mothers | #26 |
screening diagnosis | #26 |
maob gene | #26 |
wm microstructure | #26 |
add | #26 |
neurodevelopmental genes | #26 |
social impairment | #26 |
structured interviews | #26 |
rate remission | #27 |
based association | #27 |
weaker effects | #27 |
disorders executive | #27 |
international meeting | #27 |
osterrieth | #27 |
greater severity | #27 |
d22s278 | #27 |
genetic susceptibility schizophrenia | #27 |
offspring risk | #27 |
t102c polymorphism | #27 |
bipolar disorder comorbidity | #27 |
aff | #27 |
cnvs adhd | #27 |
association signals | #27 |
childreniv | #27 |
potential confounds | #27 |
intelligence male | #27 |
schizophrenia genetic | #27 |
consecutively | #27 |
hyperactivity disorder adhd | #27 |
mdd asd | #27 |
treatment atomoxetine | #27 |
asherson | #27 |
ptsd adults | #27 |
child clinical | #28 |
cortical gyrification | #28 |
polysomnography actigraphy | #28 |
maternal adhd | #28 |
symptoms inattention | #28 |
snp18 | #28 |
adults study | #28 |
ocd disorders | #28 |
genetic etiology | #28 |
clinical correlates | #28 |
new genetics | #28 |
guze | #28 |
metaalgorithm | #28 |
symptom reports | #28 |
persons bipolar disorder | #28 |
disorder compared | #28 |
adhd differences | #28 |
raters | #28 |
dopamine transporter binding | #28 |
subjects bpd | #28 |
families schizophrenia | #28 |
emotional dysregulation | #28 |
male methylphenidate | #28 |
genomewide studies | #28 |
preliminary findings | #28 |
slc6a3 | #28 |
sustained attention deficits | #28 |
vigilance performance | #28 |
6179 | #28 |
rest task | #28 |
schizophrenia onset | #28 |
dopamine receptor d4 | #28 |
adhd autism | #28 |
parent teacher | #28 |
image study | #28 |
assessment negative symptoms | #28 |
hyperactivity impulsivity | #29 |
studies genes | #29 |
dsmiiir | #29 |
etiological heterogeneity | #29 |
comorbidity ptsd | #29 |
adhd patients controls | #29 |
disorders offspring | #29 |
misuse diversion | #29 |
infants weight | #29 |
inattention hyperactivity impulsivity | #29 |
shared genetic basis | #29 |
childhood diagnosis | #29 |
medication usage | #29 |
childhood antecedents | #29 |
medication misuse | #29 |
offspring parents | #29 |
disorder bipolar | #29 |
attention‐deficit | #29 |
parents bipolar disorder | #29 |
psychosocial dysfunction | #29 |
bipolar disorder youth | #29 |
african‐american | #29 |
male polymorphism | #29 |
kcnn3 | #29 |
comorbid | #30 |
relatives age | #30 |
specific psychopathology | #30 |
juvenile bipolar disorder | #30 |
adhd child | #30 |
diagnosticians | #30 |
robust statistical methods | #30 |
structural brain features | #30 |
growth childhood | #30 |
hyperactive symptoms | #30 |
bmi growth | #30 |
antisocial behavior asb | #30 |
individual studies | #30 |
problems attention | #30 |
association paternal age | #30 |
nimh | #30 |
caarsinv | #30 |
genetic perspective | #30 |
nonaffected | #30 |
nicotine pregnancy | #30 |
parental predictors | #30 |
treatment adolescents | #30 |
potential endophenotypes | #31 |
genotype haplotypes | #31 |
neuropsychologic deficits | #31 |
prs adhd | #31 |
twin concordance | #31 |
reanalyzed | #31 |
discriminates | #31 |
depression genetic | #31 |
rgs4 schizophrenia | #31 |
smoking substance | #31 |
variable tandem | #31 |
extant literature | #31 |
sex effects | #31 |
bpd risk | #31 |
neuroimage | #31 |
methylphenidate | #31 |
lodscore | #31 |
charles river | #31 |
nonadhd | #31 |
95 adhd | #31 |
kif16b | #31 |
n305 | #31 |
impulsivity inattention | #31 |
studies adolescent | #32 |
wiscr | #32 |
anxiety disorders | #32 |
aggression attention | #32 |
child psychiatric | #32 |
asd symptoms children | #32 |
psychiatric disorders | #32 |
psychosis youth | #32 |
schizophrenia affective psychosis | #32 |
gender | #32 |
kremen | #32 |
randomized crossover study | #32 |
rs206936 | #32 |
slc6a4 | #32 |
impulsecontrol | #32 |
studies schizophrenia | #32 |
adhd adolescents | #32 |
70–80 | #32 |
parents child | #32 |
psdq | #32 |
10p13 | #32 |
anterior insular | #32 |
repeat length | #32 |
subfields hippocampus | #32 |
attentiondeficit | #32 |
psychiatric genetic | #32 |
bipolar disorder bpi | #32 |
10repeat allele | #33 |
disorder symptom | #33 |
briefa | #33 |
wfirs | #33 |
mood anxiety | #33 |
neuropsychological deficits | #33 |
comorbidity cross | #33 |
rhobtb3 | #33 |
youth bipolar disorder | #33 |
animal model adhd | #33 |
children risk | #33 |
current adhd | #33 |
original study | #33 |
val allele | #33 |
psychiatric status | #33 |
quetiapine monotherapy | #33 |
qsf | #33 |
autism symptoms | #33 |
neural reward processing | #33 |
frontopolar | #33 |
maternal smoking pregnancy | #33 |
adhd evidence | #33 |
rs1130214 | #33 |
ld adhd | #33 |
psychiatric sample | #33 |
association genes | #33 |
neuropsychiatric sle | #33 |
single snps | #33 |
pharmacotherapy trials | #33 |
twins factor analysis | #33 |
prior findings | #33 |
aspd bpd | #33 |
adhd patients | #33 |
subcortical brain | #33 |
disorders mood | #34 |
social anxiety children | #34 |
snp4 | #34 |
young adults adhd | #34 |
treatment memantine | #34 |
inattention | #34 |
grm5 | #34 |
disorder traits | #34 |
gxr | #34 |
disorders diagnostic | #34 |
treatment sud | #34 |
structural brain asymmetries | #34 |
linkage studies | #34 |
psychological tests | #34 |
dsm5 dsmiv | #34 |
pharmacotherapy adhd | #34 |
md risk | #34 |
risk psychiatric disorders | #34 |
candidate gene polymorphisms | #34 |
emerging consensus | #34 |
harvard | #34 |
cognition interaction | #34 |
adhd sleep problems | #35 |
complex figure | #35 |
schizophrenia relatives | #35 |
risk females | #35 |
n265 | #35 |
bipolar spectrum disorders | #35 |
humans intelligence | #35 |
recall patients | #35 |
schizophrenia schizotypy | #35 |
choice impulsivity | #35 |
familial risk | #35 |
schizophrenia gene | #35 |
catechol‐o‐methyltransferase | #35 |
lifetime rates | #35 |
sample description | #35 |
hyperactive disorder | #35 |
adhd rating | #35 |
bipolar disorder offspring | #35 |
participants bpd | #35 |
lithium quetiapine | #35 |
n64 | #35 |
htr1b | #35 |
plink | #35 |
#35 | |
schizophrenia genes | #36 |
annett | #36 |
siblings controls | #36 |
disorder bpd | #36 |
neurocognitive markers | #36 |
stimulant medications | #36 |
d6s274 | #36 |
adhd control groups | #36 |
gypc | #36 |
groups adhd | #36 |
95 siblings | #36 |
adult antisocial | #36 |
intracranial volume icv | #36 |
retrospective recall | #36 |
structure psychopathology | #36 |
orosmph | #36 |
comorbidity children | #36 |
suny | #36 |
young adult females | #36 |
term neuropsychological | #36 |
neurotransmissions | #36 |
infant gender | #36 |
overanxious disorder | #36 |
adhd drug | #36 |
n185 | #36 |
nocebo response | #36 |
tests schizophrenia | #37 |
studies comorbidity | #37 |
odd dimensions | #37 |
n278 | #37 |
rs5 | #37 |
symptom criteria | #37 |
disorder severity | #37 |
combined sample | #37 |
delayedaction preparations | #37 |
dat1 gene | #37 |
genetics | #37 |
child behavioral | #37 |
predictive utility | #37 |
functioning adults | #37 |
parents adhd children | #37 |
adhd asd | #37 |
lisdexamfetamine | #37 |
mapping genomic loci | #37 |
slc22a16 | #37 |
offspring association | #37 |
methylphenidate treatment | #38 |
height children | #38 |
boys | #38 |
familial risk depression | #38 |
rs2391191 | #38 |
genetic risk schizophrenia | #38 |
genome‐wide search | #38 |
kiddie schedule | #38 |
pik4ca | #38 |
family‐based | #38 |
polymorphism gene | #38 |
d15s1360 | #38 |
16 genes | #38 |
school age children | #38 |
adhd problems | #38 |
dsm criteria | #38 |
unfamiliar | #38 |
pediatric adhd | #38 |
mood stabilization | #39 |
increased risk adhd | #39 |
adhd behavior | #39 |
asthma systematic review | #39 |
mdd ocd | #39 |
nonparanoid | #39 |
female cases | #39 |
markers genetic | #39 |
behavioral traits | #39 |
test association | #39 |
pharmacologic treatment | #39 |
antisocial traits | #39 |
structural brain abnormalities | #39 |
git1 | #39 |
dsm5 criteria | #39 |
suggestive | #39 |
washu | #39 |
iii personality | #39 |
ocd adhd | #39 |
manic symptoms | #39 |
wisconsin card | #39 |
mlod | #39 |
onset children | #39 |
onset | #40 |
bipolars | #40 |
reln gene | #40 |
gxe | #40 |
heinrichs | #40 |
anx | #40 |
genetic studies | #40 |
familial effects | #40 |
rs2283265 | #40 |
genome scan | #40 |
diagnosis bipolar disorder | #40 |
cardiovascular adverse effects | #40 |
genetics schizophrenia | #40 |
brainspan | #40 |
chromosome 10p | #40 |
dsmiv criteria | #40 |
rare copy variants | #40 |
schizophrenia severity illness | #41 |
chromosomes 6q | #41 |
sibpairs | #41 |
effects growth | #41 |
methodological advances | #41 |
bdnf adhd | #41 |
sirolimus patients | #41 |
pediatric subjects | #41 |
methylphenidate response | #41 |
normal comparison subjects | #41 |
psychosocial adversity | #41 |
fhrs | #41 |
neuropsychiatr | #41 |
parent‐of‐origin | #41 |
male parents | #41 |
gwas meta | #42 |
child female | #42 |
schizophrenia disorders | #42 |
sorting test | #42 |
diagnostic comorbidity | #42 |
individual items | #42 |
fiveyear followup | #42 |
disorder social | #42 |
adhd deficits | #42 |
tic disorders | #42 |
dtnbp1 schizophrenia | #42 |
serotonergic pathway | #42 |
schizophrenia | #42 |
male panic | #42 |
n262 | #42 |
p023 | #43 |
digs | #43 |
adhd prs | #43 |
p094 | #43 |
disorder prevalence | #43 |
candidate endophenotype | #43 |
n176 | #43 |
neuropsychological differences | #43 |
snp1 | #43 |
brain scans | #43 |
neuropsychological tasks | #43 |
mri study | #43 |
n242 | #43 |
children enuresis | #43 |
practitioner review | #43 |
adhd depression | #43 |
simplex families | #43 |
n232 | #43 |
youngadult | #43 |
massachusetts general | #43 |
multidimensionality | #44 |
treatment adult | #44 |
secondborns | #44 |
prior studies | #44 |
asd adults | #44 |
sidp | #44 |
nosologic | #44 |
adolescents attention | #44 |
n140 | #44 |
immediaterelease | #44 |
mental disorders diseases | #44 |
odds ratio association | #44 |
dopamine d5 | #44 |
altered brain activation | #45 |
adhd parents | #45 |
inflation rate | #45 |
substance disorder | #45 |
wnl | #45 |
behavior rating | #45 |
genetic loading | #45 |
institute mental | #45 |
cep85l | #45 |
tcerg1l | #45 |
snpbased heritability | #45 |
prevalence psychiatric | #45 |
suggestive associations | #45 |
illness stress | #45 |
risk reduction strategies | #45 |
uncaring | #45 |
controls subjects | #45 |
pharmacogenetic studies | #45 |
volume reductions | #45 |
schizophrenia genome | #45 |
baseline adhd | #45 |
genetic underpinnings | #45 |
offspring adhd | #45 |
risk schizophrenia | #45 |
pooled size | #45 |
n164 | #46 |
neuropsychological performance | #46 |
sex bias | #46 |
cbt intervention | #46 |
machine learning study | #46 |
adhd effects | #46 |
lyons | #46 |
natural reward | #46 |
nat genet | #46 |
familial coaggregation | #46 |
stronger connectivity | #46 |
gender influences | #46 |
referral bias | #46 |
10year followup | #46 |
response mph | #46 |
12 months treatment | #46 |
converging evidence | #46 |
previous findings | #46 |
disorders studies | #47 |
or125 | #47 |
desipramine dmi | #47 |
velocardiofacial syndrome | #47 |
meehl | #47 |
oppositional symptoms | #47 |
n280 | #47 |
pooled odds ratio | #47 |
loci chromosomes | #47 |
compromised | #47 |
childhood disorders | #47 |
trauma risk | #47 |
parents depression | #47 |
association bipolar disorder | #47 |
abstract objective | #47 |
ocd mdd | #47 |
comt | #47 |
baiap2 | #47 |
psychiatric status rating | #47 |
genetic study | #47 |
schizophrenia alleles | #47 |
shared polygenic risk | #47 |
scientific foundation | #48 |
1711 | #48 |
n27 | #48 |
effects gender | #48 |
adhd dyslexia | #48 |
revised | #48 |
association test | #48 |
adhd prevalence | #48 |
nullhypothesis | #48 |
n103 | #48 |
disorder case | #48 |
rtv | #48 |
mpp3 | #48 |
shared heritability | #48 |
anxa7 | #49 |
negative schizotypy | #49 |
inbred wky rats | #49 |
hyperactivity autism | #49 |
rs2494732 | #49 |
schizophrenia cognition | #49 |
drug holidays | #49 |
mental disorders children | #49 |
serotonin plasma | #49 |
familial loading | #49 |
nurture | #49 |
snap‐25 | #49 |
weak evidence | #49 |
disorder cognitive | #49 |
volume differences | #49 |
impulsivity symptoms | #50 |
dsmiv dsm5 | #50 |
caseness | #50 |
proteins polymorphism | #50 |
rocf | #50 |
maoauvntr | #50 |
early onset schizophrenia | #50 |
vdm | #50 |
n168 | #50 |
intergenerational effects | #50 |
genomic relationships | #50 |
geneenvironment interactions | #50 |
pair 6 | #50 |
studies biomarkers | #50 |
wiat | #50 |
life outcomes | #50 |
extended pedigrees | #50 |
wais | #50 |
parent teacher ratings | #50 |
compelling | #51 |
1542 | #51 |
adults ocd | #51 |
substantial role | #51 |
bpd | #51 |
common psychiatric disorders | #51 |
disorders children | #51 |
male personality | #51 |
gender association | #51 |
psychology adult | #51 |
epilepsy adhd | #51 |
peer affiliation | #51 |
adhd knowledge | #51 |
manovas | #51 |
youth asd | #52 |
metaanalysis association | #52 |
chronic schizophrenia patients | #52 |
selenbp1 | #52 |
bipolar disorder children | #52 |
asdadhd | #52 |
adra1a | #52 |
schizophrenia sex | #52 |
growth height | #52 |
schizophrenia controls | #52 |
gray matter alterations | #52 |
oros methylphenidate | #52 |
combined adhd | #52 |
a218c | #52 |
major depression | #52 |
intracranial volume | #52 |
dopamine plasma | #53 |
placebo children | #53 |
risk analysis | #53 |
n138 | #53 |
tourettes disorder | #53 |
snps candidate genes | #53 |
scales schizophrenia | #53 |
smoking schizophrenia | #53 |
parahippocampal gyrus | #53 |
extended‐release | #53 |
schizophrenia adolescent | #53 |
adoption study | #53 |
mania depression | #53 |
psychopathology | #53 |
adhdc | #53 |
risktaking behavior | #53 |
ppm1h | #53 |
schizophrenia psychotic disorders | #54 |
risk study | #54 |
pregnancy time | #54 |
genetic reproducibility | #54 |
chromosome 6p | #54 |
psychlit | #54 |
unphased | #54 |
ablim1 | #54 |
bpd children | #54 |
onset bipolar | #54 |
alcohol drug | #54 |
jackknife | #54 |
dnms | #54 |
longitudinal case | #55 |
disorders risk | #55 |
sample children | #55 |
flat affect | #55 |
tova | #55 |
child behavior | #55 |
emotional lability | #55 |
neuropsychological studies | #55 |
mid adolescence | #55 |
1252 | #55 |
childhood trauma exposure | #55 |
viloxazine | #55 |
children diagnosis | #55 |
disorders prevalence | #55 |
gene interaction | #55 |
endophenotype | #55 |
alcohol substance | #56 |
pair chromosomes | #56 |
degree relatives | #56 |
children siblings | #56 |
entry points | #56 |
disorder agoraphobia | #56 |
extendedrelease | #56 |
cotwin | #56 |
schizophrenia offspring | #56 |
subfield | #56 |
n43 | #56 |
hyperactive | #56 |
tics children | #56 |
brain structure function | #57 |
etdt | #57 |
methylphenidate hydrochloride | #57 |
zdhhc8 | #57 |
apol | #57 |
shared genetic etiology | #57 |
model attention | #57 |
oddsratio | #57 |
interregional profiles differences | #57 |
barkley | #57 |
atomoxetine hydrochloride | #57 |
rating inventory | #57 |
controlled study | #58 |
repeat alleles | #58 |
comorbid psychiatric disorders | #58 |
single snp | #58 |
vntr polymorphisms | #58 |
compelling evidence | #58 |
dbq | #58 |
children | #58 |
childhood young adulthood | #58 |
heritable receptors | #58 |
association comt | #58 |
controls children | #58 |
adhd atomoxetine | #58 |
analysis schizophrenia | #58 |
100 children | #58 |
function schizophrenia | #58 |
conners | #58 |
tests attention | #58 |
mdd adhd | #59 |
risk siblings | #59 |
mdd children | #59 |
rtn4r | #59 |
schizophrenia smoking | #59 |
comt schizophrenia | #59 |
neuroleptic | #59 |
risk psychiatric | #59 |
inattention hyperactivity | #60 |
3 domains | #60 |
abuse dependence | #60 |
generalize | #60 |
executive functioning | #60 |
reported associations | #60 |
duval | #60 |
disruptive behavior disorder | #60 |
disorders including | #60 |
lphn3 | #60 |
functional remission | #60 |
cronbachs alpha | #61 |
uncles | #61 |
homogeneous subgroups | #61 |
13q32 | #61 |
dysregulation profile | #61 |
comparison subjects | #61 |
disorders asd | #61 |
wide scan | #61 |
uninhibited | #61 |
oih | #61 |
disruptive behavior | #61 |
study adherence | #61 |
study adults | #61 |
unipolars | #61 |
1537 | #62 |
symptoms | #62 |
relatives schizophrenia | #62 |
substantial heritability | #62 |
polygenic risk schizophrenia | #62 |
inhibition memory | #62 |
bipolar youth | #62 |
schizophrenia human | #62 |
maternal psychopathology | #62 |
mph treatment | #62 |
factors anxiety | #62 |
tdts | #62 |
4 year | #62 |
treatments adhd | #63 |
stability time | #63 |
n179 | #63 |
disorders bipolar | #63 |
schizophrenia schizophrenic | #63 |
neurocognitive | #63 |
behavioral dysregulation | #63 |
structured interview | #63 |
ksads | #63 |
risk severity | #63 |
accounted | #63 |
rating scales | #64 |
endosomal | #64 |
childhood onset | #64 |
phacking | #64 |
methylphenidate adhd | #64 |
linkage | #64 |
child | #64 |
40 countries | #64 |
qlesq | #64 |
males association | #64 |
risk trauma | #64 |
treatment desipramine | #64 |
adhd 95 | #64 |
children mph | #64 |
prefrontal dysfunction | #64 |
methylation cpg sites | #64 |
europeanamerican | #64 |
diagnostic utility | #64 |
methylphenidate mph | #64 |
disorders genetic | #65 |
net gene | #65 |
zcchc4 | #65 |
male siblings | #65 |
prior work | #65 |
schizophrenic | #65 |
function female | #65 |
emotional regulation | #65 |
occurrence adhd | #65 |
emo | #65 |
temperamental | #65 |
comorbid diagnosis | #65 |
small sample size | #65 |
neuropsychological impairments | #65 |
oxidase gene | #65 |
adhd epilepsy | #65 |
marry | #65 |
controls siblings | #65 |
etiology schizophrenia | #65 |
simple phobia | #66 |
tic disorder | #66 |
afternoons | #66 |
extended release | #66 |
children mental retardation | #66 |
attention hyperactivity | #66 |
global ratings | #66 |
tourettes syndrome | #66 |
neuropsychological profile | #66 |
disorder chromosome | #66 |
vswm | #66 |
behavioral genetic | #66 |
ci105 | #66 |
study studies | #66 |
cbcldp | #66 |
adhd dcd | #66 |
risk bipolar | #67 |
nonrighthandedness | #67 |
entire sample | #67 |
variance attention | #67 |
treatment quetiapine | #67 |
n217 | #67 |
mental diseases | #67 |
patients bipolar disorders | #67 |
grade retention | #67 |
findings association | #67 |
parents teachers | #67 |
subjects | #67 |
label trial | #67 |
questionnaires treatment | #67 |
chronic tic disorder | #67 |
substance disorder sud | #67 |
snparray | #68 |
delay aversion | #68 |
conceptual issues | #68 |
qms | #68 |
brain gene | #68 |
offspring | #68 |
naturalistic | #68 |
hypofrontality | #68 |
stress response genes | #69 |
clarifying | #69 |
symptom checklist | #69 |
low adherence | #69 |
impulsivity hyperactivity | #69 |
regulatory enzymes | #69 |
illicit substances | #69 |
humans schizophrenia | #69 |
scale assessment | #69 |
people adhd | #69 |
physical anhedonia | #69 |
chronological age | #69 |
ctgn | #69 |
polymorphism schizophrenia | #69 |
panic disorder | #69 |
npl | #70 |
new diagnoses | #70 |
linkage scan | #70 |
latrophilin | #70 |
oros mph | #70 |
core adhd symptoms | #70 |
nonrandom mating | #70 |
smoking children | #70 |
neuropsychological consequences | #70 |
interactions genes | #70 |
subsequent diagnosis | #70 |
a2bp1 | #70 |
objective examine | #71 |
genes role | #71 |
neuroimaging genetics | #71 |
adhd anxiety disorders | #71 |
genetic | #71 |
vergence | #71 |
treated children | #71 |
adhd behaviors | #71 |
mspi polymorphism | #71 |
digital health intervention | #72 |
boys age | #72 |
digital intervention | #72 |
molecular genetic | #72 |
ocd subjects | #72 |
learning disorders | #72 |
school functioning | #72 |
methodological issues | #72 |
genetic receptors | #72 |
youth | #73 |
adhd subtype | #73 |
candidate endophenotypes | #73 |
relapse depression | #73 |
schizophrenia genetics | #73 |
poison control centers | #73 |
etiological | #73 |
3372 | #73 |
patients rest | #73 |
disorders childhood | #73 |
logodds | #73 |
kagan | #73 |
cortical abnormalities | #73 |
adhd medications | #73 |
adult | #73 |
anxiety adhd | #73 |
cellular models | #73 |
reaction time variability | #74 |
preferential transmission | #74 |
age schizophrenia | #74 |
pfkfb2 | #74 |
desipramine | #74 |
allele association | #74 |
transmission disequilibrium | #74 |
based diagnosis | #74 |
efficacy outcome | #75 |
hyperactivity adhd | #75 |
referred | #75 |
linkage schizophrenia | #75 |
child china | #75 |
weight body mass | #75 |
onset anxiety | #75 |
impairment children | #75 |
slc1a1 | #75 |
neale | #75 |
risk sample | #75 |
antisocial | #75 |
akl | #75 |
adhd traits | #75 |
mind wandering | #75 |
drd4 gene | #75 |
nondeficit | #76 |
disorders brain | #76 |
depression pregnancy | #76 |
yates | #76 |
child depressive | #76 |
chronic tic | #76 |
schizophrenia young | #76 |
positive schizotypy | #76 |
centers disease control | #76 |
adhd total | #76 |
child humans | #76 |
performance schizophrenia | #77 |
childhood adhd | #77 |
lod score | #77 |
cortex schizophrenia | #77 |
atomoxetine children | #77 |
psychological male | #77 |
performance adhd | #77 |
wcst performance | #77 |
disorders female | #78 |
bpi | #78 |
rare copy | #78 |
women antidepressants | #78 |
local gyrification | #78 |
adhd impairment | #78 |
bipolar disorder adhd | #78 |
pharmacologic treatments | #78 |
predixcan | #78 |
additive effects | #79 |
n46 | #79 |
obesity metabolic syndrome | #79 |
student athletes | #79 |
genetic linkage studies | #79 |
pregnancy mothers | #79 |
cardinal | #79 |
retrospective assessment | #79 |
schizophrenic patients | #79 |
patients adhd | #79 |
anxiety separation | #79 |
disorder panic | #79 |
studies relationship | #79 |
age adhd | #79 |
nosological | #79 |
maternal smoking | #80 |
linkage chromosome | #80 |
clinical interview | #80 |
adhd rats | #80 |
siblings schizophrenia | #80 |
total brain | #80 |
adhd drugs | #80 |
differences age | #81 |
disliking | #81 |
pathophysiology adhd | #81 |
endophenotypes | #81 |
hacking | #81 |
body mass diabetes | #81 |
oral routes | #81 |
eyhs | #81 |
major diagnostic | #81 |
interregional profiles | #81 |
subcortical brain volumes | #81 |
bipolar disorder | #81 |
children parents | #81 |
treatment adults | #81 |
adults asd | #82 |
comorbidity disorders | #82 |
frontopolar cortex | #82 |
impaired quality life | #82 |
association maternal smoking | #82 |
behavior assessment | #82 |
genes pathways | #82 |
cumulative evidence | #82 |
auditory verbal | #82 |
square distribution | #82 |
symptoms diagnosis | #82 |
gene schizophrenia | #82 |
comorbidity survey | #82 |
tests risk | #83 |
neurocognitive functioning | #83 |
unreliability | #83 |
disorders anxiety | #83 |
substance disorders | #83 |
oros | #83 |
illness | #83 |
paterson | #83 |
adult form | #83 |
multifactorial inheritance | #83 |
management adhd | #83 |
women adhd | #84 |
adhd adhd symptoms | #84 |
complex disorder | #84 |
15q133 | #84 |
21 months | #84 |
brain asymmetry | #85 |
atomoxetine | #85 |
adhd assessment | #85 |
9r | #85 |
adhdrsiv | #85 |
linkage loci | #85 |
hyperkinetic disorder | #85 |
humans risk | #85 |
adhd subtypes | #85 |
recycling endosome | #85 |
wide significance | #85 |
monitoring response | #85 |
european samples | #85 |
genomics consortium | #85 |
buprenorphine maintenance | #85 |
siblings children | #86 |
findings implications | #86 |
paranoid | #86 |
affective psychosis | #86 |
child conduct | #86 |
parents | #86 |
humans inhibition | #86 |
pord | #86 |
n203 | #87 |
ptsd trauma | #87 |
bipolar spectrum disorder | #87 |
synaptosomal protein | #87 |
putamen volume | #87 |
comparison children | #87 |
3utr | #87 |
bipolar | #87 |
risk alleles | #87 |
comorbid psychopathology | #88 |
druggable | #88 |
hyperkinetic | #88 |
common risk | #88 |
bonferroni correction | #88 |
drug effects | #88 |
prenatal nicotine exposure | #89 |
machine learning analysis | #89 |
nucleotide schizophrenia | #89 |
2455 | #89 |
chrna2 | #89 |
22 studies | #89 |
auditory attention | #89 |
comprehensive identification | #89 |
metaanalytic review | #89 |
empirically | #89 |
euphoric | #89 |
caars | #89 |
verbal ability | #90 |
1month | #90 |
snps haplotypes | #90 |
linkage genome | #90 |
pervasive | #90 |
male neuropsychological | #90 |
242 | #90 |
association metaanalysis | #90 |
antidepressants pregnancy | #90 |
attention deficit hyperactivity | #90 |
watt | #90 |
callousness | #91 |
parental socioeconomic status | #91 |
assertion | #91 |
complicates | #91 |
identified studies | #91 |
wcst | #91 |
cortical brain | #91 |
adhd efficacy | #91 |
adhd treatments | #91 |
naturalistic study | #91 |
adhd males | #91 |
h2snp | #92 |
candidate gene | #92 |
treatment mania | #92 |
raise | #92 |
studies sex | #92 |
documenting | #92 |
studies association | #92 |
adults schizophrenia | #92 |
controls participants | #93 |
referral consultation | #93 |
narrowly | #93 |
ymrs | #93 |
lifetime cannabis | #93 |
rate adult | #93 |
standardized differences | #93 |
gprc5b | #94 |
brain case | #94 |
hyperactivity autistic | #94 |
cdh13 | #94 |
adhd measures | #94 |
social development | #94 |
hfasd | #94 |
gottman | #94 |
aldh1l1 | #94 |
performance variability | #94 |
growing body | #94 |
sustained attention | #94 |
underachievement | #94 |
asd study | #95 |
studies differences | #95 |
total brain volume | #95 |
adolescents bipolar | #95 |
infa | #95 |
mdd bip | #95 |
executive | #95 |
minisatellite | #95 |
cadps2 | #95 |
behavior rating inventory | #96 |
nominally | #96 |
phenotype polymorphism | #96 |
nxph1 | #96 |
uvntr | #96 |
chromosome 9q34 | #96 |
scq | #96 |
studies asthma | #97 |
7q36 | #97 |
children tics | #97 |
low cardiorespiratory fitness | #97 |
adolescent onset | #97 |
hcadherin | #97 |
genome‐wide association study | #97 |
oppositionality | #98 |
identically | #98 |
massachusetts general hospital | #98 |
driving behavior | #98 |
wdpcp | #98 |
concerta | #98 |
linkage study | #98 |
induced hyperalgesia | #98 |
hyperactivity brazil | #98 |
nonfamilial | #98 |
bipolar disorder risk | #98 |
syn2 | #98 |
single nucleotide receptor | #98 |
xp114 | #99 |
disease genetics | #99 |
substrains | #99 |
methodssubjects | #99 |
chd6 | #99 |
disorder diagnosis | #99 |
nonspecificity | #99 |
adhd role | #99 |
abuse potential | #99 |
medication effects | #99 |
psychoactive | #99 |
motor timing | #99 |
metaanalysis trials | #99 |
neurodevelopmental processes | #99 |
12year | #100 |
clinical effects | #100 |
hippocampal subfield volumes | #100 |
adhd methylphenidate | #100 |
reticence | #100 |
pelham | #100 |
obesity abdominal obesity | #100 |
terror | #100 |
genomewide | #101 |
roh | #101 |
upsit | #101 |
genetic risk scores | #101 |
schizophrenia psychotic | #101 |
empirical test | #101 |
neurocognitive impairments | #101 |
diagnostic boundaries | #101 |
slc6a4 gene | #101 |
cosegregation | #101 |
harlan | #101 |
tsls | #101 |
addictive drugs | #101 |
torture | #101 |
advanced paternal age | #101 |
depression pregnant women | #101 |
inhibition psychological | #102 |
individuals aud | #102 |
treatment seeking | #102 |
male neuropsychological tests | #102 |
disorder psychiatric | #102 |
klf13 | #102 |
functional pathways | #102 |
sob | #102 |
parents offspring | #102 |
ocd children | #103 |
patients 12 months | #103 |
schizophrenia mood disorders | #103 |
touchstone | #103 |
genetic pedigree polymorphism | #103 |
clinical picture | #103 |
genome wide association | #103 |
symptom profile | #103 |
pgc | #103 |
genetic mechanism | #104 |
schizophrenia metaanalysis | #104 |
motor competence | #104 |
controlled studies | #104 |
tourette disorder | #104 |
genomic region | #104 |
individual sites | #104 |
1934 | #104 |
academic problems | #105 |
dsmiv diagnosis | #105 |
adhd review | #105 |
schizophrenia probands | #105 |
neuropsychological dysfunction | #105 |
school dropout | #105 |
current article | #105 |
drug dyskinesia | #105 |
children odd | #106 |
cogs | #106 |
humans lod | #106 |
children methylphenidate | #106 |
growth outcomes | #107 |
matter volumes | #107 |
oral methylphenidate | #107 |
adolescents bipolar disorder | #107 |
ldn | #107 |
λs | #107 |
lenticular | #107 |
disorder female | #107 |
mothers adhd | #107 |
chronic tic disorders | #107 |
functional correlates | #107 |
consecutive sample | #107 |
sequential analysis | #107 |
daao | #107 |
maternal warmth | #108 |
site differences | #108 |
symptoms childhood | #108 |
afni | #108 |
association cigarette smoking | #108 |
nesarc | #108 |
n197 | #108 |
proband | #108 |
pervasive developmental | #108 |
aged psychiatric | #108 |
origin effects | #108 |
918 | #108 |
pediatric psychopharmacology | #108 |
antimanic agents | #108 |
gabra6 | #109 |
worthy | #109 |
risk bipolar disorder | #109 |
longitudinal trajectories | #109 |
adhd medication | #109 |
psychosis proneness | #109 |
total scores | #109 |
depression bipolar | #109 |
irrespective | #109 |
neuroleptic medication | #109 |
linkage association | #110 |
enlistment | #110 |
adult adhd symptoms | #110 |
rat models | #110 |
adhd parent | #110 |
markers genome | #110 |
dimorphisms | #111 |
n107 | #111 |
symptom ratings | #111 |
affective symptoms | #111 |
affective psychoses | #111 |
selective reporting | #111 |
dao | #111 |
5httlpr genotype | #111 |
independent studies | #112 |
bipolar parents | #112 |
unmedicated | #112 |
impact exposure | #112 |
childhood risk factors | #112 |
pediatric obsessive | #112 |
factors social | #112 |
brain gene expression | #112 |
dopamine d4 receptors | #112 |
substantial proportion | #112 |
xr | #113 |
neuropsychological functions | #113 |
male prevalence | #113 |
cronbach | #113 |
analysis statistical | #114 |
comorbid anxiety | #114 |
omim | #114 |
functional neuroanatomy | #114 |
–r | #115 |
n34 | #115 |
schizophrenia severity | #115 |
nuclear families | #115 |
endorsed | #115 |
genet | #115 |
liability | #115 |
diseases twins | #116 |
wm abnormalities | #116 |
formulating | #116 |
neuropsychological | #116 |
schizophrenic psychology | #116 |
polygenic association | #117 |
unipolar | #117 |
trait impulsivity | #117 |
coordinated analysis | #117 |
current symptoms | #117 |
z29 | #117 |
prenatal smoking | #117 |
neurocognitive endophenotypes | #117 |
quality life outcomes | #117 |
spm2 | #118 |
satisfaction questionnaire | #118 |
grandfathers | #118 |
genetic receptor serotonin | #118 |
grandiosity | #118 |
academic functioning | #118 |
major female | #118 |
large study | #118 |
prevention science | #118 |
definitively | #118 |
schizophrenia linkage | #119 |
naa ratio | #119 |
dopaminergic genes | #119 |
method data | #119 |
efd | #119 |
midadolescence | #119 |
misunderstandings | #120 |
differences children | #120 |
t01 | #120 |
cgibp | #121 |
aunts | #121 |
disorder autism | #121 |
neurocognitive deficits | #121 |
n108 | #121 |
subfield volumes | #121 |
remittance | #121 |
new avenues | #121 |
anxious | #122 |
psychopathology symptoms | #122 |
urvs | #122 |
levels adhd | #122 |
disorder depressive | #122 |
male risk | #122 |
adhd comorbidity | #122 |
refute | #122 |
schizoaffective | #122 |
pabs | #122 |
structural brain alterations | #122 |
msit | #122 |
disregard | #122 |
brain alterations | #122 |
neuropsychiatric disorders | #122 |
v11 | #122 |
chr psychosis | #123 |
age initiation | #123 |
clinical status | #123 |
adcy2 | #123 |
wechsler | #123 |
adhd ocd | #123 |
trios | #124 |
wechsler intelligence scale | #124 |
9q34 | #124 |
p097 | #124 |
maximum lod score | #124 |
drug placebo | #124 |
attention regulation | #124 |
treatment subjects | #124 |
g×s interaction | #124 |
laboratory observations | #124 |
twothirds | #124 |
longitudinal sample | #124 |
patients chronic schizophrenia | #125 |
psychosis individuals | #125 |
anxiety problems | #125 |
segregation analysis | #125 |
caregiver strain | #125 |
machine learning prediction | #125 |
disorder risk | #125 |
memory adhd | #126 |
drug disorders | #126 |
familial influences | #126 |
parent version | #126 |
biological parents | #126 |
complex genetics | #126 |
positive negative symptoms | #126 |
developmental aspects | #126 |
odd conduct disorder | #126 |
drd2 | #127 |
taiwanese population | #127 |
stevenson | #127 |
adult alleles | #127 |
psychiatric diagnoses | #127 |
genes | #127 |
attention child | #127 |
disinhibited | #127 |
neuropsychological measures | #128 |
aged 6 | #128 |
behavioral outcome | #129 |
n102 | #129 |
familial | #129 |
personality assessment | #129 |
intactness | #129 |
opiate antagonists | #129 |
implicate | #129 |
1990a | #130 |
retrospective data analysis | #130 |
adhd inattention | #130 |
families | #130 |
register study | #131 |
snps | #131 |
pair 15 chromosomes | #131 |
animals attention | #131 |
mood anxiety disorders | #131 |
incapacitation | #131 |
differed | #131 |
bip mdd | #131 |
moderating effects | #131 |
kinesthesia | #131 |
adolescents ocd | #131 |
strong evidence | #131 |
late adolescents | #132 |
p074 | #132 |
male prospective | #132 |
linkage humans | #132 |
sodas | #132 |
childhood anxiety disorders | #132 |
learning disabilities | #132 |
n79 | #132 |
child cognition | #132 |
large european cohort | #132 |
hkd | #132 |
entire brain | #132 |
onset bipolar disorder | #133 |
mph | #133 |
heroin dependence | #133 |
children adults | #134 |
disorders social | #134 |
vntr | #134 |
preliminary examination | #134 |
association analyses | #135 |
social deficits | #135 |
male massachusetts | #135 |
olfactory identification | #136 |
sorcs3 | #136 |
social environments | #136 |
tspan8 | #136 |
risk factors smoking | #136 |
adolescents young | #136 |
firstborns | #136 |
relied | #136 |
association asthma | #137 |
studies examined | #137 |
adolescent bipolar | #137 |
gaming | #137 |
schizophrenia affective disorders | #137 |
psychological male memory | #137 |
memantine treatment | #137 |
longitudinal evidence | #137 |
expressed emotion | #137 |
control individuals | #138 |
evidence association | #138 |
mtor activation | #138 |
6q | #138 |
biomarkers diagnosis | #138 |
asds | #138 |
neuropsychiatric | #139 |
schizophrenia studies | #139 |
n129 | #139 |
symptoms disorders | #139 |
fhr | #139 |
mgh | #139 |
meet | #139 |
intriguing | #140 |
schizotypal traits | #140 |
n115 | #140 |
parental anxiety | #140 |
prss | #141 |
genetic vulnerability | #141 |
disorder comorbidity | #141 |
haplotype block | #141 |
emotional symptoms | #141 |
neurotrophic | #142 |
disorders personality | #142 |
5ht1b receptors | #142 |
covid19 restrictions | #142 |
22q112 deletion syndrome | #142 |
disorders psychotic | #142 |
peripheral biomarkers | #143 |
molecular genetics | #143 |
risk factors obesity | #143 |
fetal movement | #143 |
hydrogen exchangers | #143 |
conduct | #143 |
statistical female humans | #144 |
agents tricyclic | #144 |
blind study | #144 |
diagnostic procedure | #144 |
diagnosed attention | #144 |
g72 | #144 |
humans linear | #144 |
child psychopathology | #144 |
elston | #144 |
rfg | #144 |
drug alcohol | #145 |
p00018 | #145 |
early initiation | #145 |
individual symptoms | #145 |
n105 | #145 |
pcb exposure | #145 |
genetic heterogeneity | #145 |
major psychoses | #145 |
studies depressive | #145 |
affs | #145 |
genome‐wide association studies | #145 |
common genetic variants | #145 |
intelligence quotient | #146 |
prenatal nicotine | #146 |
genders | #146 |
oppositional behavior | #146 |
atypicality | #146 |
adult psychopathology | #146 |
warranted | #146 |
twin studies | #146 |
lras | #147 |
intraindividual variability | #147 |
abbreviated | #147 |
comprising | #147 |
p0016 | #147 |
histrionic | #147 |
cognitive variables | #148 |
basc | #148 |
single locus | #148 |
sabp | #148 |
adolescent young | #148 |
adhd symptoms children | #149 |
parental substance | #149 |
schizotypy | #149 |
brain correlates | #149 |
risk mdd | #149 |
cdrsr | #149 |
sud treatment | #150 |
highlighting | #150 |
categorical | #150 |
nonmedical | #150 |
adhd relationship | #150 |
chrnb2 | #150 |
impulsive | #150 |
consisted | #151 |
higher burden | #151 |
synaptic biology | #151 |
atxn1 | #152 |
metaanalytic | #152 |
xq21 | #152 |
schizophrenia diagnosis | #152 |
autistic traits | #152 |
httlpr | #152 |
increases risk | #152 |
diagnostic systems | #152 |
undegraded | #152 |
implicates | #152 |
large sample | #152 |
copy variants cnvs | #152 |
placebo subjects | #152 |
functional impairment | #152 |
linkage disequilibrium mapping | #152 |
parent report | #152 |
schizophrenia bipolar disorder | #153 |
genomewide linkage | #153 |
editions | #153 |
marginally | #153 |
caucasian children | #153 |
demoralization | #153 |
5 httlpr | #153 |
alcohol conditions | #153 |
humans learning | #153 |
schizophrenia deficits | #153 |
wisc | #154 |
atomoxetine placebo | #154 |
disorder phenotype | #154 |
exposure maternal | #154 |
emphasizing | #154 |
schizophrenia magnetic resonance | #154 |
dsm | #154 |
humans polymorphism | #155 |
year follow | #155 |
genomewide scan | #155 |
snpheritability | #155 |
ncsr | #155 |
clarification | #155 |
interpersonal functioning | #156 |
n84 | #156 |
genetic risk | #156 |
tests male | #156 |
600000 | #156 |
prospective controlled study | #156 |
dopamine d4 | #157 |
panic disorder agoraphobia | #157 |
enigma consortium | #157 |
new knowledge | #157 |
ppp2r2b | #158 |
greatest | #158 |
primary setting | #158 |
genetic linkage | #158 |
adolescents | #158 |
sledai | #158 |
htr2c | #158 |
cognitive tempo | #158 |
myo5b | #158 |
clinical diagnostic | #158 |
oprm1 | #158 |
drd4 genotype | #158 |
dav | #159 |
quetiapine treatment | #159 |
adult human brain | #159 |
patients substance | #159 |
selfratings | #159 |
nonpersistent | #159 |
teachers parents | #159 |
smds | #160 |
medial temporal | #160 |
separation anxiety disorder | #160 |
age onset | #160 |
humans impulsive | #160 |
tic symptoms | #161 |
behavioral difficulties | #161 |
adult adhd patients | #161 |
population samples | #161 |
schizophrenia bipolar | #161 |
genetic component | #161 |
hyperactivity disorders | #161 |
140 | #162 |
rats wky | #162 |
disorder depression | #162 |
disorder clinical | #162 |
ksadspl | #162 |
empirical tests | #162 |
cooccurring disorders | #162 |
paternal age | #163 |
neuropsychological tests | #163 |
dsmiv | #163 |
neurobiology | #163 |
dn cells | #163 |
5htt | #163 |
sample | #163 |
diagnostic status | #164 |
illness schizophrenia | #164 |
impairments | #164 |
familial liability | #164 |
anxiety attention | #164 |
complex phenotype | #164 |
boys girls | #165 |
years children | #165 |
risk subsequent | #165 |
washington university | #165 |
neurocognitive performance | #165 |
domain criteria | #166 |
cotwins | #166 |
receptor gene | #166 |
earlyonset schizophrenia | #166 |
genetic influence | #166 |
shared environment | #166 |
12–14 | #166 |
antidepressant therapy | #166 |
linkage genetic | #166 |
symptom reduction | #166 |
alcohol disorders aud | #166 |
ipsych | #167 |
moderates | #167 |
association obesity | #167 |
children 6 years | #168 |
neurocognitive functions | #168 |
wisciii | #168 |
polygenic architecture | #168 |
leonard | #168 |
international congress | #169 |
matter microstructure | #169 |
n111 | #169 |
duration illness | #169 |
perseverations | #169 |
genetic association analysis | #169 |
multifactorial | #169 |
conditional probability | #170 |
disorders young | #170 |
traumas | #170 |
pharmacodynamic properties | #170 |
lgi | #170 |
cfg | #170 |
single nucleotide schizophrenia | #170 |
risk gene | #170 |
arrb2 | #170 |
anxiety child | #170 |
genesets | #171 |
functional laterality humans | #171 |
n91 | #171 |
child psychiatry | #171 |
treatment studies | #172 |
immune disorders | #172 |
inattention impulsivity | #172 |
disorders study | #173 |
enuresis | #173 |
interpersonal sensitivity | #173 |
gabbr1 | #174 |
male mental | #174 |
large samples | #175 |
tics | #175 |
subsyndromal | #175 |
development schizophrenia | #176 |
mph placebo | #176 |
confounds | #176 |
independent datasets | #177 |
disorders sex | #177 |
ascertainment | #177 |
kraepelin | #177 |
confounded | #177 |
hyperactive children | #177 |
suicide death | #177 |
patients opioid | #177 |
strong genetic component | #178 |
parent rated | #178 |
n78 | #178 |
cortical surface | #178 |
genetic confounding | #179 |
pregnancy children | #179 |
gene interactions | #179 |
underpinnings | #179 |
atomoxetine atx | #179 |
behaviorally | #179 |
strongest evidence | #179 |
nagelkerke | #180 |
copy variants | #180 |
cvlt | #180 |
connectivity networks | #180 |
unemotional traits | #181 |
mothers pregnancy | #181 |
combinatory | #181 |
perceptual disorders | #181 |
phenocopies | #182 |
htr4 | #182 |
structured | #182 |
control participants | #182 |
scz bip | #182 |
271 | #182 |
rating | #183 |
genotype humans | #183 |
studies gwas | #183 |
psychometric testing | #183 |
mechanistic target | #183 |
reading difficulties | #184 |
based morphometry | #184 |
wei | #184 |
effects atomoxetine | #184 |
pdd | #185 |
long acting | #185 |
n‐acetylcysteine | #185 |
genome human | #185 |
phenocopy | #185 |
allison | #185 |
reward sensitivity | #185 |
statistical female | #186 |
218 | #186 |
biomarker studies | #186 |
predominately | #186 |
hyperactivity symptoms | #186 |
schizophrenia evidence | #187 |
schizophrenia major depression | #187 |
risperidone placebo | #187 |
stratifying | #187 |
depression treatment | #188 |
parahippocampus | #188 |
3 untranslated region | #188 |
enigma | #188 |
autocorrelation | #188 |
blood biomarkers | #188 |
differential association | #189 |
genetic correlations | #189 |
bna | #189 |
undertreatment | #189 |
functioning children | #190 |
childhood | #190 |
scwt | #190 |
medication adhd | #190 |
linkage evidence | #190 |
schedule female | #191 |
mood disorder | #191 |
implicated | #191 |
greater activation | #191 |
clarify | #191 |
dopamine genes | #191 |
psychiatric phenotypes | #191 |
social dysfunction | #191 |
fsiq | #191 |
mph children | #191 |
612 years | #192 |
association response | #192 |
iasp | #192 |
joseph | #194 |
inconsistent findings | #194 |
freedman | #194 |
placebo p001 | #195 |
sza | #195 |
cognitive endophenotypes | #195 |
polymorphisms snps | #195 |
clinical global | #195 |
overactivity | #197 |
perinatal complications | #197 |
wm performance | #197 |
neural substrates | #197 |
arhgef9 | #197 |
dependence symptoms | #197 |
ptk2b | #198 |
mdd scz | #198 |
lifetime diagnosis | #198 |
g×s | #198 |
snps schizophrenia | #198 |
developmentally | #198 |
asic1a | #199 |
male phenotype | #199 |
raises | #199 |
specific genes | #199 |
male | #199 |
bsd | #199 |
childhood symptoms | #199 |
small samples | #200 |
asd adhd | #200 |
childhood attention | #200 |
mri data | #200 |
disruptive disorders | #200 |
neuropsychological battery | #200 |
catecholomethyltransferase | #201 |
functional genomics | #201 |
parents schizophrenia | #201 |
disorder humans | #201 |
pain tolerance | #202 |
cognitive flexibility | #202 |
genetic liability | #203 |
unaffected | #203 |
pdq | #203 |
childhood adulthood | #203 |
stopsignal task | #203 |
control association | #203 |
neuropsychological correlates | #203 |
attentional control | #204 |
microsatellite marker | #204 |
respond | #204 |
adolescent psychiatry | #204 |
concurrent validity | #204 |
schizophreniform | #204 |
extend | #204 |
selfdirectedness | #206 |
nonshared | #206 |
uptodate | #206 |
genes risk | #206 |
method drug | #207 |
sluggish cognitive tempo | #207 |
susceptibility schizophrenia | #208 |
prolactin levels | #208 |
prkg1 | #208 |
parental alcohol | #208 |
baseline follow | #209 |
variable expression | #209 |
clinical benefits | #209 |
n96 | #210 |
correspondence | #210 |
acds | #210 |
5year followup | #210 |
60mg | #210 |
park2 | #210 |
maudsley | #210 |
greater risk | #211 |
vntr polymorphism | #211 |
predisposition disease | #211 |
stroop task | #212 |
ps005 | #212 |
adult patients adhd | #212 |
hkdc1 | #212 |
dimensional models | #212 |
apoe4 allele | #212 |
grm7 | #212 |
trauma ptsd | #213 |
negative outcomes | #213 |
sampling strategy | #213 |
sought | #213 |
replication studies | #213 |
humans neuropsychological | #214 |
rare cnvs | #214 |
suggestive evidence | #214 |
cvltii | #214 |
schizophrenia chinese | #214 |
continuous performance test | #214 |
disorders models | #214 |
bilag | #215 |
lifetime version | #215 |
male mental disorders | #215 |
adult cognition | #215 |
functional mri study | #216 |
vivo correlation | #216 |
glr | #217 |
chromosome 15 | #217 |
antisocial personality | #217 |
male schizophrenia | #217 |
panic | #218 |
parental | #218 |
gene based | #218 |
trim31 | #218 |
hippocampal subfield | #218 |
misunderstood | #219 |
study selection | #219 |
polygenic | #219 |
snpa | #220 |
drug double | #220 |
normal controls | #220 |
triangularis | #221 |
irritable mood | #221 |
telephone interview | #221 |
parental psychopathology | #221 |
studies cognition | #221 |
symptoms adults | #221 |
score male | #222 |
patient engagement | #222 |
n76 | #222 |
diagnoses | #222 |
methyltransferase comt | #222 |
childhoodonset | #222 |
revisited | #223 |
learning disability | #223 |
study findings | #223 |
adhd sleep | #224 |
sensing ion | #224 |
axis disorders | #224 |
gria2 | #224 |
abnormalities schizophrenia | #224 |
effective treatments | #224 |
bipolar spectrum | #225 |
coordination disorder | #225 |
default network | #225 |
children placebo | #226 |
subfields | #226 |
hk3 | #226 |
inattentiveness | #226 |
scales psychotic | #227 |
criteria diagnosis | #227 |
unemotional | #227 |
dependent variables | #227 |
disorder study | #227 |
individual variability | #227 |
subcortical regions | #227 |
age subjects | #228 |
comorbid anxiety disorders | #228 |
male twins | #228 |
atomoxetine treatment | #228 |
control based | #228 |
overlapped | #229 |
equally | #229 |
birth complications | #229 |
structural abnormalities | #229 |
psychiatric outcomes | #230 |
heritable | #231 |
commission errors | #231 |
international multicenter | #231 |
4years | #231 |
risk indicators | #231 |
differences prevalence | #232 |
hyperactivity behavior | #232 |
serotonin transporter gene | #232 |
study sample | #234 |
worse performance | #234 |
candidate genes | #234 |
discriminating | #235 |
disorder medication | #235 |
probabilistic forecasts | #235 |
shr wky rats | #236 |
placebo response | #238 |
reliably | #238 |
route administration | #238 |
agoraphobia | #238 |
fifty years | #238 |
allelic heterogeneity | #239 |
nosology | #240 |
acid oxidase | #240 |
healthy siblings | #240 |
pdag | #240 |
scientific data | #240 |
patients siblings | #240 |
disorder asd | #241 |
adequately | #241 |
adolescent offspring | #241 |
doubleblind | #241 |
symptoms quality | #241 |
joint analysis | #242 |
reward processing | #242 |
psychiatric comorbidities | #242 |
sodium hydrogen | #242 |
impulsive choice | #242 |
neurodevelopmental model | #242 |
onset obsessive | #243 |
valid | #243 |
female | #243 |
patients relatives | #243 |
aggressive behaviors | #243 |
n74 | #244 |
giftedness | #244 |
5ht2a receptor | #245 |
interregional | #245 |
paliperidone | #245 |
population differences | #245 |
adversity | #245 |
disorder ptsd | #245 |
community controls | #246 |
dsmivtr | #246 |
cadm2 | #246 |
expression genetic | #246 |
motor performance | #247 |
812 | #247 |
studies associations | #248 |
epigenetic studies | #248 |
cigarette smoking | #248 |
chinese families | #248 |
developmental disorder | #249 |
childs | #251 |
behavioral characteristics | #251 |
german patients | #252 |
hypoactivation | #252 |
tourette | #253 |
genomewide association | #253 |
intellect | #253 |
iqs | #253 |
female subjects | #253 |
cpt performance | #254 |
studies metaanalysis | #254 |
benzodiazepine | #254 |
schizophrenia adult | #254 |
study schizophrenia | #254 |
kappas | #254 |
conduct problems | #255 |
biochemical studies | #256 |
larsson | #256 |
shared genetic | #256 |
cacna1c gene | #256 |
carlson | #257 |
children adhd symptoms | #257 |
endorsement | #259 |
parental depression | #259 |
year study | #259 |
piq | #260 |
n61 | #260 |
pharmacotherapy | #261 |
dexamphetamine | #261 |
diagnosis | #261 |
anxiety depressive disorders | #261 |
22q11ds | #263 |
genomewide linkage scan | #263 |
selfreports | #263 |
obsessive compulsive disorder | #263 |
sex factors | #263 |
fluid intelligence | #263 |
conceptualized | #264 |
disorder personality | #264 |
adverse health | #264 |
distinct subtypes | #264 |
confirm | #264 |
attention problems | #264 |
long term outcomes | #265 |
diagnostic validity | #266 |
schizophrenia cases | #266 |
5090 | #266 |
new models | #266 |
ptsd risk | #266 |
scz mdd | #267 |
phenotype schizophrenia | #267 |
strong support | #268 |
diagnosis schizophrenia | #268 |
genetic approaches | #268 |
neuropsychological impairment | #268 |
diagnostic process | #269 |
test scores | #269 |
years baseline | #269 |
age effects | #270 |
segregate | #270 |
withdrawn | #270 |
phlda1 | #270 |
largest | #270 |
adult psychiatric | #271 |
circadian genes | #271 |
genetic overlap | #271 |
symptoms assessed | #271 |
social adversity | #271 |
sibling pairs | #271 |
diagnostic issues | #272 |
structural brain | #272 |
alcohol smoking | #273 |
4year | #273 |
statistics topic | #273 |
szs | #273 |
schizophrenia siblings | #273 |
444 | #273 |
age | #273 |
search terms | #273 |
rora | #273 |
sleep behavior | #274 |
22 years | #274 |
reading disability | #275 |
maf1 | #275 |
surgency | #275 |
underlie | #275 |
2q | #276 |
missingness | #276 |
t102c | #276 |
familial schizophrenia | #276 |
nicotinic schizophrenia | #277 |
adhd healthy controls | #277 |
adolescent risk | #277 |
mania symptoms | #277 |
growing evidence | #277 |
nr3c1 | #278 |
manual | #278 |
synaptosomal | #278 |
early psychosis | #278 |
clinical setting | #278 |
silico approach | #279 |
nicotine dependence | #279 |
ocd | #279 |
intelligence scale | #279 |
brain volumes | #280 |
cognition female | #280 |
polygenic risk | #280 |
abuser | #280 |
child parent | #280 |
acting | #280 |
remitted | #280 |
rating scale | #280 |
n47 | #280 |
premature death | #281 |
individuals | #281 |
psychotic bipolar | #281 |
phenotyped | #281 |
disorders adult | #281 |
collaborative analysis | #282 |
reading problems | #282 |
5ht1b | #282 |
response inhibition | #282 |
onset ocd | #282 |
continue | #283 |
velo | #283 |
titrated | #283 |
antisocial behaviors | #283 |
aspd | #284 |
quantitative traits | #285 |
normal variation | #285 |
gria3 | #285 |
3untranslated region | #285 |
neoffi | #285 |
neuroanatomical | #285 |
siblings patients | #286 |
clues | #286 |
quantitative analyses | #286 |
swanson | #286 |
explication | #286 |
scale children | #286 |
effects age | #287 |
deficit schizophrenia | #288 |
schizophrenia abnormalities | #288 |
bmisds | #289 |
postmortem brain | #289 |
psychiatric traits | #290 |
22q112 | #290 |
disease haplotypes | #290 |
pediatric ocd | #290 |
low serum levels | #291 |
publication bias | #291 |
subcortical volumes | #291 |
substrain | #292 |
groups children | #293 |
modest | #293 |
subjective responses | #294 |
hypertensive rat | #294 |
cognition disorders | #294 |
salary | #294 |
psychosis schizophrenia | #295 |
post‐traumatic stress disorder | #295 |
interference control | #295 |
adverse impact | #295 |
european populations | #295 |
dtnbp1 | #295 |
risk factors children | #295 |
ldsc | #296 |
continuous performance | #296 |
executive functions | #296 |
obesity overweight | #297 |
early onset | #297 |
asd traits | #297 |
anxiety disorder | #297 |
reanalysis | #298 |
discriminated | #298 |
diagnostic approach | #298 |
negative symptom | #299 |
predisposition | #299 |
effects stress | #300 |
cortical thickness | #300 |
qvalues | #300 |
cognitive measures | #301 |
psychiatric hospitalization | #301 |
roc analysis | #301 |
intrasubject variability | #302 |
states adolescent | #302 |
emotional problems | #302 |
published literature | #302 |
prefrontal function | #302 |
permuted | #303 |
height body | #303 |
psychometrics | #303 |
795 | #304 |
psychiatric conditions | #304 |
manifest | #305 |
aggressive behavior | #305 |
interviewers | #305 |
ats | #305 |
case subjects | #305 |
affective disorders | #305 |
dsm5 | #305 |
dopamine transporter | #306 |
early morning | #306 |
n62 | #307 |
learning disorder | #307 |
general psychopathology | #308 |
spencer | #309 |
documented | #309 |
myh9 | #309 |
perseveration | #309 |
membrane transport | #309 |
omission errors | #309 |
gene environment | #309 |
adolescent aggression | #310 |
memory wm | #310 |
efficacy treatment | #310 |
motor domain | #310 |
genetic schizophrenia | #310 |
life social support | #310 |
rdoc | #311 |
childhood adolescence | #312 |
stroop test | #312 |
mainstays | #312 |
gender age | #312 |
npsr1 | #313 |
mapping female | #313 |
underscore | #314 |
genetic analyses | #314 |
bedtimes | #315 |
risk estimation | #315 |
asb | #317 |
dorsolateral prefrontal cortex | #317 |
replicated | #317 |
schizophrenia review | #318 |
demonstrable | #318 |
individual genes | #319 |
n55 | #319 |
5ht2c | #319 |
adolescent adrenergic | #320 |
gene | #321 |
shared genetic influences | #321 |
intelligence tests | #321 |
addictive disorders | #321 |
127 | #322 |
humans longitudinal | #322 |
bipolar type | #322 |
robins | #322 |
risperidone treatment | #322 |
abusers | #323 |
time variability | #323 |
guanfacine | #324 |
conceptual models | #324 |
nolan | #324 |
manic | #325 |
neonatal abstinence syndrome | #326 |
sex characteristics | #326 |
yielded | #326 |
impaired | #327 |
xq26 | #327 |
status female | #327 |
spurious | #327 |
comprised | #328 |
etiologic | #328 |
disorders pervasive | #329 |
8q | #329 |
sexdifferences | #330 |
overrepresented | #330 |
metaanalyses | #330 |
htr2a | #331 |
scores patients | #331 |
drug response | #331 |
women schizophrenia | #332 |
expression brain | #333 |
naltrexone | #333 |
familial factors | #333 |
txndc5 | #333 |
multiple comparisons | #334 |
cognitive dysfunctions | #334 |
obesity diabetes | #334 |
forthcoming | #335 |
24weeks | #335 |
mood disorders | #335 |
adler | #335 |
rey | #336 |
inferior parietal lobule | #336 |
persist | #336 |
methylphenidate placebo | #336 |
humans mental | #336 |
neuropsychological test | #337 |
asd individuals | #337 |
777 | #337 |
tph2 | #337 |
mobp | #337 |
disentangle | #338 |
psychopathological | #339 |
replications | #339 |
patients attention | #339 |
evening | #339 |
consistently | #340 |
disorder ocd | #340 |
pnmt | #340 |
exclusion criteria | #340 |
evidence linkage | #340 |
intelligence | #341 |
encompassing | #341 |
placebo effects | #341 |
treatment bipolar | #341 |
neuroimaging studies | #342 |
visual memory | #342 |
multicenter analysis | #342 |
maoa genotype | #342 |
bipolarity | #342 |
phobic | #342 |
tbv | #344 |
mood problems | #344 |
schizoaffective disorder | #344 |
frontal pole | #344 |
integrated analysis | #344 |
comorbid diagnoses | #344 |
catechol methyltransferase | #345 |
casecontrol studies | #345 |
systematically | #345 |
gifts | #346 |
864 | #346 |
confused | #347 |
mdd bpd | #347 |
study genotype | #347 |
tic severity | #348 |
psychotic | #348 |
converging | #348 |
collaborative study | #349 |
temporal processing | #349 |
schizotypal personality disorder | #349 |
aetiological | #350 |
adolescent anxiety | #350 |
methylphenidate atomoxetine | #350 |
suspiciousness | #351 |
adults children | #352 |
distractibility | #352 |
receptor genes | #352 |
disequilibrium | #352 |
impairing | #353 |
disease genome | #353 |
substantial | #354 |
gabra1 | #354 |
executive attention | #354 |
child attention | #354 |
brain atlas | #354 |
maob | #354 |
genetic environmental | #354 |
disorders middle | #354 |
reln | #354 |
rgs4 | #355 |
dsmiii | #355 |
male adolescent | #355 |
prodh | #355 |
heterogeneous disorder | #356 |
schizophrenia data | #356 |
phobic disorders | #356 |
chrna7 | #357 |
children anxiety disorders | #357 |
measures attention | #357 |
gottesman | #358 |
persists | #359 |
disorder patients | #359 |
maternal cigarette smoking | #359 |
psychiatric symptoms | #359 |
deviant | #359 |
symptom scores | #360 |
linkage analysis | #360 |
neuroleptic treatment | #361 |
n54 | #361 |
chromosomal regions | #361 |
social adjustment | #362 |
dorsolateral prefrontal | #363 |
genetic findings | #364 |
tid | #365 |
paralimbic | #365 |
core symptoms | #366 |
confirmation | #366 |
elevated risk | #366 |
memory load | #367 |
pediatric populations | #367 |
771 | #367 |
bpd mdd | #368 |
study entry | #368 |
comparison groups | #368 |
risk psychopathology | #368 |
hyperactivityimpulsivity | #369 |
differential involvement | #369 |
702 | #369 |
young adulthood | #369 |
representativeness | #370 |
nervousness | #370 |
differential susceptibility | #370 |
damphetamine | #371 |
current concepts | #371 |
schizophrenia risk | #371 |
replicate | #372 |
endorse | #372 |
comt gene | #372 |
prevention strategies | #372 |
5httlpr | #373 |
genomewide association studies | #373 |
executive function | #373 |
snp heritability | #374 |
driving performance | #374 |
small sample | #374 |
wide analysis | #375 |
916 | #375 |
scz | #375 |
dozens | #375 |
emphases | #376 |
teenage | #376 |
medication children | #376 |
sas | #377 |
genetic architecture | #377 |
child adolescent | #377 |
data studies | #377 |
children medication | #377 |
memory short | #377 |
schizotypal personality | #378 |
children adolescents | #378 |
impression | #378 |
control adults | #379 |
marriages | #379 |
pearson | #380 |
ht1b | #380 |
opd | #380 |
converged | #380 |
youths | #380 |
invaluable | #381 |
methylphenidate children | #381 |
relevant articles | #381 |
overlap | #381 |
general cognitive ability | #381 |
receptors dopamine | #381 |
culmination | #381 |
disorder diagnostic | #381 |
chisquare | #382 |
adolescent patients | #382 |
antimanic | #383 |
psychopathologies | #383 |
carefully | #383 |
psychopharmacological treatment | #383 |
researched | #384 |
summary statistics | #384 |
7r | #385 |
gad2 | #385 |
18p | #386 |
multigenerational | #386 |
treatment children | #386 |
neural activation | #387 |
chinese subjects | #387 |
evenings | #388 |
npas2 | #388 |
contrasted | #388 |
versa | #388 |
childhood depression | #389 |
adhd symptomatology | #389 |
handedness | #390 |
studies children | #390 |
perinatal morbidity | #390 |
disorder symptoms | #390 |
brain circuits | #390 |
lefthandedness | #390 |
interaction genetic | #391 |
genetic predisposition | #391 |
schizophrenia susceptibility | #392 |
comorbid substance | #392 |
lambert | #392 |
p54 | #393 |
genes expression | #394 |
substance users | #394 |
dopamine norepinephrine | #395 |
hippocampal subfields | #395 |
function humans | #395 |
adolescents adults | #396 |
psychometric | #397 |
fbat | #397 |
mental health children | #397 |
disorders schizophrenia | #397 |
schizophrenia disorder | #397 |
3methoxy4hydroxyphenylglycol | #397 |
clinical risk psychosis | #398 |
wandering | #398 |
spm8 | #398 |
earlier onset | #398 |
neuropsychological testing | #400 |
control sample | #401 |
suffocation | #402 |
core symptom | #402 |
academic outcomes | #402 |
inattention symptoms | #402 |
implications findings | #403 |
inconsistencies | #403 |
relations male | #403 |
hyperparameter | #405 |
psychostimulants | #405 |
vntrs | #406 |
neuropsychiatric conditions | #406 |
parahippocampal | #406 |
diagnosis children | #406 |
n52 | #406 |
attending | #407 |
cognitive inhibition | #408 |
childhood risk | #408 |
0038 | #409 |
communitybased | #409 |
behavior genetics | #409 |
distinct subsets | #410 |
substance | #410 |
impulsive behavior | #411 |
dextroamphetamine | #411 |
reading comprehension | #411 |
twin study | #411 |
children studies | #411 |
consistent evidence | #412 |
neanderthal | #412 |
apoe4 | #412 |
psychotic disorders | #412 |
interview | #412 |
tourette syndrome | #412 |
childhood anxiety | #412 |
anticipation | #413 |
systematic literature search | #413 |
moderated | #413 |
151 | #414 |
performance tests | #414 |
reviewing | #414 |
volition | #415 |
polymorphism snp | #415 |
schizotypal | #416 |
genetic receptor | #416 |
elucidating | #416 |
functional effects | #417 |
effects brain | #417 |
conferred | #418 |
adolescent psychiatric | #418 |
adult intelligence | #418 |
questionnaires adolescent | #419 |
genetic association | #419 |
srsa | #419 |
deletion syndrome | #419 |
dopamine d4 receptor | #420 |
antidepressive agents | #420 |
kdm4a | #420 |
daily doses | #420 |
modestly | #421 |
sexes | #421 |
adult subjects | #421 |
iccs | #422 |
operating characteristic | #422 |
cdis | #422 |
drug dependence | #422 |
medicated | #423 |
tricyclic | #423 |
reliability validity | #423 |
characteristic curve | #424 |
gcta | #424 |
discovery sample | #425 |
subtests | #425 |
transport proteins | #425 |
cardiff | #426 |
parent ratings | #426 |
attain | #427 |
hum | #427 |
diversion | #428 |
spectrum disorders | #428 |
brain volume | #428 |
persistent symptoms | #429 |
male obsessive | #430 |
personality development | #431 |
disentangling | #431 |
teacher | #432 |
operating characteristics | #432 |
uniquely | #433 |
peps | #434 |
wistarkyoto | #435 |
frequency genotype | #436 |
perceptual organization | #436 |
12q | #436 |
1433 | #436 |
cprs | #436 |
lower scores | #437 |
grin2a | #437 |
relatives patients | #437 |
disorder brain | #437 |
adolescent psychopathology | #438 |
srs2 | #438 |
toddlerhood | #438 |
visual learning | #438 |
correlation coefficients | #438 |
impulsiveness | #438 |
nominal | #439 |
digit span | #439 |
22q112ds | #439 |
risk psychosis | #439 |
genetic genetic predisposition | #439 |
aged neuropsychological | #440 |
snps association | #440 |
major risk factor | #440 |
method female | #440 |
post hoc analysis | #441 |
white matter microstructure | #441 |
allelic association | #441 |
meaningful | #441 |
gmo | #441 |
trex | #441 |
corroborated | #441 |
female functional | #442 |
planum temporale | #442 |
logistic regression model | #442 |
virtual histology | #442 |
adult analysis | #442 |
disorders autism | #442 |
n80 | #443 |
disorders surveys | #444 |
emphasize | #444 |
10 year | #444 |
conferring | #444 |
differential female | #444 |
pcdh10 | #445 |
statistic | #446 |
ntrk3 | #446 |
nucleotide receptors | #446 |
534 | #446 |
862 | #446 |
holland | #447 |
originally | #448 |
behavior child | #448 |
motor coordination | #448 |
genome wide | #448 |
expressiveness | #449 |
earlier age | #449 |
wistar kyoto | #450 |
risk variants | #450 |
early response | #450 |
sex | #451 |
exceptions | #451 |
clinical expression | #452 |
prevalence correlates | #452 |
brain abnormalities | #452 |
subsequent risk | #452 |
children adolescent | #456 |
chat | #456 |
zscores | #457 |
psychiatry | #457 |
79 | #457 |
structural magnetic | #458 |
preliminary study | #458 |
masse | #458 |
independently | #458 |
22q112 deletion | #460 |
polygenic risk score | #460 |
lander | #460 |
522 | #460 |
genetic correlation | #460 |
psychotic disorders schizophrenia | #460 |
hyperkinesis | #461 |
smoking pregnancy | #461 |
jw | #462 |
d4 | #463 |
neuroanatomy | #465 |
pregnancy complications | #465 |
affection | #465 |
life treatment | #465 |
decrements | #465 |
runs | #466 |
gene sets | #466 |
control rates | #466 |
anxiety depressive | #467 |
mini | #467 |
inbred wky | #467 |
bpad | #468 |
subjects patients | #469 |
patient adherence | #470 |
genetic effects | #470 |
disorders treatment | #470 |
cacna1c | #470 |
receiver operating | #471 |
remission relapse | #471 |
risk allele | #472 |
psychology adolescent | #472 |
chrna4 | #473 |
response remission | #473 |
environmental risk factors | #474 |
plp1 | #474 |
norepinephrine transporter | #474 |
cautious | #476 |
developmental coordination | #476 |
opioid addiction | #476 |
obesity children | #477 |
multiple measures | #477 |
broader | #478 |
5th | #479 |
dysthymia | #479 |
multiplex families | #479 |
adds | #480 |
genetic risk variants | #480 |
symptom | #480 |
humans | #480 |
semistructured | #481 |
diagnostic categories | #481 |
cortex child | #481 |
maternal anxiety | #482 |
genotyped | #482 |
data extraction | #482 |
etiology | #483 |
arithmetic | #483 |
treatment methylphenidate | #484 |
nfil3 | #484 |
verbal learning | #484 |
sml | #484 |
conception | #484 |
agents bipolar | #485 |
adulthood | #485 |
756 | #485 |
outcome variables | #486 |
baseline age | #486 |
epidemiologically | #486 |
evaluates | #487 |
symptom dimensions | #487 |
123 | #487 |
adult anxiety | #487 |
spontaneity | #488 |
longterm effects | #489 |
unpublished | #489 |
genetic disorders | #489 |
female adolescents | #489 |
neuropsychiatric disorder | #490 |
administration schedule | #490 |
schizophrenia autism | #490 |
shared environmental | #490 |
schizophrenia age | #492 |
common variant | #492 |
smoking prevention | #492 |
pnds | #493 |
overlapping | #493 |
late adolescence | #495 |
frequency genetic | #495 |
antisocial personality disorder | #495 |
psychobiology | #497 |
restlessness | #497 |
separation anxiety | #497 |
schizophrenia patients | #497 |
anxiety | #497 |
pair human | #497 |
longitudinal studies | #498 |
bonferroni | #498 |
daoa | #499 |
genetic mechanisms | #499 |
addressed | #499 |
placebos | #499 |
candidate | #499 |
case reports | #500 |
identifying | #500 |
comt val158met polymorphism | #500 |
rat strains | #501 |
d4 receptors | #501 |
nocebo | #501 |
865 | #503 |
verbal memory | #503 |
additional evidence | #503 |
child executive | #505 |
circadian clock genes | #505 |
fallacy | #506 |
n26 | #506 |
subscale | #506 |
continued | #507 |
cooperativeness | #507 |
reflecting | #508 |
tobacco disorder | #508 |
delay discounting | #509 |
developing schizophrenia | #509 |
agg | #510 |
educational status | #511 |
dichotomous | #511 |
shared | #511 |
obsessive compulsive | #512 |
p80 | #512 |
95 death | #512 |
identifiable | #512 |
risk haplotype | #513 |
lod | #513 |
disproportionate | #514 |
coaggregation | #514 |
disorders depression | #515 |
assessments | #515 |
morning | #515 |
phis | #515 |
normal control | #516 |
total sample | #516 |
n39 | #517 |
cognitive traits | #517 |
contributing | #517 |
15q | #518 |
missing link | #519 |
environmental influences | #520 |
pbat | #520 |
fn1 | #520 |
specificity ppv | #521 |
dichotic | #521 |
gyrus cinguli | #521 |
social class | #522 |
selfreport | #522 |
polymorphism single | #522 |
disorder obsessive | #522 |
attention memory | #523 |
dibenzothiazepines | #523 |
assortative | #524 |
adult bipolar | #524 |
phg | #524 |
dmi | #524 |
dedication | #524 |
clinical diagnoses | #525 |
disorder treatment | #525 |
sciencedirect | #525 |
covariates | #525 |
pacific island | #525 |
affiliations | #526 |
criminality | #527 |
persistence | #527 |
functioning | #527 |
symptomatic remission | #528 |
design study | #528 |
adolescent children | #528 |
adverse life events | #528 |
depression anxiety disorders | #528 |
flnc | #529 |
parental reports | #529 |
compulsive disorder | #529 |
abrupt | #529 |
community samples | #529 |
ruled | #529 |
tagsnps | #530 |
control children | #530 |
strongest | #531 |
increased burden | #531 |
medications | #531 |
autism schizophrenia | #532 |
existing studies | #532 |
n40 | #532 |
subjects age | #533 |
clinical sample | #533 |
temperament character | #534 |
analyses conducted | #534 |
selective review | #535 |
intercorrelations | #535 |
asd | #535 |
global impression | #537 |
parsing | #537 |
autistic symptoms | #538 |
child adhd | #538 |
models genetic | #538 |
d4 receptor | #539 |
milder | #541 |
personality factors | #541 |
lobe humans | #542 |
single nucleotide | #543 |
taiwanese | #543 |
disease genotype | #543 |
severe symptoms | #544 |
independent samples | #544 |
complexities | #544 |
population sample | #545 |
ld | #545 |
cognitive impairments | #546 |
choice behavior | #546 |
genetic influences | #547 |
computer program | #548 |
functional variant | #548 |
healthy control subjects | #548 |
behavior male | #549 |
dichotomized | #549 |
clash | #549 |
schizophrenia study | #549 |
nonclinical sample | #549 |
oral route | #549 |
patients schizophrenia | #549 |
risk children | #549 |
genetic pathways | #550 |
fam | #550 |
765 | #550 |
case control | #551 |
ideally | #551 |
motor inhibition | #551 |
define | #551 |
major diagnosis | #552 |
performance test | #552 |
verbal | #553 |
n29 | #553 |
preadolescent | #554 |
release oral | #555 |
viewed | #555 |
prs schizophrenia | #555 |
suggests | #555 |
phenotypic features | #556 |
spectrum disorder | #556 |
neuropsychiatric diseases | #557 |
child anxiety | #557 |
nogo task | #557 |
neurodevelopmental | #558 |
africanamerican | #558 |
equivocal | #558 |
justify | #559 |
gray matter volumes | #560 |
response variability | #560 |
higher rate | #561 |
profoundly | #563 |
caregivers children | #563 |
risk smoking | #565 |
adolescents risk | #565 |
4th edition | #566 |
patients sud | #566 |
intermediate phenotypes | #566 |
twins female | #566 |
risky behaviors | #566 |
haplotype | #567 |
neurocognitive impairment | #567 |
3050 | #567 |
unaffected relatives | #568 |
replication study | #569 |
diverging | #570 |
environment interaction | #570 |
10−8 | #570 |
onsets | #570 |
risk genes | #571 |
keywords | #571 |
birthday | #571 |
dose reduction | #573 |
irritability | #574 |
obesity body mass | #574 |
white matter abnormalities | #574 |
questionnaires adult | #575 |
inbred shr | #575 |
asd diagnosis | #576 |
spaced | #576 |
gyri | #576 |
individually | #577 |
medical genetics | #577 |
chromosomes human | #577 |
schizophrenia sample | #577 |
parent | #577 |
impulsivity | #578 |
82 | #578 |
finetuning | #578 |
symptoms children | #579 |
subsample | #579 |
cold pressor test | #580 |
development anxiety | #580 |
preschool age | #580 |
5httlpr polymorphism | #580 |
haplotype analysis | #581 |
psychiatric association | #582 |
drd1 | #582 |
apol1 | #582 |
rdc | #582 |
delinquent behavior | #583 |
3rd | #583 |
new approaches | #584 |
hk1 | #584 |
fine mapping | #585 |
data children | #585 |
separately | #585 |
neuroanatomical correlates | #586 |
traumatized | #587 |
nback task | #588 |
compared controls | #588 |
defaultmode network | #588 |
examine | #588 |
138 | #589 |
haplotypes humans | #590 |
40mg | #591 |
estonian | #591 |
patients comorbid | #591 |
behavior adult | #591 |
criticism | #593 |
concordant | #594 |
2005 | #594 |
brain child | #595 |
cognition schizophrenia | #596 |
overrepresentation | #596 |
snap25 | #597 |
nonpharmacologic | #597 |
discounted | #597 |
generalizable | #597 |
new directions | #598 |
899 | #598 |
affymetrix | #598 |
differences brain | #600 |
genetic factors | #601 |
specific phobia | #603 |
diagnostic specificity | #604 |
diagnosing | #604 |
clinical settings | #604 |
performance children | #606 |
disorganized | #606 |
clinician | #606 |
cognitive outcomes | #606 |
personality traits | #607 |
social environment | #607 |
4 6 | #608 |
small fraction | #608 |
sizeable | #608 |
true | #609 |
gold standard | #609 |
antisocial behavior | #609 |
executive dysfunctions | #609 |
polygenic risk scores | #610 |
functional outcomes | #610 |
informant | #611 |
complex disorders | #612 |
pleiotropic | #612 |
chromosome 6 | #613 |
educational achievement | #614 |
schizophrenia brain | #614 |
grandmothers | #614 |
curve analysis | #615 |
disease etiology | #615 |
snp markers | #615 |
behavior disorder | #615 |
prevalence severity | #616 |
genetic epidemiology | #616 |
memory deficits | #616 |
genome scans | #617 |
tscores | #617 |
genetic associations | #618 |
differ | #618 |
african children | #618 |
val158met | #618 |
digeorge | #619 |
correcting | #619 |
genetic markers | #620 |
vigilance | #620 |
md | #621 |
antisocial behaviour | #621 |
confer | #622 |
adverse health outcomes | #623 |
receptor serotonin | #624 |
juvenile delinquency | #624 |
executive control | #625 |
executive dysfunction | #625 |
misconceptions | #625 |
mood stabilizers | #626 |
attentional deficits | #627 |
hrr | #627 |
seeks | #627 |
treatment disorder | #629 |
fibromyalgia | #629 |
child gender | #629 |
schizophrenia findings | #630 |
reject | #631 |
deficits schizophrenia | #631 |
teacher ratings | #632 |
needed | #633 |
girls boys | #634 |
genetic basis | #635 |
tiny | #637 |
generalisability | #638 |
icv | #638 |
obsessivecompulsive disorder | #638 |
disease genotype humans | #639 |
longitudinal | #640 |
adult outcomes | #641 |
advertisement | #641 |
ranks | #641 |
illness duration | #642 |
inconsistent | #643 |
gateway | #643 |
expression genes | #644 |
twin pairs | #645 |
premorbid | #645 |
subjects schizophrenia | #646 |
functioning autism | #646 |
exacerbate | #647 |
methodological | #648 |
17 years | #649 |
galantamine | #650 |
gene association | #652 |
avoidant | #652 |
treatment effects | #652 |
128 | #653 |
physical conditions | #653 |
hyperactivity inattention | #653 |
federation | #654 |
stroop | #654 |
intergenerational transmission | #655 |
reward anticipation | #656 |
random allocation rats | #656 |
bipolar disorder schizophrenia | #656 |
studies evidence | #657 |
boldness | #658 |
impairment | #658 |
groups compared | #658 |
psychosocial treatment | #658 |
volumes | #659 |
hypomanic | #659 |
association exposure | #660 |
poorer performance | #661 |
core feature | #661 |
structural alterations | #662 |
peer relations | #662 |
referrals | #662 |
digeorge syndrome | #665 |
lowlevel | #665 |
permission | #665 |
subcortical | #666 |
dacc | #666 |
psychiatric illnesses | #667 |
mood | #668 |
swedish population | #669 |
prominent | #669 |
phenotypic expression | #672 |
neurobiological | #675 |
time children | #676 |
impulsive behaviors | #677 |
disorders memory | #678 |
unselected | #678 |
129 | #679 |
sleep difficulties | #679 |
mental disorders humans | #680 |
psychopathological symptoms | #680 |
middle childhood | #680 |
neurotic | #681 |
gene frequency | #681 |
soviet union | #682 |
trait | #682 |
semantic fluency | #682 |
quetiapine | #682 |
severe phenotype | #683 |
remitting | #685 |
east asian | #685 |
scales | #685 |
p0019 | #687 |
17q | #688 |
chromosomal region | #688 |
children groups | #688 |
postmortem brains | #689 |
fibromyalgia patients | #689 |
younger children | #689 |
disorder schizophrenia | #694 |
tcas | #694 |
average age | #694 |
testretest reliability | #695 |
cortical surface area | #696 |
parcellation | #696 |
participants | #696 |
pharmacokinetic profile | #697 |
5years | #697 |
4–5 | #697 |
relevant studies | #699 |
drug abuse | #699 |
122 | #699 |
effects methylphenidate | #700 |
nonrandom | #701 |
illness surveys | #701 |
quota | #701 |
adult mental | #701 |
pleiotropic effects | #704 |
treatmentnaïve | #704 |
gwa studies | #704 |
follow studies | #705 |
pathogenesis schizophrenia | #706 |
adaptive functioning | #706 |
preschool years | #706 |
autism spectrum | #708 |
p009 | #709 |
school settings | #709 |
children diagnosed | #710 |
informative | #713 |
chronic schizophrenia | #713 |
dysphoric | #714 |
prs | #714 |
maternal report | #714 |
eric | #714 |
misuse | #714 |
728 | #715 |
stress disorder | #715 |
ethanol consumption | #715 |
disorders substance | #715 |
3 weeks | #716 |
641 | #716 |
contradictory | #717 |
abstraction | #719 |
groundwork | #719 |
meta‐analysis | #720 |
clinical population | #721 |
multiple genes | #721 |
household income | #722 |
recurrence risk | #722 |
memory | #723 |
cognitive load | #724 |
cinguli | #725 |
proponents | #725 |
gender dysphoria | #726 |
male adolescents | #726 |
common snps | #726 |
lateonset | #726 |
schizophrenics | #727 |
attention deficits | #727 |
dizygotic | #728 |
statistical | #728 |
structured clinical interview | #729 |
assortative mating | #729 |
786 | #730 |
fmri study | #730 |
metabotropic glutamate | #731 |
prevention programs | #732 |
voxel based | #733 |
git | #733 |
correlates | #733 |
phenotypic heterogeneity | #734 |
finding | #734 |
wky | #735 |
gyrification | #737 |
life cycle | #737 |
health intervention | #737 |
opioid dependence | #738 |
substancerelated disorders | #738 |
inflation | #739 |
polygenic score | #739 |
validating | #740 |
rapid cycling | #741 |
boston | #742 |
caudate | #742 |
refill | #742 |
time task | #743 |
comparators | #744 |
amphetamines | #744 |
bupropion | #745 |
soviet | #745 |
topic twins | #745 |
neuropsychological status | #746 |
compulsive | #746 |
manifested | #747 |
duplications | #748 |
child interaction | #748 |
adrb1 | #749 |
934 | #750 |
examining | #750 |
fulfilling | #752 |
twins dizygotic | #752 |
347 | #754 |
molecular genetic analysis | #754 |
comt val158met | #755 |
post hoc | #755 |
recalled | #756 |
neuroleptics | #756 |
bipolar depression | #756 |
mental disorders | #756 |
nhe | #757 |
schizophrenia scz | #757 |
disease haplotypes humans | #759 |
renewal | #760 |
sads | #761 |
variation genome | #762 |
artifact | #763 |
matter abnormalities | #764 |
workday | #764 |
likelihoods | #765 |
humans logistic | #765 |
autism asd | #766 |
people schizophrenia | #767 |
substance misuse | #768 |
disinhibition | #769 |
comt polymorphism | #772 |
emerged | #772 |
performance patients | #774 |
parent reported | #776 |
birth rates | #776 |
behavioral phenotypes | #777 |
depressive | #777 |
human pair | #777 |
phenotypes | #778 |
euthymic | #779 |
deletion polymorphism | #779 |
risky behavior | #780 |
weaknesses | #780 |
schizophrenia relationship | #780 |
inheritance | #781 |
wky rats | #782 |
iowa gambling task | #782 |
combined analysis | #783 |
questioning | #783 |
fourth edition | #783 |
emerging roles | #784 |
mega | #784 |
teaes | #785 |
reformulation | #785 |
faced | #786 |
adolescence | #787 |
pbd | #787 |
963 | #787 |
niacin | #788 |
child temperament | #789 |
medial temporal lobe | #790 |
cgi | #791 |
behavioral | #791 |
spelling | #791 |
subtypes | #792 |
individuals schizophrenia | #793 |
clinical criteria | #793 |
association polymorphisms | #794 |
symptom burden | #794 |
motivations | #794 |
caveats | #796 |
delinquent | #796 |
separate | #797 |
363 | #800 |
additional studies | #800 |
genomic regions | #802 |
prenatal exposure | #803 |
dopamine d1 receptors | #803 |
randomized clinical trials | #804 |
stimulant drugs | #804 |
dysfunction | #805 |
clinically | #805 |
superior frontal | #805 |
novelty seeking | #806 |
male memory | #806 |
latent classes | #806 |
dorsolateral | #806 |
developmental perspective | #807 |
lobule | #808 |
hdrs | #809 |
dopamine function | #810 |
ucla | #810 |
preschool female humans | #811 |
dopamine serotonin | #811 |
adjusting | #811 |
phonemic | #811 |
blind | #813 |
coadministration | #815 |
declarative | #816 |
mhpg | #816 |
lasting | #817 |
tryptophan hydroxylase | #817 |
quantitative measures | #817 |
breakthroughs | #817 |
cfb | #817 |
memory attention | #818 |
epigenetic factors | #818 |
substance dependence | #818 |
single gene | #818 |
meeting | #820 |
cortical development | #820 |
rated | #821 |
patients psychotic disorders | #821 |
counties | #821 |
hme | #822 |
switches | #822 |
transcriptomic analysis | #824 |
parental report | #824 |
prefrontal regions | #824 |
rare coding variants | #825 |
common genetic | #825 |
adolescents asd | #827 |
humans models | #827 |
s100a6 | #828 |
treatment interventions | #829 |
multipoint | #830 |
timeframe | #830 |
lifetime prevalence | #831 |
multiple testing | #831 |
prevalent | #831 |
association tests | #832 |
conduct disorders | #832 |
liabilities | #833 |
college students | #834 |
sleep disorder | #837 |
n60 | #837 |
gray | #837 |
inbred shr rats | #838 |
matter humans | #838 |
aversion | #838 |
obstetric complications | #839 |
prescription | #839 |
symptom profiles | #839 |
neurocognition | #841 |
parenthood | #842 |
participants completed | #843 |
sporadic cases | #843 |
consensus statement | #844 |
biological basis | #844 |
facial emotion recognition | #845 |
n35 | #846 |
dnm | #847 |
exception | #847 |
gwas summary | #848 |
dysregulated | #848 |
dgcr8 | #848 |
factor model | #851 |
prefrontal | #855 |
nonsignificant | #857 |
putative | #857 |
schizophrenia healthy | #858 |
estimated prevalence | #858 |
heightened risk | #858 |
putamen | #858 |
6p | #859 |
nineteen | #859 |
preschool | #861 |
handbook | #862 |
heterogeneity | #863 |
delayed effects | #865 |
global assessment | #866 |
seventy | #866 |
glossary | #866 |
crosssectional studies | #867 |
nnt | #869 |
mental | #869 |
hypothesized | #869 |
neurobiological basis | #870 |
specialized | #872 |
753 | #873 |
pediatric | #874 |
perseverative errors | #874 |
shr rats | #874 |
existing evidence | #875 |
comorbidity depression | #875 |
hypotheses | #876 |
manova | #876 |
genetic counseling | #876 |
positive symptoms | #876 |
test performance | #877 |
gender differences | #879 |
externalizing disorders | #879 |
sizes | #881 |
memory functions | #882 |
association genetic | #883 |
altered | #884 |
12p | #886 |
psychedelics | #886 |
171 | #887 |
dynamism | #888 |
delayed | #890 |
cpts | #891 |
n95 | #893 |
n17 | #893 |
obsessive | #893 |
decade | #894 |
bonn | #894 |
veterans affairs | #895 |
480 | #897 |
164 | #898 |
cortical thinning | #902 |
biological psychiatry | #903 |
anterior cingulate | #903 |
sibling | #904 |
weight body | #904 |
bipolar illness | #904 |
genetic contribution | #904 |
reinforcer | #904 |
aptitude | #904 |
visit | #905 |
826 | #906 |
late childhood | #906 |
psychosocial functioning | #906 |
adult aggression | #907 |
standardized difference | #909 |
morphometric | #910 |
symptom control | #911 |
ggc | #911 |
amygdala reactivity | #912 |
pedigrees | #912 |
psychosocial | #912 |
complications pregnancy | #913 |
visuospatial memory | #913 |
versions | #914 |
underlying pathophysiology | #914 |
association age | #916 |
disorder specific | #917 |
school performance | #917 |
cousins | #918 |
sleep children | #920 |
177 | #923 |
screening tool | #924 |
pharmacogenetic | #924 |
vulnerability | #925 |
dysthymic | #925 |
wide | #926 |
developmental trajectories | #927 |
dividing | #927 |
affective disorder | #928 |
cpg sites | #930 |
nucleotide | #930 |
participating | #930 |
heroin addiction | #933 |
permutation | #933 |
194 | #933 |
20mg | #934 |
d5 | #935 |
adolescence young adulthood | #935 |
smoking risk | #936 |
environment interactions | #936 |
3040 | #937 |
diagnostic | #938 |
female genotype | #938 |
study designs | #938 |
robustly | #940 |
irrs | #940 |
critics | #941 |
severe form | #941 |
tdt | #943 |
gwas | #946 |
brain regions | #946 |
sles | #948 |
22q | #948 |
risk developing | #949 |
albeit | #950 |
fetal exposure | #950 |
subtest | #952 |
relapsers | #954 |
personality disorder | #954 |
amphetamine | #954 |
behavioral treatment | #955 |
prompted | #956 |
effects sex | #956 |
112 | #959 |
qam | #960 |
clinical disorders | #960 |
cytoarchitecture | #962 |
clinical assessment | #963 |
children epilepsy | #963 |
female frontal | #963 |
dopamine uptake | #965 |
scores | #965 |
tandem repeat | #965 |
cgis | #965 |
scarce | #966 |
body height | #966 |
heritability estimates | #967 |
splicing factor | #968 |
cuneus | #968 |
freesurfer | #969 |
examined | #970 |
pharmacological treatment | #970 |
schizophrenia association | #970 |
mtbi | #970 |
medication treatment | #971 |
aggression | #972 |
risky sexual behavior | #972 |
262 | #973 |
chromosome mapping | #974 |
diva | #975 |
autism spectrum disorder | #976 |
fluphenazine | #977 |
vmat2 | #978 |
psychosis risk | #978 |
resolve | #978 |
2–4 | #980 |
neurodevelopmental disorder | #980 |
educational | #982 |
459 | #982 |
pertaining | #982 |
seriousness | #985 |
logistic regression models | #986 |
symptoms age | #986 |
alleles | #986 |
patients sle | #987 |
difficulties | #988 |
tci | #990 |
small proportion | #990 |
ranked | #990 |
depressed mothers | #991 |
polymorphism genetic | #994 |
pathway analysis | #995 |
colleagues | #996 |
temporal stability | #996 |
internal consistency | #997 |
comorbid conditions | #998 |
keystone | #999 |
detoxification | #999 |
diathesis | #999 |
adolescent analysis | #1000 |
child child | #1001 |
interviews | #1003 |
stata | #1003 |
comparative efficacy | #1004 |
haplotypes | #1006 |
confounding factors | #1007 |
allele | #1007 |
preschool cohort | #1007 |
0016 | #1007 |
long‐term outcome | #1007 |
daughter | #1007 |
norms | #1008 |
structural mri | #1008 |
risk alcohol | #1009 |
posttraumatic stress disorder | #1009 |
multiplex | #1009 |
qualifications | #1009 |
discriminant | #1010 |
genes environment | #1012 |
ltc | #1014 |
7 years | #1014 |
metabotropic | #1020 |
maturational | #1020 |
conclusive | #1021 |
relates | #1024 |
risk prediction | #1024 |
insufficient | #1026 |
pharmacotherapies | #1027 |
004 | #1027 |
persistent | #1028 |
obsessive – | #1028 |
pharmacologic | #1029 |
weiss | #1030 |
frontostriatal | #1031 |
wwwclinicaltrialsgov | #1031 |
analytic | #1031 |
symptoms child | #1032 |
patients panic disorder | #1032 |
predicted | #1034 |
preface | #1034 |
– compulsive | #1034 |
73 | #1034 |
brain disorders | #1035 |
negative symptoms | #1035 |
total score | #1035 |
rodent models | #1035 |
eventual | #1037 |
exploratory analyses | #1037 |
major depressive episode | #1039 |
general framework | #1040 |
serotonin | #1041 |
general intelligence | #1041 |
twin | #1043 |
mental health treatment | #1044 |
gaf | #1044 |
relate | #1045 |
heightened | #1045 |
antecedents | #1046 |
inv | #1046 |
ffi | #1050 |
late gestation | #1051 |
subtle | #1052 |
onset schizophrenia | #1052 |
benzodiazepines | #1053 |
disorders post | #1054 |
school age | #1055 |
vice | #1056 |
psychiatric morbidity | #1056 |
major humans | #1058 |
nogo | #1058 |
youth report | #1060 |
obscure | #1060 |
adolescence adulthood | #1061 |
bipolar disorders | #1062 |
199 | #1063 |
illicit | #1063 |
genes involved | #1063 |
memory disorders | #1064 |
europe female | #1065 |
paediatric patients | #1065 |
pooled | #1068 |
awakenings | #1068 |
heritability | #1068 |
paranoia | #1068 |
childhood trauma | #1068 |
emotional | #1069 |
negative impact | #1069 |
memantine | #1069 |
word reading | #1070 |
memory impairments | #1070 |
human genetics | #1070 |
single nucleotide receptors | #1071 |
risk scores | #1071 |
reading ability | #1071 |
social problems | #1071 |
controlled clinical | #1071 |
genetic model | #1071 |
character inventory | #1072 |
4q | #1072 |
associations | #1073 |
validity | #1073 |
obesity risk | #1074 |
studying | #1075 |
3′utr | #1075 |
general hospital | #1076 |
mapping chromosomes | #1077 |
schizophrenia spectrum disorders | #1078 |
transdiagnostic | #1080 |
exposure delayed | #1080 |
adult antipsychotic | #1082 |
schizophrenia social | #1082 |
anxiety children | #1083 |
contiguous | #1084 |
onset psychosis | #1086 |
autoreceptors | #1086 |
psds | #1086 |
european continental | #1088 |
alcohol marijuana | #1089 |
distinctive | #1090 |
subtype | #1090 |
polygenic scores | #1092 |
development disorders | #1092 |
obsessivecompulsive disorder ocd | #1093 |
gifted | #1094 |
scientific literature | #1096 |
semistructured interview | #1096 |
irritable | #1096 |
smoking | #1099 |
metaanalysis | #1102 |
external validity | #1103 |
future work | #1103 |
daughters | #1103 |
cnvs | #1104 |
odds | #1106 |
diagnostic groups | #1107 |
10 weeks | #1107 |
psychosis | #1107 |
emotional behavioral | #1108 |
bip | #1108 |
experimental test | #1110 |
psychoses | #1110 |
prioritized | #1110 |
10−5 | #1111 |
share | #1111 |
male children | #1112 |
depressive disorder | #1113 |
new developments | #1114 |
effects children | #1116 |
discusses | #1117 |
schizophrenia subjects | #1119 |
psychotropic | #1121 |
children anxiety | #1122 |
632 | #1123 |
exchangers | #1123 |
556 | #1124 |
coexisting | #1125 |
mts | #1125 |
projects | #1127 |
quantifies | #1128 |
similarities | #1128 |
enriched | #1128 |
dysthymic disorder | #1128 |
investigator | #1129 |
weighting | #1130 |
adult alcoholism | #1130 |
attention performance | #1134 |
n28 | #1134 |
psychiatric diagnosis | #1135 |
birth outcomes | #1136 |
independent sample | #1136 |
laterality humans | #1138 |
blood pressure response | #1138 |
susceptibility loci | #1139 |
clinical samples | #1142 |
social phobia | #1142 |
signal task | #1144 |
cognitive domains | #1145 |
prodromal | #1145 |
early adolescent | #1145 |
demographic factors | #1146 |
normal volunteers | #1147 |
emotionality | #1147 |
measurement invariance | #1147 |
refine | #1149 |
humans intellectual | #1150 |
discriminability | #1150 |
children association | #1150 |
discounting | #1150 |
quick | #1152 |
developmental model | #1152 |
continents | #1152 |
normals | #1153 |
generalizability | #1153 |
refinements | #1153 |
sensory gating | #1154 |
clinical profiles | #1154 |
alspac | #1154 |
uncorrected | #1160 |
ht2c | #1160 |
differential humans | #1160 |
phenotype | #1161 |
review findings | #1163 |
” “ | #1163 |
phobia | #1164 |
studies data | #1164 |
neurocognitive function | #1165 |
affective | #1166 |
deteriorated | #1166 |
clinical groups | #1166 |
congress | #1167 |
catecholaminergic | #1168 |
medication status | #1169 |
social outcomes | #1170 |
292 | #1171 |
quality measures | #1174 |
mspi | #1175 |
bpd patients | #1176 |
cohen | #1176 |
gwas data | #1176 |
nicotine exposure | #1177 |
genetic risk factors | #1177 |
male subjects | #1178 |
clinical validation | #1178 |
study gwas | #1179 |
cinguli humans | #1182 |
reward | #1182 |
childhood exposure | #1182 |
persisting | #1182 |
nonverbal | #1183 |
triads | #1184 |
paradox | #1184 |
addressing | #1184 |
standardized | #1187 |
functional polymorphisms | #1188 |
hydrochloride | #1189 |
dysbindin | #1189 |
64 | #1190 |
child preschool | #1192 |
psychology | #1193 |
assess | #1194 |
parenting behavior | #1197 |
onequarter | #1198 |
compulsivity | #1198 |
addictions | #1198 |
placebo | #1199 |
wm | #1199 |
230 | #1200 |
asian continental | #1200 |
wisconsin | #1201 |
morbidity | #1202 |
sib | #1204 |
systematic search | #1204 |
millennium | #1207 |
problems children | #1209 |
externalizing symptoms | #1209 |
nationwide cohort study | #1209 |
neuropsychology | #1210 |
conceptualizations | #1210 |
p004 | #1211 |
term treatment | #1215 |
sample sizes | #1218 |
male mass | #1219 |
underlying | #1220 |
lbw | #1220 |
antecedent | #1221 |
child cognitive | #1222 |
prospects | #1222 |
study role | #1224 |
profile | #1226 |
approximated | #1227 |
partly | #1227 |
0011 | #1229 |
subgroup | #1232 |
refining | #1232 |
molecular alterations | #1232 |
poster | #1233 |
pregnancy prenatal | #1234 |
health organization | #1234 |
gprotein | #1235 |
children ages | #1235 |
shortcomings | #1237 |
educational attainment | #1239 |
brain structure | #1242 |
tandem repeats | #1242 |
interpersonal relations | #1244 |
short form | #1245 |
risk asthma | #1247 |
avenues | #1247 |
kf | #1247 |
enjoyment | #1247 |
cidi | #1248 |
psychosocial outcomes | #1248 |
cpg islands | #1249 |
roc | #1251 |
delineate | #1251 |
debilitating | #1252 |
alcohol disorders | #1255 |
summarize | #1256 |
risk ratio | #1256 |
serotonin transporter | #1256 |
nervous | #1257 |
dysfunctions | #1257 |
goal | #1257 |
onset depression | #1259 |
combine | #1260 |
consensus statements | #1263 |
characterize | #1266 |
onset age | #1267 |
likewise | #1270 |
logistic regression analyses | #1271 |
child mental | #1273 |
statistical methods | #1274 |
386 | #1277 |
entire | #1277 |
developmental pathways | #1277 |
n24 | #1278 |
study evidence | #1281 |
04 | #1281 |
priori | #1282 |
paternal | #1282 |
behavior adolescent | #1283 |
hopes | #1283 |
increased rates | #1283 |
neuroimaging | #1283 |
variance | #1284 |
spontaneously hypertensive | #1285 |
general cognitive | #1286 |
087 | #1286 |
male nerve | #1288 |
somatic complaints | #1288 |
orbitofrontal | #1288 |
warmth | #1289 |
aspect | #1289 |
unmyelinated | #1291 |
1hmrs | #1291 |
posttraumatic | #1291 |
dual psychiatry | #1291 |
clomipramine | #1292 |
quantitative trait | #1292 |
animal conditioning | #1292 |
misclassification | #1292 |
negative emotion | #1295 |
pvalue | #1297 |
136 | #1297 |
chromosomes | #1298 |
cures | #1301 |
atx | #1303 |
935 | #1305 |
1520 | #1305 |
cortical volume | #1306 |
sgas | #1309 |
prediction accuracy | #1309 |
extant | #1310 |
vin | #1310 |
risperidone | #1311 |
arrests | #1312 |
motor speed | #1313 |
factor analyses | #1313 |
criteria | #1314 |
76 | #1315 |
factors smoking | #1316 |
minds | #1317 |
class analysis | #1317 |
adolescents children | #1318 |
current findings | #1320 |
hypothetical | #1321 |
predictability | #1322 |
short | #1323 |
parents adolescents | #1323 |
polymorphism | #1324 |
hypothesis | #1325 |
response treatment | #1327 |
confusion | #1330 |
influencing | #1330 |
defining | #1331 |
polysubstance | #1334 |
measures | #1334 |
253 | #1335 |
psychopharmacology | #1335 |
authors | #1336 |
genetic background | #1336 |
nonuse | #1337 |
obsessive–compulsive disorder | #1338 |
fronto | #1338 |
clinical phenotypes | #1342 |
longterm outcome | #1342 |
542 | #1344 |
registry data | #1344 |
llysine | #1345 |
explaining | #1345 |
interpretation statistical | #1349 |
compared children | #1353 |
early adulthood | #1353 |
psychoticism | #1355 |
cocaine abuse | #1356 |
diagnostic tool | #1356 |
loci genetic | #1356 |
simon | #1357 |
variabilities | #1357 |
flush | #1357 |
seekers | #1358 |
gene discovery | #1359 |
antidepressive | #1359 |
broad spectrum | #1361 |
middle frontal gyrus | #1362 |
mammalian target | #1362 |
intergenerational | #1365 |
abcd | #1367 |
uptake inhibitors | #1369 |
school teachers | #1369 |
unexplored | #1369 |
neuronal development | #1369 |
reliance | #1370 |
intellectual functioning | #1371 |
observer variation | #1374 |
covert | #1377 |
larger | #1378 |
pallidum | #1380 |
inositol | #1382 |
ghr | #1385 |
highlighted | #1386 |
thought disorder | #1386 |
new onset | #1386 |
dimensional approach | #1389 |
familial aggregation | #1391 |
6 years | #1391 |
treatment depression | #1391 |
prodrome | #1391 |
illicit drugs | #1393 |
vendors | #1394 |
satisfying | #1395 |
rats shr | #1395 |
thalamic | #1395 |
manuscripts | #1395 |
racial | #1398 |
timely | #1399 |
emotional stimuli | #1399 |
suggesting | #1400 |
lability | #1400 |
17 | #1402 |
sufficient | #1403 |
blinded | #1403 |
brain region | #1404 |
hippocampal volumes | #1405 |
placebo treatment | #1407 |
hama | #1408 |
create | #1409 |
preparations | #1410 |
personality inventory | #1412 |
1998 | #1413 |
shyness | #1414 |
issue | #1414 |
independent | #1415 |
prepubertal children | #1416 |
impressions | #1416 |
332 | #1417 |
carry | #1419 |
logical | #1419 |
humans memory | #1421 |
parents children | #1422 |
discoveries | #1422 |
exploratory factor analysis | #1423 |
greater | #1426 |
dosed | #1427 |
linkage disequilibrium | #1430 |
163 | #1431 |
taps | #1431 |
cognitive profiles | #1432 |
interaction effects | #1432 |
affairs | #1434 |
social perception | #1436 |
publication adult analysis | #1438 |
bche | #1439 |
academic | #1443 |
holidays | #1444 |
personality | #1447 |
psychotic illness | #1448 |
443 | #1448 |
chp | #1449 |
hydroxylase | #1450 |
prevalence obesity | #1450 |
ratings | #1451 |
height | #1453 |
square | #1453 |
ewas | #1453 |
78 | #1453 |
hypermethylation | #1454 |
population stratification | #1454 |
switching | #1455 |
dorsal striatum | #1457 |
collaborations | #1457 |
replicability | #1457 |
generalized anxiety | #1458 |
comparisons | #1459 |
severe depression | #1462 |
stronger | #1463 |
biological pathways | #1463 |
treatment duration | #1464 |
discordant | #1467 |
principal | #1467 |
untranslated | #1468 |
partial remission | #1468 |
valuable | #1468 |
groups differences | #1469 |
hippocampi | #1469 |
contrast effects | #1472 |
cognition patients | #1474 |
statistically | #1474 |
openlabel | #1474 |
amygdala volume | #1477 |
risk relapse | #1479 |
conducted | #1480 |
medication | #1481 |
cortex dlpfc | #1487 |
prodromal symptoms | #1488 |
issues | #1489 |
apt | #1492 |
adrb2 | #1493 |
hypomethylation | #1495 |
mri studies | #1497 |
smaller | #1497 |
allele carriers | #1497 |
twins monozygotic | #1499 |
lifespan | #1499 |
small sample sizes | #1499 |
converge | #1500 |
populationbased study | #1501 |
patients bipolar | #1502 |
cpt | #1503 |
ddc | #1505 |
male mothers | #1505 |
multisite | #1505 |
examination | #1508 |
manifestation | #1510 |
salience network | #1510 |
existing literature | #1511 |
objectivity | #1511 |
emotions female | #1513 |
reports | #1513 |
attained | #1513 |
messaging | #1514 |
cognitive ability | #1515 |
pedigree | #1516 |
eicosapentaenoic acid | #1517 |
screening instrument | #1517 |
repeat | #1518 |
criminal behavior | #1519 |
165 | #1521 |
114 | #1523 |
topic | #1523 |
cna | #1523 |
bipolar patients | #1526 |
inconsistency | #1526 |
nacetylaspartate | #1528 |
inferior frontal | #1528 |
psychiatric disorder | #1528 |
symptomatology | #1530 |
512 | #1535 |
began | #1536 |
arntl | #1540 |
default | #1541 |
nucleotide risk | #1541 |
poses | #1542 |
adult life | #1542 |
dopamine receptor | #1542 |
stress disorders | #1543 |
gwass | #1544 |
yale | #1545 |
treatment schizophrenia | #1545 |
omission | #1547 |
traits | #1549 |
card | #1551 |
problem behaviors | #1554 |
influenced | #1554 |
automobile | #1556 |
857 | #1556 |
failed | #1559 |
early exposure | #1559 |
loci | #1560 |
0009 | #1561 |
0013 | #1564 |
subscales | #1565 |
475 | #1565 |
insular | #1565 |
interpersonal | #1566 |
humans interpersonal | #1569 |
wise | #1570 |
consortium | #1573 |
swedish | #1573 |
191 | #1573 |
depression children | #1574 |
neurochemistry | #1575 |
attempted | #1576 |
life quality | #1579 |
meta | #1579 |
selfreport questionnaires | #1580 |
gene networks | #1580 |
findings studies | #1582 |
single nucleotide polymorphism | #1582 |
located | #1582 |
network dmn | #1583 |
models male | #1583 |
cutoffs | #1583 |
social functioning | #1584 |
hyperactivation | #1587 |
major depressive | #1588 |
firstepisode schizophrenia | #1588 |
rs4680 | #1588 |
genetic data | #1589 |
pain patients | #1589 |
edinburgh | #1590 |
advent | #1591 |
55 | #1592 |
phobias | #1593 |
temperament | #1594 |
162 | #1596 |
subcortical structures | #1596 |
symptom presentation | #1598 |
tpv | #1599 |
moderators | #1599 |
psychotropic medications | #1601 |
statistics nonparametric | #1601 |
jan | #1602 |
managed | #1603 |
suffer | #1604 |
utr | #1604 |
spontaneously | #1605 |
heritabilities | #1606 |
classifying | #1608 |
academic achievement | #1609 |
proneness | #1610 |
1979 | #1610 |
monoamine oxidase | #1611 |
emotional faces | #1613 |
alcoholism | #1613 |
status | #1614 |
ancestry female | #1615 |
male maternal | #1616 |
drawn | #1619 |
broadly | #1620 |
distinguishing | #1622 |
large body | #1622 |
risk mental | #1622 |
hbr | #1624 |
childhood asthma | #1624 |
snp | #1626 |
paucity | #1626 |
spatial organization | #1627 |
ht2a receptor | #1627 |
louis | #1628 |
dysphoria | #1628 |
genomics humans | #1629 |
verbal behavior | #1629 |
kyoto | #1630 |
study children | #1630 |
emrs | #1631 |
ambiguous | #1631 |
memory task | #1631 |
198 | #1633 |
susceptibility gene | #1634 |
supporting | #1635 |
mental illnesses | #1637 |
positive predictive | #1638 |
lag | #1639 |
brain female | #1640 |
tendency | #1643 |
rack1 | #1643 |
social communication | #1643 |
alpha7 | #1643 |
bprs | #1644 |
potential effects | #1646 |
socially | #1647 |
interrelations | #1649 |
treating | #1650 |
controlled | #1653 |
rea | #1653 |
nucleotide polymorphisms | #1655 |
adolescents age | #1657 |
detect | #1658 |
maximize | #1658 |
require | #1659 |
psychotic disorder | #1659 |
personality disorders | #1661 |
symptom severity | #1662 |
presentations | #1663 |
comorbid depression | #1663 |
asm | #1664 |
510 | #1665 |
chronic patients | #1666 |
mood symptoms | #1666 |
dlpfc | #1666 |
association analysis | #1667 |
indexed | #1670 |
human rights | #1670 |
bipolar disorder patients | #1671 |
13 years | #1672 |
transmitted | #1673 |
asd symptoms | #1674 |
early signs | #1675 |
alcohol spectrum | #1675 |
statements | #1675 |
53 | #1677 |
registers | #1678 |
introns | #1678 |
calling | #1678 |
homogeneous | #1679 |
social anxiety | #1679 |
seat | #1680 |
beagle | #1680 |
mathematical models | #1682 |
prescribed | #1684 |
46 | #1684 |
mildly | #1684 |
memory deficit | #1685 |
ancestries | #1685 |
autistic disorder | #1689 |
mdd | #1689 |
github | #1689 |
agenda | #1692 |
psychotropic drugs | #1692 |
impulse control | #1693 |
motor skills | #1698 |
recruited | #1698 |
diagnose | #1699 |
91 | #1702 |
item | #1704 |
memory consolidation | #1704 |
conceptualization | #1705 |
middle frontal | #1710 |
reduced activation | #1711 |
neuroscience | #1712 |
personality characteristics | #1712 |
rater | #1712 |
health records | #1712 |
schizophrenia spectrum | #1713 |
net | #1716 |
perpetrators | #1725 |
nhe1 | #1728 |
autistic | #1729 |
epigenetics | #1730 |
inhibitory control | #1731 |
107 | #1731 |
cbs | #1732 |
hindered | #1733 |
highlight | #1735 |
machine | #1735 |
stand | #1736 |
identical | #1736 |
aimed | #1739 |
predictors | #1739 |
dopamine receptors | #1741 |
sex age | #1743 |
curated | #1746 |
forum | #1746 |
longitudinal analysis | #1747 |
cognitive difficulties | #1748 |
pds | #1749 |
occipital lobe | #1750 |
tremors | #1752 |
02 | #1753 |
selfreport measures | #1753 |
questionnaires young | #1755 |
sertraline | #1756 |
326 | #1756 |
5ht2a | #1758 |
120 | #1758 |
genetic models | #1761 |
social | #1761 |
ventral striatum | #1761 |
bipolar affective | #1763 |
drowsiness | #1763 |
includes | #1765 |
chance | #1765 |
adult onset | #1766 |
operant | #1768 |
mystery | #1768 |
reflects | #1769 |
sisters | #1770 |
dopamine | #1772 |
dizygotic twins | #1773 |
treatment implications | #1773 |
depressive episode | #1775 |
patients systemic | #1775 |
patients adult | #1776 |
267 | #1776 |
establishing | #1777 |
mental recall | #1777 |
utrs | #1779 |
10−7 | #1780 |
early childhood | #1781 |
higher doses | #1786 |
commonalities | #1786 |
major | #1786 |
social anxiety disorder | #1787 |
defined | #1789 |
frustration | #1791 |
male motor | #1791 |
transdermal | #1793 |
disorder mdd | #1795 |
harbor | #1796 |
causal variants | #1797 |
positive association | #1797 |
disabilities | #1797 |
autism spectrum disorders | #1800 |
reporters | #1801 |
aged models | #1801 |
members | #1801 |
genetic variance | #1802 |
chapters | #1803 |
shr | #1804 |
females | #1805 |
families children | #1806 |
based analysis | #1807 |
covariation | #1807 |
168 | #1809 |
expanded | #1812 |
nucleotide polymorphism | #1812 |
european descent | #1813 |
146 | #1813 |
aetiology | #1813 |
frequently | #1815 |
internationality | #1815 |
purchases | #1816 |
brain imaging | #1816 |
hippocampal volume | #1819 |
cohens | #1819 |
lds | #1819 |
correlate | #1823 |
suicide attempt | #1825 |
endpoint | #1827 |
followup | #1830 |
splenium | #1831 |
binocular | #1833 |
foundation | #1833 |
psychotic patients | #1837 |
suggested | #1838 |
94 | #1840 |
patterns | #1841 |
neural activity | #1841 |
trauma exposure | #1842 |
assessment tools | #1842 |
initiative | #1845 |
distinctions | #1845 |
twins | #1845 |
literacy | #1846 |
psychological | #1847 |
pertinent | #1847 |
warrant | #1848 |
environmental risk | #1848 |
polymorphisms | #1849 |
limited | #1850 |
vocabulary | #1851 |
fearful | #1851 |
individual | #1851 |
nonparametric | #1852 |
differentiating | #1853 |
brainderived neurotrophic factor | #1853 |
young | #1853 |
persons | #1855 |
abuse | #1856 |
auditory hallucinations | #1856 |
prevalence | #1859 |
tph | #1859 |
behavioral measures | #1860 |
incentives | #1860 |
cnb | #1861 |
affiliation | #1861 |
8p | #1862 |
obstacle | #1864 |
multilevel | #1865 |
vocalization | #1865 |
poison | #1865 |
switch | #1865 |
severely | #1867 |
18 | #1869 |
structural functional | #1875 |
constitute | #1876 |
manuscript | #1877 |
histograms | #1879 |
roc curve | #1879 |
shrs | #1880 |
animal model | #1880 |
delusions | #1881 |
afb | #1882 |
longer duration | #1882 |
common genetic variation | #1883 |
genome | #1885 |
differs | #1888 |
false | #1888 |
metaanalysis studies | #1890 |
substance abuse | #1890 |
heterogeneous | #1894 |
spanning | #1894 |
susceptibility genes | #1896 |
latent class analysis | #1899 |
maintained | #1899 |
correspondences | #1901 |
psychostimulant | #1902 |
chinese | #1903 |
analyses | #1903 |
illicit drug | #1904 |
actigraphy | #1905 |
specific symptoms | #1907 |
increasingly | #1907 |
emotion | #1908 |
epidemiologic | #1909 |
majority | #1909 |
ads | #1910 |
support vector machine | #1911 |
disorders mental | #1911 |
structural differences | #1912 |
generation antipsychotics | #1913 |
africanamericans | #1915 |
χ2 | #1916 |
10h | #1920 |
inform | #1921 |
association maternal | #1923 |
liking | #1923 |
satisfied | #1923 |
aggregate | #1926 |
child cross | #1926 |
overview | #1927 |
251 | #1928 |
advertising | #1928 |
sleep problems | #1928 |
empirical studies | #1929 |
ssri | #1930 |
95 cis | #1934 |
asd children | #1934 |
borderline personality disorder | #1937 |
simulation study | #1937 |
exomes | #1938 |
stratified | #1939 |
general | #1942 |
25 years | #1945 |
literature review | #1947 |
neurobehavioral | #1949 |
representing | #1950 |
traumatic brain injury | #1950 |
trait loci | #1952 |
accumbens | #1953 |
normal children | #1954 |
efficacious | #1957 |
msp | #1958 |
neurotransmitter release | #1959 |
mems | #1961 |
intolerant | #1962 |
micronesia | #1963 |
896 | #1964 |
sdq | #1967 |
brain networks | #1968 |
vital signs | #1969 |
sorting | #1971 |
clinical implications | #1972 |
correctly | #1972 |
depression | #1972 |
connectivity | #1974 |
hoc | #1975 |
factors surveys | #1976 |
child depression | #1977 |
repeats | #1977 |
conflicting | #1978 |
listing | #1978 |
hippocampus humans | #1981 |
ptsd | #1981 |
common mental disorders | #1984 |
chinese population | #1984 |
pax5 | #1986 |
phase 3 trial | #1986 |
secondary analysis | #1987 |
brain | #1989 |
school | #1990 |
predisposing | #1991 |
current paper | #1994 |
genetic differences | #1996 |
226 | #1997 |
fmr | #1998 |
pattern | #1999 |
diagnosed | #2001 |
comparable | #2002 |
spouses | #2003 |
asian continental ancestry | #2005 |
formulations | #2005 |
harm avoidance | #2007 |
functional variants | #2010 |
behavioral symptoms | #2011 |
nos1 | #2012 |
absence | #2014 |
muscle function | #2014 |
akt1 | #2014 |
sms | #2015 |
noradrenergic | #2015 |
cognitive deficits | #2016 |
possibility | #2016 |
prescribers | #2021 |
schoolage children | #2023 |
159 | #2023 |
serve | #2026 |
sleep disturbances | #2030 |
phenomenology | #2030 |
brain responses | #2031 |
memory verbal | #2031 |
regional brain | #2032 |
neurodevelopmental disorders | #2033 |
morbid | #2036 |
receptors nicotinic | #2037 |
prenatally | #2037 |
diminished | #2040 |
retest reliability | #2040 |
erythematosus systemic | #2041 |
asperger | #2041 |
nicotinic acetylcholine | #2045 |
cognitive processing | #2046 |
227 | #2046 |
informants | #2048 |
erythematosus | #2049 |
functional | #2050 |
cognition | #2050 |
juvenile | #2052 |
contribute | #2054 |
adolescent behavior | #2056 |
external control | #2057 |
chapman | #2058 |
common diseases | #2061 |
insula | #2061 |
educated | #2062 |
stabilizers | #2064 |
ongoing | #2065 |
demography | #2066 |
overweight obesity | #2066 |
val158met polymorphism | #2067 |
preschool humans | #2068 |
functional mri | #2069 |
massachusetts | #2069 |
0008 | #2071 |
parental education | #2072 |
phenotypic | #2072 |
psychotic symptoms | #2077 |
international consensus | #2078 |
degree | #2078 |
descent | #2079 |
wake disorders | #2079 |
heterogeneity studies | #2082 |
psychomotor | #2084 |
male gender | #2085 |
5 ht2a | #2087 |
43 | #2090 |
latent class | #2090 |
factors child | #2093 |
49 | #2095 |
wky shr | #2096 |
aud | #2096 |
subsets | #2099 |
69 | #2100 |
dopaminergic | #2100 |
142 | #2102 |
general factor | #2106 |
age children | #2107 |
ht2a | #2108 |
adult population | #2108 |
causation | #2109 |
specific genetic | #2112 |
child relations | #2112 |
nicotinic | #2112 |
279 | #2115 |
brain dysfunction | #2115 |
83 | #2117 |
poorer | #2119 |
relative age | #2119 |
monoamine | #2119 |
postpartum period | #2119 |
84 | #2121 |
career | #2122 |
51 | #2122 |
pgs | #2122 |
sixth | #2124 |
identifies | #2126 |
pbls | #2126 |
dysfunctional | #2128 |
biased | #2129 |
ovid | #2130 |
functional polymorphism | #2132 |
rates | #2134 |
dbh | #2137 |
episode schizophrenia | #2137 |
psychosocial factors | #2140 |
adversities | #2141 |
interpretability | #2141 |
discrepant | #2142 |
relevant literature | #2143 |
pvs | #2145 |
methods participants | #2145 |
behavioral disorders | #2146 |
receptors adrenergic | #2147 |
intraclass | #2147 |
105 | #2147 |
juveniles | #2148 |
abnormalities | #2149 |
232 | #2150 |
finemapping | #2150 |
glutamatergic | #2150 |
represents | #2150 |
assessing | #2151 |
repositioning | #2151 |
rrr | #2153 |
mao | #2153 |
psychiatric patients | #2155 |
abdominal obesity | #2164 |
differentiated | #2164 |
clinical assessments | #2166 |
declarative memory | #2167 |
shr wky | #2167 |
differential diagnostic | #2168 |
genetic association studies | #2168 |
differing | #2168 |
glx | #2169 |
major depressive disorder | #2170 |
adversely | #2171 |
prevalences | #2171 |
mb | #2171 |
tardive dyskinesia | #2172 |
severity | #2172 |
aggregated | #2177 |
irt | #2180 |
externalizing | #2181 |
moderating | #2181 |
environmental factors | #2183 |
author | #2185 |
report measures | #2186 |
teachers | #2187 |
computerassisted imaging | #2188 |
thought | #2188 |
differential expression | #2189 |
processing speed | #2189 |
scale | #2192 |
generalized anxiety disorder | #2192 |
regular | #2192 |
serotonin 5 | #2193 |
imaging fmri | #2195 |
lifecycle | #2197 |
conceptual | #2197 |
pharmacological agents | #2199 |
achievement | #2200 |
confounding | #2201 |
ages | #2201 |
double | #2205 |
brain mapping | #2206 |
developing brain | #2206 |
abstract background | #2207 |
remained | #2209 |
ottawa | #2209 |
169 | #2209 |
homozygosity | #2210 |
accidents | #2210 |
surveys questionnaires | #2210 |
antenatal | #2211 |
illness severity | #2211 |
genetic relationship | #2212 |
occurrences | #2217 |
adverse event | #2217 |
intronic | #2219 |
complex diseases | #2220 |
biologically | #2220 |
completed | #2220 |
hippocampal formation | #2220 |
autism | #2221 |
val66met | #2222 |
cognitive task | #2225 |
visuospatial | #2225 |
20th | #2226 |
replicating | #2227 |
single | #2228 |
caudate putamen | #2229 |
trail making | #2230 |
clinical profile | #2232 |
attainment | #2234 |
community sample | #2235 |
controls age | #2238 |
hexokinase | #2241 |
prototypical | #2241 |
implications | #2242 |
qualities | #2244 |
insensitivity | #2245 |
consultation | #2246 |
preliminary data | #2248 |
hamilton | #2253 |
val66met polymorphism | #2254 |
pubertal development | #2257 |
genomic analysis | #2260 |
treatment guidelines | #2260 |
cognitive deficit | #2263 |
novo mutations | #2263 |
earlier | #2264 |
cigarette | #2264 |
criterion | #2265 |
rewards | #2266 |
pathways | #2266 |
bds | #2266 |
clinical measures | #2267 |
evident | #2273 |
overdiagnosis | #2274 |
remain | #2275 |
axis | #2275 |
cognitive development | #2275 |
gray matter volume | #2275 |
tend | #2276 |
random allocation | #2277 |
mtl | #2277 |
imaging male | #2277 |
systemic lupus | #2279 |
apneahypopnea | #2279 |
moderation | #2283 |
lithium | #2283 |
psychiatric illness | #2285 |
cognitive | #2287 |
controlling | #2290 |
minority | #2292 |
update | #2293 |
physical health | #2294 |
regions | #2294 |
diverse populations | #2294 |
socialization | #2295 |
retained | #2297 |
monitored | #2298 |
11 years | #2299 |
corticotropin | #2301 |
239 | #2304 |
clinic | #2304 |
biology | #2304 |
adjunctive | #2306 |
virtue | #2307 |
consisting | #2308 |
lupus | #2310 |
difficult | #2310 |
enormous | #2311 |
brain anatomy | #2313 |
pregnancy | #2313 |
edition | #2315 |
behaviors | #2317 |
adequate | #2318 |
performance reaction | #2319 |
tests | #2321 |
brain systems | #2321 |
fmri | #2325 |
casecontrol study | #2326 |
memory performance | #2328 |
higher prevalence | #2330 |
257 | #2331 |
organ size | #2332 |
questionnaires | #2332 |
subset | #2333 |
mind | #2334 |
archives | #2335 |
disorganization | #2335 |
covariate | #2335 |
early risk | #2336 |
depression female | #2340 |
utility | #2342 |
lesser extent | #2342 |
nature | #2344 |
functional networks | #2344 |
20th century | #2345 |
cingulate | #2346 |
schedule | #2350 |
time perception | #2353 |
providing | #2353 |
mapping child | #2358 |
powered | #2362 |
adolescent brain | #2364 |
endosome | #2365 |
factor structure | #2367 |
limited evidence | #2368 |
concurrently | #2368 |
smallest | #2369 |
symptoms schizophrenia | #2369 |
efforts | #2376 |
social cognitive | #2377 |
antipsychotic agents | #2379 |
catecholamine | #2379 |
tapping | #2384 |
predicts | #2385 |
ecologically | #2386 |
gyrus | #2388 |
drugs abuse | #2391 |
unresolved | #2393 |
convergence | #2395 |
raising | #2395 |
problem solving | #2398 |
gray matter | #2401 |
essence | #2401 |
frontal | #2403 |
pubmed | #2406 |
addictive | #2407 |
sirolimus | #2407 |
adolescent alcohol | #2408 |
distinguished | #2410 |
validate | #2412 |
preserved | #2414 |
genetic factor | #2417 |
alternative | #2418 |
statistical significance | #2418 |
modules | #2419 |
illumina | #2422 |
starting | #2423 |
classified | #2425 |
disease genetic | #2426 |
salience | #2426 |
143 | #2428 |
term outcome | #2429 |
bdnf | #2429 |
confounders | #2431 |
fmri data | #2431 |
241 | #2433 |
clinical trial | #2433 |
protein interactions | #2433 |
protein interaction | #2436 |
analyzes | #2440 |
careful | #2443 |
intellectual | #2447 |
timepoints | #2448 |
dimorphism | #2448 |
items | #2449 |
multiple studies | #2450 |
mvr | #2452 |
deconvolution | #2452 |
systemic lupus erythematosus | #2456 |
overweight children | #2456 |
prefrontal cortical | #2456 |
moderately | #2458 |
myoinositol | #2459 |
genetic susceptibility | #2459 |
brain maturation | #2460 |
anxiety symptoms | #2460 |
logistic | #2461 |
traumatic stress | #2461 |
concordance | #2461 |
autosomes | #2462 |
crossover study | #2464 |
sex distribution | #2464 |
factor bdnf | #2466 |
hungary | #2469 |
unique | #2473 |
unclear | #2473 |
relatedness | #2482 |
brain activation | #2486 |
reaction time | #2488 |
higher scores | #2489 |
prescriptions | #2489 |
psychomotor performance | #2491 |
cerebrum | #2494 |
normative data | #2495 |
180 | #2496 |
hoc analysis | #2496 |
caucasian | #2497 |
israeli | #2500 |
workplace | #2502 |
original | #2504 |
establish | #2504 |
random forest | #2507 |
interactome | #2509 |
randomized placebo | #2511 |
preschool diagnosis | #2512 |
21st | #2512 |
heterosis | #2513 |
quotient | #2515 |
thresholds | #2515 |
preceded | #2516 |
tricyclic antidepressants | #2518 |
evaluate | #2521 |
perceptual | #2523 |
temporal gyrus | #2526 |
12 years | #2528 |
rel | #2531 |
october | #2532 |
alterations | #2532 |
preliminary report | #2533 |
indicators | #2534 |
thinner | #2539 |
limitations | #2541 |
categories | #2545 |
neurosecretory | #2546 |
medication adherence | #2548 |
animals anxiety | #2550 |
risky | #2553 |
psychotic features | #2553 |
depressive disorders | #2554 |
exploratory study | #2555 |
neural responses | #2555 |
quantitative | #2555 |
memory tasks | #2557 |
bipolar affective disorder | #2557 |
risk loci | #2560 |
chronological | #2560 |
income | #2560 |
assisted magnetic | #2561 |
060 | #2562 |
273 | #2563 |
447 | #2565 |
demographic characteristics | #2565 |
sensation seeking | #2569 |
174 | #2570 |
discontinued | #2571 |
document | #2572 |
30 years | #2573 |
numerous | #2573 |
19 years | #2574 |
cool | #2575 |
depressed | #2576 |
socioeconomic | #2579 |
osmosis | #2580 |
smoking alcohol | #2581 |
adolescent females | #2584 |
elucidate | #2585 |
correction | #2585 |
brothers | #2586 |
pvalues | #2586 |
problems | #2586 |
pituitary adrenal | #2587 |
baseline | #2591 |
post traumatic | #2594 |
disrupted | #2595 |
exist | #2595 |
229 | #2596 |
brain response | #2598 |
internalizing externalizing | #2598 |
temporal pole | #2600 |
encouraging | #2601 |
simplex | #2603 |
iowa | #2603 |
n10 | #2605 |
neo | #2606 |
percentile | #2607 |
literature | #2608 |
infrequent | #2610 |
increased activation | #2611 |
advances | #2611 |
occipital | #2612 |
draft | #2614 |
lateralization | #2616 |
surveys humans | #2619 |
pooling | #2620 |
genotype | #2623 |
multiple levels | #2624 |
evidence role | #2624 |
psycinfo | #2625 |
kynurenine | #2625 |
mothers | #2630 |
bdnf gene | #2633 |
imaging studies | #2633 |
preliminary | #2634 |
institute | #2636 |
odors | #2638 |
182 | #2639 |
fetal alcohol | #2642 |
global functioning | #2642 |
genetic variants | #2644 |
behavior | #2644 |
preschool female | #2644 |
medical conditions | #2645 |
inability | #2645 |
future | #2648 |
borderline personality | #2652 |
brain derived | #2655 |
tmax | #2659 |
dysregulation | #2663 |
electronic health | #2664 |
periodicals | #2665 |
puzzle | #2665 |
n14 | #2666 |
089 | #2669 |
health disorders | #2669 |
genetic evidence | #2670 |
chromosome | #2670 |
88 | #2670 |
polysomnography | #2671 |
spectrum | #2675 |
pcps | #2675 |
inconclusive | #2676 |
partially | #2676 |
mediating | #2676 |
adolescent development | #2678 |
physiotherapy | #2678 |
memory tests | #2678 |
maternal behavior | #2679 |
increased activity | #2681 |
disadvantaged | #2685 |
adrenergic | #2687 |
widespread | #2688 |
conditional | #2689 |
triad | #2689 |
age range | #2689 |
listening | #2690 |
reading | #2692 |
entry | #2692 |
promoter region | #2694 |
evaluating | #2695 |
tfs | #2696 |
evidenced | #2698 |
immaturity | #2698 |
extended | #2700 |
chr | #2701 |
attenuate | #2702 |
interrogation | #2702 |
neurite | #2702 |
flares | #2703 |
delinquency | #2707 |
ext | #2707 |
hemispheric asymmetry | #2709 |
internalizing problems | #2710 |
404 | #2713 |
aggressive | #2714 |
occurring | #2714 |
quarter | #2718 |
positively correlated | #2719 |
purposes | #2721 |
choosing | #2723 |
thinking | #2724 |
internalizing | #2726 |
hold | #2727 |
teens | #2731 |
curve | #2731 |
awakening | #2732 |
thicker | #2733 |
systematic literature review | #2733 |
doubt | #2733 |
alcohol dependence | #2736 |
potential association | #2740 |
pdi | #2752 |
cortices | #2753 |
prepubertal | #2753 |
eventually | #2755 |
collaboration | #2760 |
patients bipolar disorder | #2760 |
naa | #2760 |
gt | #2761 |
manifestations | #2762 |
unadjusted | #2765 |
4 years | #2765 |
created | #2768 |
ccs | #2769 |
psychiatric diseases | #2773 |
reproducibility | #2773 |
phencyclidine | #2775 |
depression severity | #2776 |
preventive measures | #2777 |
25 | #2777 |
clinical heterogeneity | #2783 |
mechanisms underlying | #2783 |
bivariate | #2784 |
children symptoms | #2784 |
panic attacks | #2785 |
6 12 | #2788 |
tactile | #2790 |
411 | #2791 |
dna copy | #2791 |
dyslexia | #2792 |
overt | #2794 |
neurotrophic factor | #2794 |
auditory perception | #2796 |
constellation | #2796 |
suicidality | #2799 |
explained | #2802 |
958 | #2803 |
dependence | #2804 |
references | #2806 |
recognition visual | #2808 |
clinical experience | #2808 |
monetary | #2809 |
misdiagnosis | #2809 |
397 | #2809 |
goodness | #2810 |
predefined | #2812 |
disc1 | #2815 |
gene polymorphism | #2816 |
midnight | #2816 |
primary caregivers | #2817 |
subsequent | #2819 |
indexes | #2823 |
circuitry | #2823 |
1300 | #2824 |
telephone | #2824 |
comorbidities | #2825 |
pediatric obesity | #2827 |
intervention strategies | #2828 |
and or | #2830 |
refusal | #2833 |
disorder characterized | #2835 |
tested | #2838 |
early recognition | #2839 |
discriminant validity | #2839 |
adoption | #2841 |
reelin | #2843 |
treatment study | #2843 |
prefrontal cortex | #2844 |
socioeconomic status | #2846 |
emotional intelligence | #2849 |
early identification | #2850 |
matter volume | #2852 |
parent child | #2853 |
disabled | #2856 |
restless legs syndrome | #2857 |
suicide attempted | #2858 |
depression scale | #2863 |
continental ancestry | #2863 |
parenting parents | #2865 |
screened | #2866 |
addresses | #2866 |
mothers children | #2867 |
internal external | #2867 |
cognition humans | #2868 |
discordance | #2868 |
focus | #2869 |
silico | #2870 |
psychosocial stress | #2872 |
splicing | #2875 |
diagnosis differential | #2876 |
gwa | #2878 |
sixteen | #2880 |
measure | #2884 |
appeared | #2884 |
citations | #2885 |
age differences | #2885 |
shifting | #2885 |
rare variants | #2887 |
protective effects | #2889 |
trinucleotide | #2890 |
brain size | #2900 |
asr | #2901 |
alternate | #2902 |
debate | #2903 |
duplicate | #2905 |
low birth weight | #2906 |
alcohol disorder | #2907 |
newer | #2909 |
independent component analysis | #2911 |
etiologies | #2912 |
behavior children | #2913 |
precursor | #2914 |
amph | #2916 |
cognitive control | #2916 |
institutes | #2919 |
biological mechanisms | #2919 |
variability | #2919 |
age study | #2921 |
genetic contributions | #2922 |
115 | #2924 |
attentional | #2925 |
subject | #2928 |
486 | #2931 |
behavioral outcomes | #2931 |
adherence | #2932 |
92 | #2935 |
machine learning | #2941 |
causal relationship | #2942 |
disorders sleep | #2942 |
disorders patients | #2946 |
distinct | #2946 |
motor control | #2953 |
pcb | #2956 |
smoked | #2959 |
journal | #2965 |
facilitating | #2967 |
previous | #2968 |
331 | #2970 |
markers | #2971 |
overlaps | #2971 |
models neurological | #2976 |
stratification | #2981 |
725 | #2983 |
qtl | #2983 |
weight height | #2988 |
investigators | #2989 |
attempts | #2991 |
imaging mri | #2991 |
performance measures | #2997 |
tic | #2997 |
overweight | #2998 |
variants | #2999 |
subjective | #3000 |
bold | #3002 |
referral | #3005 |
196 | #3006 |
centres | #3006 |
377 | #3007 |
19th century | #3010 |
genetic variation | #3011 |
remission | #3011 |
genetic promoter regions | #3012 |
resonance imaging | #3016 |
987 | #3017 |
chen | #3018 |
worldwide | #3020 |
response relationship | #3021 |
inferior frontal gyrus | #3022 |
disease susceptibility | #3023 |
mouse models | #3024 |
choice | #3028 |
conference | #3030 |
models psychological | #3033 |
familiarity | #3034 |
emotion dysregulation | #3036 |
difficulties questionnaire | #3039 |
symptoms patients | #3039 |
female humans life | #3040 |
thomson | #3044 |
neural correlates | #3047 |
variants genes | #3053 |
developmental | #3054 |
treatment adherence | #3054 |
protective factor | #3057 |
improvement | #3058 |
280 | #3061 |
pilot | #3061 |
fear female | #3063 |
117 | #3064 |
ultimately | #3065 |
339 | #3068 |
216 | #3072 |
stress reactivity | #3073 |
p0004 | #3074 |
frontal lobe | #3076 |
appears | #3077 |
driving | #3078 |
cortical | #3078 |
positive | #3079 |
sociodemographics | #3081 |
males | #3089 |
key findings | #3092 |
pairwise | #3093 |
allelic | #3094 |
pregnancy women | #3095 |
stressful life | #3098 |
predictable | #3098 |
modified version | #3099 |
central nervous | #3104 |
intron | #3105 |
076 | #3107 |
brain health | #3107 |
naïve | #3110 |
siemens | #3111 |
interviewed | #3114 |
symptoms study | #3116 |
amygdala hippocampus | #3123 |
articles | #3123 |
marijuana abuse | #3124 |
mass screening | #3125 |
383 | #3127 |
ptsd symptoms | #3127 |
functional laterality | #3129 |
tcc | #3132 |
psychiatrist | #3133 |
temporal cortex | #3134 |
childhood adversity | #3135 |
pharmacies | #3137 |
maternal | #3142 |
accuracies | #3144 |
european countries | #3146 |
nation | #3146 |
exploratory | #3150 |
99 | #3150 |
ancestry | #3151 |
behavior social | #3152 |
pharmacokinetic | #3157 |
oxford | #3157 |
spd | #3165 |
explanations | #3165 |
functional consequences | #3166 |
biological processes | #3166 |
aggregation | #3168 |
hippocampal | #3169 |
teenagers | #3170 |
status humans | #3171 |
caution | #3171 |
report | #3174 |
hypophyseal | #3175 |
math | #3176 |
wealth | #3178 |
contrast | #3180 |
methyltransferase | #3187 |
adolescents young adults | #3187 |
imaging study | #3187 |
receiver | #3188 |
prodrug | #3189 |
published | #3190 |
view | #3190 |
emotion processing | #3195 |
collect | #3195 |
comprehension | #3201 |
initial treatment | #3202 |
attempt | #3202 |
erythematosus sle | #3205 |
answers | #3208 |
normative | #3209 |
naming | #3212 |
snvs | #3214 |
pathophysiological | #3216 |
gene polymorphisms | #3216 |
psychotherapy | #3222 |
environment | #3223 |
angeles | #3228 |
discontinuity | #3229 |
situation | #3229 |
scanner | #3229 |
65 | #3235 |
depression study | #3236 |
mediation analysis | #3237 |
htt | #3237 |
414 | #3239 |
abstinence | #3241 |
databases genetic | #3247 |
determine | #3250 |
features | #3254 |
210 | #3255 |
correlated | #3257 |
211 | #3257 |
caudate nucleus | #3265 |
publicly | #3265 |
interactive effects | #3266 |
17p | #3266 |
humans magnetic | #3266 |
moderator | #3269 |
370 | #3270 |
symbols | #3271 |
researchers | #3272 |
prefrontal cortex pfc | #3274 |
expertise | #3276 |
memory processing | #3281 |
longitudinal cohort | #3282 |
increased likelihood | #3282 |
cognitive functioning | #3289 |
condition | #3291 |
glutamate receptor | #3296 |
replication | #3297 |
surveys | #3299 |
strict | #3304 |
contributed | #3305 |
synaptic function | #3306 |
clinical severity | #3306 |
genomics | #3309 |
restrictions | #3314 |
corrected | #3315 |
attribute | #3316 |
spearman | #3321 |
digit | #3322 |
neuroimaging data | #3323 |
differently | #3325 |
fewer | #3331 |
earlier studies | #3333 |
mrt | #3334 |
metropolitan | #3336 |
ambiguity | #3336 |
clock gene | #3336 |
417 | #3340 |
6 | #3343 |
slide | #3345 |
revealing | #3348 |
clinical | #3351 |
hoc analyses | #3352 |
healthy control | #3354 |
affect | #3357 |
national institute | #3359 |
functional studies | #3361 |
april | #3362 |
friend | #3366 |
motivational | #3367 |
retest | #3369 |
067 | #3370 |
frontal regions | #3371 |
battery | #3371 |
glycolysis | #3371 |
treatment strategies | #3373 |
cortex pfc | #3375 |
088 | #3376 |
marker | #3379 |
functional neuroimaging | #3382 |
initially | #3384 |
sex chromosomes | #3385 |
impaired performance | #3386 |
typically developing | #3386 |
stressful life events | #3387 |
monozygotic | #3389 |
multimorbidity | #3390 |
clock genes | #3390 |
health children | #3392 |
accounting | #3393 |
cnp | #3393 |
ifg | #3398 |
358 | #3402 |
baseline followup | #3404 |
traumatic brain | #3405 |
depression symptoms | #3405 |
desirability | #3406 |
oxidase | #3411 |
performing | #3413 |
pool | #3413 |
aucs | #3415 |
lack | #3419 |
health surveys | #3422 |
therapeutic response | #3423 |
longitudinal data | #3426 |
stepwise | #3431 |
03 | #3433 |
pediatric population | #3436 |
experiencing | #3439 |
definition | #3439 |
exert | #3441 |
fluency | #3446 |
showing | #3448 |
children mothers | #3448 |
lca | #3448 |
schoolaged children | #3449 |
lowered | #3450 |
supports | #3455 |
psychotropic medication | #3455 |
inception | #3457 |
schooling | #3461 |
estimating | #3463 |
differentiate | #3464 |
genomewide association study | #3466 |
cognitive behavioral | #3466 |
hallucinations | #3466 |
male sex | #3472 |
bilaterally | #3473 |
scan | #3475 |
remaining | #3477 |
methylation | #3477 |
behavioral response | #3478 |
irr | #3480 |
transmission | #3482 |
postmortem | #3482 |
slower | #3488 |
convergent | #3489 |
exposure pregnancy | #3489 |
lesser | #3489 |
epidemiological study | #3492 |
applying | #3492 |
alpha2 | #3497 |
social behaviors | #3497 |
short stature | #3497 |
aged polymorphism | #3497 |
083 | #3497 |
matched healthy | #3502 |
p002 | #3506 |
brain function | #3506 |
identifier | #3506 |
antidepressants | #3512 |
checklist | #3514 |
sans | #3518 |
104 | #3519 |
specificity | #3519 |
113 | #3520 |
antipsychotic | #3524 |
spouse | #3525 |
pediatricians | #3527 |
constitutes | #3527 |
basis | #3527 |
asperger syndrome | #3529 |
reflect | #3529 |
clinical phenotype | #3533 |
rett syndrome | #3535 |
reliable | #3536 |
preferentially | #3536 |
enrichment analysis | #3538 |
social behavior | #3539 |
school aged | #3540 |
mother child | #3541 |
sleep wake | #3544 |
cognitive behavioral therapy | #3544 |
fact | #3544 |
coming | #3545 |
rts | #3546 |
documentation | #3547 |
score | #3548 |
dmn | #3550 |
344 | #3557 |
preventive interventions | #3558 |
ecgs | #3558 |
neuronal function | #3558 |
prevalence estimates | #3563 |
suggestions | #3564 |
genetic analysis | #3567 |
psychiatrists | #3568 |
prevent | #3569 |
prospectively | #3570 |
developmental stages | #3573 |
psychosocial interventions | #3579 |
genotyping | #3580 |
reliability | #3583 |
mse | #3585 |
collaborative | #3585 |
neurite outgrowth | #3587 |
mpfc | #3587 |
crh | #3603 |
interrater reliability | #3604 |
cardio | #3606 |
major gene | #3606 |
consists | #3609 |
299 | #3613 |
screen | #3614 |
modalities | #3617 |
questions | #3618 |
methylation status | #3618 |
348 | #3620 |
races | #3621 |
pharmacogenetics | #3622 |
objectives | #3623 |
reviewed | #3624 |
article | #3625 |
214 | #3626 |
101 | #3628 |
neglect | #3630 |
185 | #3631 |
hypothalamo | #3634 |
posttraumatic stress | #3640 |
prior | #3640 |
seeking | #3641 |
wgs | #3648 |
cohesion | #3653 |
enrolment | #3654 |
facilitate | #3660 |
negative | #3661 |
downward | #3662 |
study association | #3663 |
increased prevalence | #3666 |
socioeconomic factors | #3668 |
weight | #3669 |
93 | #3670 |
administration oral | #3672 |
captured | #3675 |
360 | #3681 |
1st | #3682 |
genotype data | #3686 |
behavior problems | #3690 |
frontal lobes | #3691 |
marijuana | #3695 |
online survey | #3696 |
nacetylcysteine | #3700 |
disorders animals | #3703 |
oe | #3705 |
problem behavior | #3707 |
effort | #3711 |
brain cognition | #3719 |
manipulations | #3722 |
9 years | #3729 |
situations | #3730 |
pha | #3732 |
070 | #3733 |
ultimate | #3734 |
daily life | #3735 |
neurotransmission | #3735 |
fifty | #3736 |
depressed mood | #3737 |
hapmap | #3737 |
population | #3738 |
international | #3744 |
therapy cbt | #3744 |
relative | #3745 |
offer | #3746 |
reply | #3750 |
persisted | #3751 |
shortterm | #3753 |
epigenesis genetic | #3755 |
depression risk | #3756 |
proportional | #3757 |
333 | #3758 |
neurophysiological | #3758 |
interim analysis | #3760 |
comprehensive assessment | #3767 |
315 | #3777 |
addiction | #3780 |
transitions | #3781 |
recognition psychology | #3782 |
cocaine disorders | #3783 |
peers | #3787 |
promoter polymorphism | #3787 |
1012 | #3791 |
nonresponse | #3794 |
predictive validity | #3797 |
discriminate | #3800 |
forecast | #3802 |
monozygotic twins | #3803 |
statistical analyses | #3806 |
355 | #3809 |
ways | #3814 |
scientific | #3822 |
dimensions | #3824 |
030 | #3825 |
neurotransmitter | #3829 |
acetylcysteine | #3835 |
inclusion | #3837 |
exchanger | #3844 |
male marijuana | #3844 |
children aged | #3850 |
disease genes | #3850 |
developmental disorders | #3850 |
risk development | #3851 |
elevations | #3851 |
midlife | #3852 |
36 | #3854 |
rely | #3856 |
test | #3858 |
animal dopamine | #3859 |
superior temporal | #3862 |
strong | #3863 |
drug administration | #3866 |
prospective | #3872 |
explain | #3874 |
74 | #3876 |
208 | #3876 |
influences | #3876 |
p001 | #3879 |
ireland | #3882 |
mark | #3883 |
globus | #3886 |
child cohort | #3888 |
reevaluation | #3888 |
tesla | #3890 |
p0003 | #3895 |
neurology | #3898 |
plasma membrane | #3898 |
histories | #3901 |
obstetric | #3905 |
congruent | #3913 |
clinicians | #3915 |
ethnicities | #3922 |
monotherapy | #3923 |
variable | #3924 |
illnesses | #3925 |
robust | #3929 |
dbd | #3930 |
drug targets | #3931 |
suicidal behavior | #3932 |
antidepressant treatment | #3935 |
preexisting | #3937 |
frontal gyrus | #3937 |
specific factors | #3937 |
females males | #3944 |
2nd | #3945 |
directions | #3947 |
controversy | #3951 |
integrate | #3953 |
nicotine | #3956 |
normalization | #3959 |
support | #3960 |
systematic review metaanalysis | #3962 |
indicating | #3967 |
older children | #3969 |
trauma | #3970 |
disease control | #3971 |
untreated | #3976 |
alcohol | #3978 |
brain functional | #3980 |
forecasts | #3981 |
factorial | #4000 |
preliminary evidence | #4000 |
categorization | #4000 |
vulnerabilities | #4003 |
medial prefrontal | #4004 |
primary aim | #4005 |
initiating | #4012 |
kappa | #4013 |
cortex | #4018 |
eqtls | #4021 |
construct | #4023 |
fusiform gyrus | #4032 |
represent | #4036 |
clinical improvement | #4046 |
common variants | #4047 |
diabetes risk | #4047 |
mathematics | #4051 |
modeled | #4051 |
discussion | #4051 |
consequences | #4052 |
relevant | #4057 |
jointly | #4058 |
contextual factors | #4058 |
criminal | #4060 |
divergent | #4062 |
intellectual disability | #4063 |
causal role | #4064 |
magnetic resonance | #4068 |
cag | #4068 |
serotonin uptake | #4068 |
forecasting | #4071 |
statistics | #4072 |
118 | #4074 |
portion | #4075 |
child age | #4076 |
outcomes children | #4078 |
birth order | #4082 |
belgium | #4086 |
genetic loci | #4088 |
study efficacy | #4090 |
heroin | #4090 |
clinical characteristics | #4096 |
temporal lobe | #4098 |
lobe | #4098 |
genetic variations | #4100 |
maternal depression | #4100 |
limbic | #4102 |
age matched | #4103 |
psychologists | #4103 |
list | #4105 |
evidence base | #4107 |
062 | #4109 |
eicosapentaenoic | #4113 |
traumatic | #4115 |
vary | #4117 |
comprises | #4121 |
plausible | #4121 |
epigenesis | #4128 |
cortical areas | #4130 |
relationship | #4136 |
principal components | #4139 |
244 | #4140 |
dosing | #4145 |
german | #4145 |
span | #4146 |
neuronal migration | #4148 |
sectional | #4150 |
mj | #4156 |
regression | #4158 |
extensively | #4160 |
259 | #4161 |
124 | #4164 |
indicative | #4166 |
pathophysiology | #4167 |
fm | #4169 |
somatization | #4170 |
risk depression | #4174 |
bioinformatics | #4177 |
mapping | #4178 |
sedation | #4180 |
340 | #4182 |
dopamine d3 | #4184 |
109 | #4187 |
mri scans | #4188 |
preventive | #4190 |
military | #4191 |
lupus erythematosus | #4192 |
morphometry | #4193 |
structural connectivity | #4194 |
study differences | #4195 |
268 | #4196 |
describes | #4198 |
116 | #4199 |
transporter | #4204 |
growing | #4213 |
children age | #4215 |
route | #4216 |
helpful | #4216 |
based sample | #4218 |
suicidal thoughts | #4219 |
subgroups | #4219 |
functional magnetic | #4223 |
copy variations | #4224 |
determining | #4227 |
valproic | #4230 |
calcineurin | #4237 |
administration | #4239 |
tap | #4245 |
rat model | #4247 |
1987 | #4251 |
gpcr | #4253 |
predict | #4253 |
differential female humans | #4254 |
emerge | #4256 |
mortem | #4259 |
representative | #4263 |
trajectory | #4263 |
confers | #4264 |
posttreatment | #4268 |
antipsychotic medication | #4269 |
225 | #4270 |
follow‐up | #4273 |
early intervention | #4276 |
paediatric | #4280 |
principal component analysis | #4282 |
contributors | #4285 |
polymorphisms genes | #4292 |
select | #4293 |
deletion | #4296 |
pressor | #4302 |
outpatients | #4305 |
demographic variables | #4309 |
child development | #4314 |
adequacy | #4315 |
potential targets | #4315 |
highest risk | #4319 |
mutual | #4324 |
cardiovascular effects | #4326 |
patients diagnosed | #4327 |
buprenorphine | #4332 |
occasion | #4341 |
cingulate cortex | #4348 |
occurs | #4350 |
chart review | #4352 |
catechol | #4353 |
acute treatment | #4353 |
segregation | #4358 |
dropouts | #4361 |
searched | #4362 |
adjunct | #4363 |
166 | #4369 |
cambridge | #4370 |
aging brain | #4372 |
logistic regression analysis | #4373 |
relation | #4375 |
exists | #4375 |
intolerance | #4378 |
mediate | #4378 |
066 | #4382 |
clarity | #4383 |
psychological adolescent | #4383 |
transcriptomic | #4391 |
solving | #4391 |
docosahexaenoic | #4391 |
human | #4393 |
volumetric | #4395 |
privacy | #4396 |
low dose | #4399 |
exon | #4404 |
sexual dimorphism | #4409 |
corpus striatum | #4410 |
impulse | #4412 |
survive | #4413 |
diverse | #4413 |
membrane glycoproteins | #4416 |
polychlorinated biphenyls | #4418 |
ethnic differences | #4424 |
intranasal | #4426 |
opioids | #4429 |
terminology | #4434 |
concurrent | #4438 |
morbidities | #4444 |
197 | #4445 |
bias | #4447 |
human studies | #4449 |
striatal dopamine | #4449 |
genotypes | #4454 |
62 | #4454 |
192 | #4461 |
symposium | #4462 |
locomotor | #4464 |
serotonergic | #4465 |
outgrowth | #4467 |
dna methylation | #4470 |
219 | #4471 |
entered | #4473 |
emissioncomputed | #4476 |
smell | #4477 |
synapse | #4482 |
compilation | #4486 |
ethical | #4490 |
criterion validity | #4491 |
fourth | #4495 |
informal | #4500 |
superior temporal gyrus | #4501 |
parametric | #4508 |
313 | #4509 |
visits | #4516 |
valuation | #4516 |
disorders cognitive | #4516 |
alcohol abuse | #4517 |
investigate | #4521 |
notion | #4525 |
laterality | #4526 |
considerable | #4540 |
postnatal day | #4540 |
multiple | #4541 |
children families | #4542 |
incentive | #4546 |
transmit | #4548 |
pharmacology | #4552 |
employment | #4553 |
higher level | #4553 |
preschool children | #4564 |
birth | #4564 |
emr | #4565 |
component | #4572 |
22 | #4573 |
neuronal differentiation | #4587 |
psd | #4587 |
address | #4593 |
origin | #4595 |
initiated | #4599 |
006 | #4603 |
≤ | #4609 |
february | #4610 |
009 | #4612 |
indices | #4613 |
israel | #4617 |
attributed | #4630 |
genomic data | #4633 |
ssris | #4634 |
television | #4636 |
head injury | #4638 |
clinical risk | #4643 |
q1 | #4643 |
question | #4648 |
trouble | #4651 |
unmet | #4651 |
regression model | #4652 |
marriage | #4658 |
microsatellite | #4660 |
centers | #4660 |
deliveries | #4660 |
anterior cingulate cortex | #4661 |
243 | #4662 |
trajectories | #4662 |
children study | #4665 |
homogeneity | #4667 |
mitigate | #4668 |
fg | #4668 |
european | #4669 |
healthy individuals | #4670 |
psychometric properties | #4673 |
routes | #4676 |
disease onset | #4679 |
subsequently | #4680 |
pregnancy risk | #4682 |
264 | #4684 |
names | #4689 |
hunt | #4696 |
accurate diagnosis | #4699 |
concerns | #4705 |
5 | #4706 |
cardiorespiratory | #4707 |
imply | #4710 |
autosomal | #4711 |
vector machine | #4715 |
hazards models | #4715 |
estimate | #4716 |
smd | #4717 |
mbr | #4719 |
sed | #4719 |
appropriateness | #4720 |
positional | #4725 |
cinahl | #4729 |
fusiform | #4730 |
eqtl | #4731 |
participants included | #4732 |
biological factors | #4735 |
drug addiction | #4736 |
prototypes | #4745 |
val | #4747 |
unemployment | #4747 |
pons | #4753 |
cooperative | #4755 |
drug | #4757 |
taiwan | #4757 |
conflict | #4760 |
77 | #4760 |
tasks | #4762 |
heavily | #4763 |
portions | #4763 |
fumarate | #4773 |
231 | #4774 |
mother | #4782 |
subjects risk | #4784 |
noncarriers | #4791 |
samples | #4791 |
sharing | #4795 |
mp | #4798 |
publication administration | #4798 |
cleaning | #4804 |
coronary artery disease | #4814 |
fractional anisotropy | #4820 |
cognitive tests | #4825 |
modafinil | #4825 |
excluding | #4832 |
surge | #4835 |
visual perception | #4836 |
experts | #4837 |
223 | #4838 |
continuity | #4843 |
sparse | #4849 |
recognized | #4853 |
imaging female | #4858 |
41 | #4865 |
rg | #4873 |
specific | #4874 |
207 | #4875 |
deterioration | #4880 |
wave | #4880 |
young age | #4881 |
subsamples | #4881 |
cigarettes | #4881 |
omega3 | #4882 |
fp | #4882 |
prisma | #4885 |
facts | #4890 |
cascades | #4891 |
eliminated | #4894 |
antiepileptic drugs | #4910 |
operating | #4914 |
002 | #4915 |
preclinical studies | #4916 |
achievements | #4923 |
early adolescence | #4923 |
additive | #4924 |
bdi | #4929 |
scored | #4929 |
parietal lobe | #4930 |
outcome measures | #4932 |
034 | #4933 |
brain activity | #4937 |
inventory | #4941 |
relating | #4947 |
delays | #4949 |
hemispheric | #4949 |
powerful | #4951 |
pooled analysis | #4951 |
snap | #4957 |
rule | #4959 |
diffusion tensor imaging | #4962 |
acetylcholine receptor | #4965 |
srs | #4967 |
212 | #4969 |
altered expression | #4972 |
eye tracking | #4973 |
explosion | #4978 |
empirical data | #4979 |
continental | #4983 |
lower | #4994 |
170 | #4995 |
022 | #5001 |
treatment modalities | #5005 |
timing | #5008 |
esr1 | #5015 |
aged nerve | #5017 |
caucasians | #5021 |
selective attention | #5021 |
disagreement | #5024 |
aug | #5025 |
rarely | #5027 |
serotonin receptors | #5029 |
variation | #5030 |
adolescent health | #5031 |
specialty | #5036 |
task | #5038 |
discuss | #5039 |
probabilistic | #5039 |
correct | #5040 |
distinguish | #5040 |
auc | #5047 |
anxiety depression | #5047 |
cingulate gyrus | #5047 |
sga | #5050 |
early | #5051 |
convergent validity | #5051 |
marital | #5051 |
predictor | #5052 |
2003 | #5055 |
analgesics | #5056 |
obesity | #5064 |
bidirectional | #5067 |
gender identity | #5067 |
18 years | #5070 |
continuation | #5077 |
cadherins | #5079 |
decreasing | #5085 |
reductions | #5086 |
chinese children | #5092 |
placebo patients | #5095 |
aes | #5097 |
epilepsy | #5099 |
09 | #5101 |
reached | #5101 |
103 | #5104 |
screening | #5104 |
relative contributions | #5105 |
qtc | #5106 |
volume reduction | #5107 |
ancestral | #5112 |
time points | #5118 |
relevance | #5119 |
variables | #5127 |
substances | #5129 |
mediation | #5132 |
single nucleotide polymorphisms | #5132 |
maladaptive | #5133 |
ppv | #5134 |
individuals risk | #5136 |
mechanisms | #5142 |
readers | #5143 |
mental retardation | #5145 |
difference | #5146 |
inherent | #5146 |
involves | #5147 |
pharmacogenomics | #5147 |
carrying | #5158 |
enrichment | #5160 |
administered | #5162 |
homozygote | #5166 |
dropout | #5168 |
biological | #5170 |
diffusivity | #5177 |
picture | #5178 |
ventral | #5181 |
reuptake inhibitors | #5182 |
extent | #5183 |
dopamine d1 | #5187 |
adjustment | #5190 |
disability | #5193 |
238 | #5193 |
predictive | #5195 |
weighted | #5197 |
pleiotropy | #5205 |
characteristic | #5212 |
remains | #5215 |
molecular biology | #5215 |
term | #5218 |
conclude | #5223 |
dopaminergic neurons | #5224 |
167 | #5226 |
nonsmokers | #5231 |
dutch | #5233 |
256 | #5234 |
fail | #5237 |
smoking behavior | #5240 |
interaction | #5242 |
accurately | #5245 |
119 | #5246 |
critical period | #5248 |
tolerated | #5255 |
generated | #5260 |
boundaries | #5261 |
americans | #5263 |
exceeded | #5264 |
delineation | #5266 |
genotypic | #5269 |
daytime sleepiness | #5278 |
ws | #5278 |
cell surface receptors | #5280 |
brain injuries | #5283 |
001 | #5286 |
participated | #5287 |
variety | #5289 |
normality | #5290 |
written | #5291 |
trend | #5295 |
billion | #5295 |
eye movements | #5296 |
motor | #5298 |
oligodendrocytes | #5299 |
thalamus | #5299 |
learning | #5301 |
234 | #5302 |
emotion recognition | #5306 |
life events | #5308 |
072 | #5308 |
52 | #5309 |
healthy participants | #5310 |
environmental | #5312 |
observer | #5313 |
dense | #5316 |
hints | #5321 |
definite | #5322 |
treatment initiation | #5323 |
genomic imprinting | #5333 |
credibility | #5335 |
inferences | #5339 |
individual level | #5345 |
social interactions | #5345 |
predictive tests | #5345 |
classic | #5351 |
prenatal | #5353 |
word | #5354 |
estimated | #5359 |
cerebellum | #5363 |
nonresponders | #5368 |
nervosa | #5369 |
interplay | #5375 |
eventrelated potentials | #5376 |
higher frequency | #5380 |
penetrance | #5380 |
suicide attempts | #5382 |
lost | #5382 |
internet addiction | #5390 |
sweden | #5391 |
huntington disease | #5392 |
domains | #5396 |
potential confounders | #5402 |
37 | #5403 |
label | #5403 |
empirical | #5410 |
register | #5411 |
daily | #5413 |
0007 | #5419 |
average | #5424 |
tensor imaging | #5432 |
224 | #5436 |
pcp | #5449 |
172 | #5451 |
wiley | #5452 |
adjunctive therapy | #5454 |
modifiers | #5464 |
hour | #5467 |
york | #5468 |
risk individuals | #5468 |
× 10 | #5471 |
aim | #5474 |
settings | #5475 |
borderline | #5478 |
environmental effects | #5484 |
brains | #5486 |
copy | #5488 |
recall | #5491 |
confirms | #5494 |
locomotor activity | #5499 |
homozygotes | #5502 |
year | #5505 |
clinics | #5517 |
commission | #5518 |
termed | #5519 |
verbal fluency | #5525 |
promoter regions | #5525 |
fdr | #5534 |
320 | #5536 |
anxiety behavior | #5537 |
modulate | #5547 |
155 | #5547 |
closely | #5549 |
elevated | #5549 |
prevention | #5551 |
restraint | #5552 |
flanking | #5552 |
occur | #5553 |
154 | #5559 |
copy variation | #5562 |
health conditions | #5563 |
icd10 | #5564 |
frontal cortex | #5565 |
baseline treatment | #5565 |
15 | #5567 |
european ancestry | #5567 |
213 | #5574 |
significance | #5578 |
predominance | #5578 |
240 | #5579 |
mediators | #5579 |
spatial memory | #5581 |
subacute | #5584 |
175 | #5590 |
locus | #5592 |
epidemiological | #5593 |
scientists | #5596 |
narcolepsy | #5597 |
nrg1 | #5607 |
anhedonia | #5608 |
amygdala | #5623 |
percent | #5628 |
heavier | #5631 |
total | #5640 |
allocation | #5657 |
perinatal | #5663 |
lower risk | #5663 |
divided | #5666 |
exploring | #5670 |
probability | #5677 |
calculate | #5678 |
proportional hazards | #5684 |
1999 | #5686 |
40 years | #5686 |
gene variants | #5687 |
vbm | #5688 |
markov | #5688 |
published data | #5689 |
oculomotor | #5690 |
brain development | #5694 |
databases | #5696 |
normal | #5696 |
systems biology | #5703 |
cognitive functions | #5713 |
primary outcome measure | #5713 |
58 | #5723 |
signal detection | #5725 |
pleasure | #5727 |
thirty | #5728 |
focused | #5728 |
psychological surveys | #5735 |
020 | #5739 |
19 | #5745 |
definitions | #5746 |
cognitive tasks | #5751 |
missing data | #5755 |
divorce | #5758 |
approaches | #5761 |
nac | #5762 |
interactive | #5765 |
aged children | #5767 |
additional | #5773 |
deficient | #5778 |
oral | #5779 |
72 | #5780 |
rats inbred | #5786 |
susceptibility locus | #5788 |
extracted | #5792 |
206 | #5796 |
preferential | #5797 |
16 | #5799 |
139 | #5802 |
deaths | #5811 |
intracranial | #5814 |
nuclear | #5815 |
0002 | #5819 |
0005 | #5820 |
aaa | #5823 |
133 | #5826 |
98 | #5827 |
nerve net | #5827 |
ethnic groups | #5834 |
multidimensional | #5836 |
fell | #5841 |
dependency | #5846 |
cannabis | #5849 |
deletions | #5857 |
current understanding | #5860 |
signaling peptides | #5862 |
gene expression profiles | #5869 |
fetuses | #5872 |
membership | #5874 |
auditory | #5875 |
retrospective chart review | #5879 |
sexual behavior | #5880 |
synaptophysin | #5887 |
16 years | #5894 |
small | #5898 |
september | #5901 |
imputation | #5910 |
council | #5910 |
appendix | #5916 |
characterizing | #5917 |
broad | #5919 |
activity level | #5919 |
ethics | #5923 |
parietal | #5925 |
region | #5928 |
linked | #5928 |
statement | #5928 |
individuality | #5929 |
rights | #5930 |
prolactin | #5931 |
medical treatment | #5933 |
rapamycin | #5937 |
biphenyls | #5940 |
striatal | #5955 |
community | #5956 |
electroencephalography evoked | #5964 |
clearance | #5965 |
132 | #5966 |
cmax | #5969 |
091 | #5971 |
missed | #5974 |
explore | #5994 |
website | #6000 |
exclusively | #6001 |
threshold | #6003 |
moderating role | #6005 |
rois | #6005 |
matched | #6006 |
chromosomal | #6009 |
module | #6011 |
functional connectivity | #6013 |
newcastle | #6017 |
extreme | #6020 |
Sacar un reporte | |
Prominent publications by Stephen V Faraone∗
IMPORTANCE: Attention-deficit/hyperactivity disorder (ADHD) is a heritable neurodevelopmental disorder. It has been linked to reductions in total brain volume and subcortical abnormalities. However, owing to heterogeneity within and between studies and limited sample sizes, findings on the neuroanatomical substrates of ADHD have shown considerable variability. Moreover, it remains unclear whether neuroanatomical alterations linked to ADHD are also present in the unaffected siblings of ...
Conocido por Unaffected Siblings | Putamen Volume | Participants Adhd | Hyperactivity Disorder | Total Brain |
Motor coordination problems in children and adolescents with ADHD rated by parents and teachers: effects of age and gender
[ PUBLICATION ]
Summary.Objective. ADHD is frequently accompanied by motor coordination problems. However, the co-occurrence of poor motor performance has received less attention in research than other coexisting problems in ADHD. The underlying mechanisms of this association remain unclear. Therefore, we investigated the prevalence of motor coordination problems in a large sample of children with ADHD, and the relationship between motor coordination problems and inattentive and hyperactive/impulsive ...
Conocido por Motor Coordination Problems | Children Adhd | Boys Girls | Hyperactivity Child Child | Parents Prevalence |
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
[ PUBLICATION ]
We examined the status of the neural network mediating the default mode of brain function, which typically exhibits greater activation during rest than during task, in patients in the early phase of schizophrenia and in young first-degree relatives of persons with schizophrenia. During functional MRI, patients, relatives, and controls alternated between rest and performance of working memory (WM) tasks. As expected, controls exhibited task-related suppression of activation in the default ...
Conocido por Default Network | Patients Relatives | Rest Task | Wm Performance | Mpfc Dlpfc |
Patterns of Psychopathology and Dysfunction in High-Risk Children of Parents With Panic Disorder and Major Depression
[ PUBLICATION ]
OBJECTIVE: The purpose of the study was to evaluate 1) whether an underlying familial predisposition is shared by all anxiety disorders or whether specific risks are associated with specific disorders, and 2) whether panic disorder and major depression have a familial link.
METHOD: The study compared four groups of children: 1) offspring of parents with panic disorder and comorbid major depression (N=179), 2) offspring of parents with panic disorder without comorbid major depression ...
Conocido por Major Depression | Panic Disorder | Offspring Parents | Risk Children | Factors Social |
OBJECTIVE: Attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and obsessive-compulsive disorder (OCD) are common neurodevelopmental disorders that frequently co-occur. The authors sought to directly compare these disorders using structural brain imaging data from ENIGMA consortium data.
METHODS: Structural T1-weighted whole-brain MRI data from healthy control subjects (N=5,827) and from patients with ADHD (N=2,271), ASD (N=1,777), and OCD (N=2,323) from 151 ...
Conocido por Adhd Asd | Cortical Thickness | Children Adolescents | Brain Volume | Disorder Ocd |
BACKGROUND: Neuroimaging studies have shown structural alterations in several brain regions in children and adults with attention deficit hyperactivity disorder (ADHD). Through the formation of the international ENIGMA ADHD Working Group, we aimed to address weaknesses of previous imaging studies and meta-analyses, namely inadequate sample size and methodological heterogeneity. We aimed to investigate whether there are structural differences in children and adults with ADHD compared with ...
Conocido por Brain Volume | Adults Adhd | Attention Deficit | Hyperactivity Disorder | Subcortical Structures |
AIMS: To determine comorbidity patterns in treatment-seeking substance use disorder (SUD) patients with and without adult attention deficit hyperactivity disorder (ADHD), with an emphasis on subgroups defined by ADHD subtype, taking into account differences related to gender and primary substance of abuse.
DESIGN: Data were obtained from the cross-sectional International ADHD in Substance use disorder Prevalence (IASP) study.
SETTING: Forty-seven centres of SUD treatment in 10 ...
Conocido por Disorder Patients | Psychiatric Comorbidity | Attention Deficit | Seeking Substance | Presence Adhd |
CONTEXT: Controversy exists about the appropriate criteria for a diagnosis of adult attention-deficit/hyperactivity disorder (ADHD).
OBJECTIVE: To examine the structure and symptoms most predictive of DSM-IV adult ADHD.
DESIGN: The data are from clinical interviews in enriched subsamples of the National Comorbidity Survey Replication (n = 131) and a survey of a large managed health care plan (n = 214). The physician-administered Adult ADHD Clinical Diagnostic Scale (ACDS) was used to ...
Conocido por Adult Adhd | Hyperactivity Disorder | Illness Surveys | Clinical Diagnostic | Symptoms Childhood |
The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives
[ PUBLICATION ]
With the single exception of SUDs, no statistically significant gender-by ADHD interactions were identified in the multiple, outcomes evaluated. These results suggest that with the exception of SUDs, ADHD expresses itself similarly in boys and girls relative to comparison subjects of the same gender, indicating that ADHD-associated impairments are correlates of ADHD in both genders. Gender differences, such as the higher prevalence of symptoms of inattention and lower rates of ...
Conocido por Girls Adhd | Hyperactivity Disorder | Gender Differences | Higher Prevalence | Symptoms Inattention |
OBJECTIVE: To complete an exploratory uncontrolled study of the effects of lisdexamfetamine dimesylate (LDX) on growth of children treated for attention-deficit/hyperactivity disorder (ADHD).
METHOD: Height, weight, and body mass index (BMI) from 281 children ages 6 to 13 years from longitudinal assessments up to 15 months were compared to norms from the Centers for Disease Control.
RESULTS: At study entry, children were taller and heavier than average. Growth delays were largest for ...
Conocido por Lisdexamfetamine Dimesylate | Height Weight | Growth Children | Ldx Bmi | Centers Disease Control |
Psychopathology in Adolescent Offspring of Parents With Panic Disorder, Major Depression, or Both: A 10-Year Follow-Up
[ PUBLICATION ]
OBJECTIVE: The authors examined the specificity and course of psychiatric disorders from early childhood through adolescence in offspring of parents with confirmed panic disorder and major depressive disorder.
METHOD: The authors examined rates of psychiatric disorders at 10-year-follow-up (mean age, 14 years) in four groups: offspring of referred parents with panic and depression (N=137), offspring of referred parents with panic without depression (N=26), offspring of referred parents ...
Conocido por Panic Disorder | Offspring Parents | Parental Depression | Disruptive Behavior | Year Follow |
BACKGROUND: The goal of this study was to investigate the occurrence, severity and clinical correlates of emotional lability (EL) in children with attention deficit/hyperactivity disorder (ADHD), and to examine factors contributing to EL and familiality of EL in youth with ADHD.
METHODS: One thousand, one hundred and eighty-six children with ADHD combined type and 1827 siblings (aged 6-18 years) were assessed for symptoms of EL, ADHD, associated psychopathology and comorbid psychiatric ...
Conocido por Symptoms Adhd | Emotional Lability | Hyperactivity Disorder | Attention Deficit | Odd Disruptive Behavior |
A Controlled Study of Behavioral Inhibition in Children of Parents With Panic Disorder and Depression
[ PUBLICATION ]
OBJECTIVE: "Behavioral inhibition to the unfamiliar" has been proposed as a precursor to anxiety disorders. Children with behavioral inhibition are cautious, quiet, introverted, and shy in unfamiliar situations. Several lines of evidence suggest that behavioral inhibition is an index of anxiety proneness. The authors sought to replicate prior findings and examine the specificity of the association between behavioral inhibition and anxiety.
METHOD: Laboratory-based behavioral observations ...
Conocido por Behavioral Inhibition | Major Depression | Children Parents | Panic Disorder | Controlled Study |
Traumatic Brain Injury and Schizophrenia in Members of Schizophrenia and Bipolar Disorder Pedigrees
[ PUBLICATION ]
OBJECTIVE: Schizophrenia following a traumatic brain injury could be a phenocopy of genetic schizophrenia or the consequence of a gene-environment interaction. Alternatively, traumatic brain injury and schizophrenia could be spuriously associated if those who are predisposed to develop schizophrenia have greater amounts of trauma for other reasons. The authors investigated the relationship between traumatic brain injury and psychiatric diagnoses in a large group of subjects from families ...
Conocido por Traumatic Brain Injury | Bipolar Disorder | Subjects Schizophrenia | Mental Illness | Genetic Vulnerability |
Gente clave para Hyperactivity Disorder
Stephen V Faraone∗:Impacto experto
Conceptos para los cualesStephen V Faraone∗tiene influencia directa:Hyperactivity disorder, Bipolar disorder, Attention deficit, Deficit hyperactivity, Disorder adhd, Anxiety disorders, Disorder hyperactivity, Children adhd.
Stephen V Faraone∗:Impacto de Kol
Conceptos relacionados con el trabajo de otros autores para los cualesfor which Stephen V Faraone∗ tiene influencia:Bipolar disorder, Attention deficit, Children adhd, Executive function, Mental health, Schizophrenia patients.
Tools
¿Es este tu perfil? Reclama tu perfil Copiar URL Incrustar el enlace a su perfil |